CD81		O
signals		O
for		O
antiproliferation		O
when		O
bound		O
by		O
antibodies		O
.		O
However		O
,		O
the		O
nature		O
of		O
the		O
3		O
-		O
substituent		O
was		O
found		O
to		O
have		O
a		O
major		O
effect		O
on		O
the		O
alpha		O
(		O
2		O
)		O
-		O
adrenoceptor		O
affinity		O
of		O
these		O
compounds		O
with		O
the		O
3		B-PARTIUPAC
-		I-PARTIUPAC
hydroxymethyl		I-PARTIUPAC
-		I-PARTIUPAC
and		O
3		B-IUPAC
-		I-IUPAC
fluoromethyl		I-IUPAC
-		I-IUPAC
THIQs		I-IUPAC
having		O
the		O
highest		O
affinity		O
and		O
THIQs		O
containing		O
the		O
3		B-PARTIUPAC
-		I-PARTIUPAC
chloromethyl		I-PARTIUPAC
moiety		B-MODIFIER
the		O
least		O
.		O
It		O
is		O
proposed		O
that		O
this		O
is		O
due		O
to		O
the		O
conformational		O
restriction		O
imposed		O
by		O
the		O
methyl		B-IUPAC
group		B-MODIFIER
of		O
6		O
.		O
The		O
analogue		O
has		O
the		O
same		O
primary		O
structure		O
as		O
lysine		O
-		O
vasopressin		O
,		O
except		O
that		O
two		O
additional		O
hydrogen		O
atoms		O
are		O
present		O
on		O
the		O
ring		O
moiety		O
of		O
the		O
phenylalanine		O
residue		O
in		O
position		O
3		O
.		O
Thus		O
the		O
Wittig		O
approach		O
affords		O
an		O
alternative		O
synthetic		O
route		O
to		O
10		O
-		O
EDAM		O
.		O
5		B-IUPAC
-		I-IUPAC
Acetyl		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxyuridine		I-IUPAC
(		O
15		O
)		O
was		O
prepared		O
in		O
the		O
same		O
way		O
from		O
5		B-IUPAC
-		I-IUPAC
acetyluracil		I-IUPAC
.		O
Since		O
chemical		O
carbethoxylating		O
agents		O
represented		O
by		O
the		O
O		B-MODIFIER
-		I-MODIFIER
carbethoxylated		I-MODIFIER
N		B-IUPAC
-		I-IUPAC
hydroxyphthalimide		I-IUPAC
,		O
1		B-IUPAC
-		I-IUPAC
hydroxybenzotriazole		I-IUPAC
,		O
and		O
N		B-IUPAC
-		I-IUPAC
hydroxysuccinimide		I-IUPAC
(		O
8		O
,		O
9		O
,		O
and		O
10		O
,		O
respectively		O
)		O
likewise		O
inhibited		O
yeast		O
AlDH		O
,		O
albeit		O
with		O
IC50		O
's		O
1		O
order		O
of		O
magnitude		O
higher		O
,		O
we		O
postulate		O
that		O
1c		O
and		O
6		O
act		O
as		O
irreversible		O
inhibitors		O
of		O
AlDH		O
by		O
carbethoxylating		O
the		O
active		O
site		O
of		O
the		O
enzyme		O
.		O
r		O
.		O
viteae		O
.		O
Treatment		O
of		O
2		O
or		O
3		O
with		O
the		O
appropriate		O
nucleophiles		O
at		O
room		O
temperature		O
gave		O
6		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
8		B-IUPAC
-		I-IUPAC
azapurine		I-IUPAC
ribonucleosides		I-IUPAC
(		O
7		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
2		B-PARTIUPAC
-		I-PARTIUPAC
or		O
3		B-IUPAC
-		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
ribofuranosyl		I-IUPAC
-		I-IUPAC
3H		I-IUPAC
-		I-IUPAC
1,2,3		I-IUPAC
-		I-IUPAC
triazolo		I-IUPAC
[		I-IUPAC
4,5		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidines		I-IUPAC
)		O
4-13		O
.		O
The		O
most		O
potent		O
inhibitors		O
of		O
converting		O
enzyme		O
were		O
III		O
followed		O
by		O
VII		O
and		O
VIII		O
.		O
The		O
aim		O
of		O
this		O
work		O
was		O
to		O
improve		O
the		O
oral		O
bioavailability		O
of		O
a		O
recently		O
discovered		O
,		O
novel		O
structural		O
class		O
of		O
5		O
-		O
HT1A		O
receptor		O
agonists		O
:		O
aryl		B-IUPAC
-		I-IUPAC
{		I-IUPAC
[		I-IUPAC
4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
6		I-IUPAC
-		I-IUPAC
R		I-IUPAC
-		I-IUPAC
pyridin		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
ylmethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
}		I-IUPAC
-		I-IUPAC
piperidin		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
-		I-IUPAC
metha		I-IUPAC
none		I-IUPAC
.		O
A		O
number		O
of		O
novel		O
dihydropyridine		O
derivatives		O
based		O
upon		O
1		B-IUPAC
,		I-IUPAC
4		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
methoxycarbonyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
,		I-IUPAC
6		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
nitrophenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
(		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
,		I-IUPAC
4		I-IUPAC
-		I-IUPAC
diphenylpiperidin		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
propyl		I-IUPAC
)		I-IUPAC
aminocarbonyl		I-IUPAC
)		I-IUPAC
pyridine		I-IUPAC
(		O
4		O
)		O
have		O
been		O
synthesized		O
and		O
tested		O
at		O
cloned		O
human		O
alpha		O
adrenoceptors		O
as		O
well		O
as		O
the		O
rat		O
L		O
-		O
type		O
calcium		O
channel		O
.		O
Direct		O
alkylation		O
of		O
2		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
4,6		I-IUPAC
-		I-IUPAC
dihydroxypyrimidine		I-IUPAC
afforded		O
a		O
mixture		O
of		O
2		B-PARTIUPAC
-		I-PARTIUPAC
amino		I-PARTIUPAC
-		I-PARTIUPAC
4,6		I-PARTIUPAC
-		I-PARTIUPAC
bis		I-PARTIUPAC
[		I-PARTIUPAC
2		I-PARTIUPAC
-		I-PARTIUPAC
(		I-PARTIUPAC
phosphonomethoxy		I-PARTIUPAC
)		I-PARTIUPAC
ethyl		I-PARTIUPAC
]		I-PARTIUPAC
-		I-PARTIUPAC
and		O
2		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
1,4		I-IUPAC
-		I-IUPAC
bis		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
phosphonomethoxy		I-IUPAC
)		I-IUPAC
ethyl		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
.		O
In		O
the		O
1,2,3,4		B-IUPAC
-		I-IUPAC
tetrahydro		I-IUPAC
[		I-IUPAC
1		I-IUPAC
]		I-IUPAC
benzothieno		I-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
c		I-IUPAC
]		I-IUPAC
pyridine		I-IUPAC
series		B-MODIFIER
,		O
the		O
presence		O
of		O
ethyl		O
ester		O
(		O
3b		O
)		O
or		O
cyclohexyl		O
carboxamide		O
(		O
7		O
)		O
groups		O
at		O
C		O
-		O
3		O
conferred		O
good		O
anticonflict		O
activity		O
and		O
lessening		O
of		O
memory		O
impairment		O
,		O
while		O
N		O
-		O
acylation		O
of		O
3b		O
abolished		O
activity		O
.		O
Two		O
-		O
dimensional		O
correlation		O
spectroscopy		O
(		O
2D		O
-		O
COSY		O
)		O
studies		O
also		O
show		O
connectivities		O
for		O
four		O
cytosine		O
H5		O
-		O
H6		O
and		O
eight		O
thymine		O
methyl		O
-		O
H6		O
protons		O
and		O
thus		O
clearly		O
establish		O
the		O
presence		O
of		O
two		O
distinct		O
species		O
of		O
tomaymycin		O
-		O
d		O
(		O
ATGCAT		O
)		O
2		O
adducts		O
in		O
solution		O
.		O
These		O
inhibitors		O
generally		O
show		O
high		O
selectivity		O
for		O
tryptase		O
,		O
being		O
40		O
-		O
fold		O
weaker		O
inhibitors		O
of		O
elastase		O
,		O
being		O
100		O
-		O
fold		O
weaker		O
against		O
trypsin		O
,		O
and		O
showing		O
no		O
inhibition		O
against		O
thrombin		O
.		O
The		O
acenaphthene		B-IUPAC
derivative		B-MODIFIER
(		B-IUPAC
+		I-IUPAC
)		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
[		I-IUPAC
7		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
pyrrolidinyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
oxaspiro		I-IUPAC
[		I-IUPAC
4.5		I-IUPAC
]		I-IUPAC
dec		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
]		I-IUPAC
acenaphthenecarboxamide		I-IUPAC
monohydrochloride		I-IUPAC
(		O
9		O
)		O
was		O
found		O
to		O
have		O
high		O
kappa		O
opioid		O
receptor		O
affinity		O
and		O
selectivity		O
(		O
kappa		O
Ki		O
=		O
0.37		O
+		O
/		O
-		O
0.05		O
nM		O
,		O
mu		O
/		O
kappa		O
=		O
659		O
,		O
delta		O
/		O
kappa		O
=		O
1562		O
)		O
and		O
is		O
100		O
times		O
more		O
potent		O
than		O
morphine		O
as		O
an		O
analgesic		O
in		O
the		O
rat		O
paw		O
pressure		O
test		O
for		O
analgesia		O
after		O
intravenous		O
administration		O
(		O
MPE50		O
=		O
0.014		O
and		O
1.4		O
mg		O
/		O
kg		O
,		O
respectively		O
)		O
.		O
The		O
optimal		O
compound		O
was		O
the		O
spiro		O
analogue		O
of		O
compound		O
11a		O
.		O
The		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
acylethynyl		I-IUPAC
)		I-IUPAC
uracils		I-IUPAC
were		O
found		O
to		O
be		O
active		O
against		O
Ehrlich		O
ascites		O
carcinoma		O
(		O
EAC		O
)		O
cells		O
in		O
vivo		O
,		O
the		O
most		O
active		O
compounds		O
being		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
benzoylethynyl		I-IUPAC
)		I-IUPAC
uracil		I-IUPAC
(		O
11		O
)		O
and		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
p		I-IUPAC
-		I-IUPAC
toluoylethynyl		I-IUPAC
)		I-IUPAC
uracil		I-IUPAC
(		O
12		O
)		O
.		O
Several		O
of		O
the		O
amino		O
glycoside		O
unsubstituted		O
14		B-IUPAC
-		I-IUPAC
thiaadriamycin		I-IUPAC
analogues		B-MODIFIER
exhibited		O
DNA		O
-		O
binding		O
properties		O
equivalent		O
to		O
those		O
of		O
adriamycin		O
.		O
A		O
Reformatsky		O
reaction		O
was		O
utilized		O
to		O
extend		O
the		O
polyene		O
chain		O
of		O
the		O
starting		O
enone		O
,		O
which		O
provided		O
exclusively		O
the		O
9Z		O
-		O
configuration		O
for		O
the		O
intermediate		O
aldehyde		O
.		O
We		O
describe		O
the		O
synthesis		O
and		O
some		O
pharmacological		O
properties		O
of		O
16		O
new		O
in		O
vivo		O
antagonists		O
of		O
oxytocin		O
.		O
Such		O
compounds		O
had		O
in		O
vitro		O
dissociation		O
constants		O
(		O
KB		O
)		O
in		O
the		O
range		O
10		O
(		O
-		O
9		O
)		O
-		O
10		O
(		O
-		O
11		O
)		O
M		O
on		O
guinea		O
pig		O
trachea		O
against		O
LTE4		O
as		O
agonist		O
and		O
inhibition		O
constants		O
(		O
Ki		O
)		O
less		O
than		O
or		O
equal		O
to		O
10		O
(		O
-		O
9		O
)		O
M		O
on		O
guinea		O
pig		O
parenchymal		O
membranes		O
against		O
[		O
3H		O
]		O
LTD4		O
.		O
Under		O
these		O
conditions		O
some		O
of		O
the		O
activity		O
was		O
later		O
recovered		O
.		O
The		O
ester		O
1b		O
displayed		O
activity		O
about		O
one		O
-		O
half		O
log		O
unit		O
less		O
than		O
that		O
of		O
the		O
reference		O
while		O
1c		O
and		O
1e		O
had		O
activity		O
nearly		O
one		O
log		O
until		O
less		O
than		O
trans		O
-		O
retinoic		O
acid		O
.		O
The		O
intrinsic		O
activities		O
of		O
the		O
compounds		O
at		O
DA		O
D2		O
and		O
D3		O
receptors		O
were		O
evaluated		O
in		O
a		O
[		O
35S		O
]		O
GTP		O
gamma		O
S		O
binding		O
assay		O
.		O
Both		O
thieno2		B-IUPAC
,		I-IUPAC
3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
and		O
thieno3		B-IUPAC
,		I-IUPAC
2		I-IUPAC
-		I-IUPAC
d		I-IUPAC
fused		O
oxazin		B-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
ones		I-IUPAC
possess		O
extraordinary		O
chemical		O
stability		O
,		O
which		O
was		O
expressed		O
as		O
rate		O
constants		O
of		O
the		O
alkaline		O
hydrolysis		O
.		O
Conversion		O
of		O
the		O
5		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
group		B-MODIFIER
of		O
CGS15943		O
to		O
an		O
oxo		O
function		O
resulted		O
in		O
lower		O
affinity		O
but		O
15		O
-		O
fold		O
selectivity		O
for		O
human		O
A3		O
receptors		O
.		O
The		O
structure		O
of		O
the		O
new		O
heterocyclic		O
compound		O
5		O
was		O
confirmed		O
by		O
1H		O
NMR		O
,		O
mass		O
spectrum		O
,		O
and		O
X		O
-		O
ray		O
crystallography		O
.		O
The		O
biological		O
data		O
support		O
the		O
hypothesis		O
that		O
the		O
increase		O
in		O
binding		O
affinity		O
for		O
PK		O
-		O
C		O
shown		O
by		O
some		O
of		O
these		O
constrained		O
DAG		O
mimetics		O
appears		O
to		O
be		O
entropic		O
in		O
nature		O
.		O
2		B-IUPAC
-		I-IUPAC
Cl		I-IUPAC
-		I-IUPAC
(		I-IUPAC
N		I-IUPAC
)		I-IUPAC
-		I-IUPAC
methanocarba		I-IUPAC
-		I-IUPAC
ATP		I-IUPAC
and		O
its		O
N		O
(		O
6		O
)		O
-		O
Me		O
analogue		O
were		O
also		O
highly		O
selective		O
,		O
full		O
agonists		O
at		O
P2Y		O
(		O
1		O
)		O
receptors		O
.		O
The		O
electrophysiology		O
results		O
obtained		O
with		O
the		O
24		B-IUPAC
-		I-IUPAC
oxo		I-IUPAC
-		I-IUPAC
cyclosteroids		I-IUPAC
suggest		O
that		O
rat		O
alpha		O
(		O
1		O
)		O
beta		O
(		O
2		O
)		O
gamma		O
(		O
2L		O
)		O
GABA		O
(		O
A		O
)		O
receptors		O
contain		O
more		O
than		O
one		O
donor		O
for		O
the		O
hydrogen		O
-		O
bond		O
-		O
acceptor		O
group		O
of		O
anesthetic		O
steroids		O
.		O
Whereas		O
none		O
of		O
these		O
compounds		O
significantly		O
affected		O
GABAB		O
receptor		O
binding		O
or		O
GABA		O
uptake		O
,		O
they		O
showed		O
affinities		O
for		O
GABAA		O
receptor		O
sites		O
in		O
the		O
low		O
-		O
micromolar		O
range		O
.		O
In		O
spite		O
of		O
this		O
fact		O
,		O
7		O
of		O
the		O
17		O
analogues		O
(		O
1		O
,		O
2		O
,		O
8-10		O
,		O
16		O
,		O
and		O
17		O
)		O
have		O
stronger		O
anticataleptic		O
effect		O
than		O
TRH		O
,		O
with		O
negligible		O
or		O
no		O
hormonal		O
potency		O
.		O
Inhibition		O
by		O
5		B-IUPAC
-		I-IUPAC
fluoroorotyl		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
leucyl		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
leucine		I-IUPAC
was		O
competitive		O
as		O
judged		O
using		O
double		O
-		O
reciprocal		O
plots		O
.		O
In		O
contrast		O
,		O
the		O
reaction		O
of		O
1		O
and		O
2		O
was		O
limited		O
to		O
the		O
addition		O
of		O
a		O
single		O
molecule		O
of		O
glutamic		O
acid		O
.		O
In		O
vivo		O
experiments		O
with		O
rats		O
show		O
that		O
[		O
125I		O
]		O
(		O
S		O
)		O
-		O
6b		O
penetrates		O
readily		O
into		O
the		O
brain		O
and		O
is		O
preferentially		O
localized		O
in		O
the		O
striatum		O
as		O
compared		O
to		O
the		O
cerebellum		O
,		O
the		O
ratio		O
of		O
uptake		O
being		O
7.2		O
to		O
1		O
,		O
60		O
min		O
after		O
injection		O
.		O
To		O
confirm		O
the		O
presence		O
of		O
DiHPhe		O
in		O
the		O
analogue		O
,		O
an		O
enzymatic		O
procedure		O
employing		O
Aspergillus		O
oryzae		O
was		O
developed		O
that		O
liberates		O
in		O
high		O
yield		O
the		O
amino		O
acid		O
residue		O
in		O
position		O
3		O
of		O
the		O
posterior		O
pituitary		O
hormone		O
structure		O
.		O
On		O
the		O
other		O
hand		O
,		O
compounds		O
7d		O
and		O
7n		O
are		O
time		O
-		O
dependent		O
inhibitors		O
with		O
a		O
saturable		O
initial		O
complex		O
.		O
With		O
a		O
tetrazole		O
in		O
the		O
distal		O
acid		O
position		O
,		O
an		O
ethylene		O
spacer		O
(		O
9		O
)		O
is		O
optimal		O
;		O
substitution		O
with		O
oxygen		O
or		O
nitrogen		O
on		O
the		O
chain		O
in		O
the		O
position		O
adjacent		O
to		O
the		O
bicyclic		O
nucleus		O
significantly		O
reduced		O
activity		O
,		O
while		O
substitution		O
with		O
a		O
methyl		O
or		O
phenyl		O
group		O
on		O
the		O
chain		O
was		O
well		O
tolerated		O
.		O
The		O
metabolite		O
-		O
corrected		O
blood		O
radioactivity		O
had		O
a		O
half		O
-		O
life		O
of		O
29		O
min		O
.		O
By		O
contrast		O
,		O
the		O
4		B-IUPAC
-		I-IUPAC
phenyltetrahydropyranone		I-IUPAC
(		O
3		O
)		O
inactivated		O
alpha		O
-		O
chymotrypsin		O
in		O
a		O
time		O
-		O
dependent		O
manner		O
.		O
A		O
number		O
of		O
derivatives		O
structurally		O
related		O
to		O
cirazoline		O
(		O
1		O
)		O
were		O
synthesized		O
and		O
studied		O
with		O
the		O
purpose		O
of		O
modulating		O
alpha2		O
-		O
adrenoreceptors		O
selectivity		O
versus		O
both		O
alpha1		O
-		O
adrenoreceptors		O
and		O
I2		O
imidazoline		O
binding		O
sites		O
.		O
The		O
acetates		O
of		O
1,4		B-IUPAC
-		I-IUPAC
dihydronaphthoquinones		I-IUPAC
containing		O
the		O
alkyl		O
substituent		O
(		O
s		O
)		O
(		O
2		B-IUPAC
-		I-IUPAC
n		I-IUPAC
-		I-IUPAC
butyl		I-IUPAC
,		O
11		O
,		O
and		O
2,3		B-IUPAC
-		I-IUPAC
diethyl		I-IUPAC
,		O
15		O
)		O
exhibited		O
the		O
best		O
activity		O
in		O
LTC4		O
/		O
D4		O
inhibition		O
(		O
IC50		O
=		O
0.2-0.4		O
microM		O
,		O
in		O
vitro		O
)		O
as		O
well		O
as		O
in		O
LTB4		O
inhibition		O
(		O
60-75%		O
inhibition		O
)		O
.		O
The		O
linear		O
octadentate		O
ligand		O
3,4,3		O
-		O
LIHOPO		O
,		O
which		O
contains		O
four		O
1		B-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
2		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
pyridinone		I-IUPAC
(		O
1,2		O
-		O
HOPO		O
)		O
groups		O
,		O
is		O
the		O
most		O
effective		O
agent		O
for		O
in		O
vivo		O
chelation		O
of		O
Pu		O
(		O
IV		O
)		O
yet		O
prepared		O
.		O
The		O
compounds		O
were		O
prepared		O
by		O
condensing		O
4		B-IUPAC
,		I-IUPAC
6		I-IUPAC
-		I-IUPAC
diaminonicotinaldehyde		I-IUPAC
with		O
2,6		B-IUPAC
-		I-IUPAC
dichlorophenylacetonitrile		I-IUPAC
and		O
selectively		O
converting		O
the		O
2		O
-		O
and		O
7		O
-		O
amino		O
groups		O
of		O
the		O
product		O
to		O
hydroxy		O
and		O
fluoro		O
groups		O
,		O
respectively		O
,		O
by		O
prolonged		O
diazotization		O
in		O
50%		O
aqueous		O
fluoboric		O
acid		O
.		O
The		O
compounds		O
that		O
bear		O
a		O
3		B-IUPAC
-		I-IUPAC
dimethylaminopropyl		I-IUPAC
substituent		B-MODIFIER
on		O
the		O
quinolone		O
nitrogen		O
(		O
3b		O
,		O
3c		O
-		O
f		O
,		O
3h		O
)		O
showed		O
higher		O
antitumor		O
activity		O
than		O
compounds		O
bearing		O
the		O
same		O
substituent		O
on		O
the		O
amidic		O
nitrogen		O
(		O
7a		O
and		O
7b		O
)		O
.		O
Finally		O
,		O
we		O
have		O
employed		O
conventional		O
MD		O
simulations		O
to		O
investigate		O
the		O
structural		O
perturbations		O
caused		O
by		O
each		O
mutation		O
to		O
further		O
examine		O
the		O
role		O
played		O
by		O
each		O
individual		O
residue		O
in		O
PKC		O
-		O
ligand		O
binding		O
.		O
None		O
of		O
the		O
new		O
nucleosides		O
or		O
heterocycles		O
displayed		O
selective		O
activity		O
against		O
human		O
cytomegalovirus		O
(		O
HCMV		O
)		O
or		O
herpes		O
simplex		O
virus		O
type		O
1		O
(		O
HSV		O
-		O
1		O
)		O
.		O
Its		O
potency		O
was		O
comparable		O
with		O
TCP		O
in		O
vitro		O
.		O
With		O
these		O
results		O
,		O
the		O
order		O
of		O
importance		O
of		O
five		O
-		O
membered		O
ring		O
lactones		O
as		O
competent		O
templates		O
for		O
the		O
construction		O
of		O
semirigid		O
DAG		O
surrogates		O
with		O
effective		O
PK		O
-		O
C		O
binding		O
affinity		O
can		O
be		O
established		O
as		O
II		O
&		O
gt		O
;		O
&		O
gt		O
;		O
I		O
approximately		O
III		O
&		O
gt		O
;		O
IV		O
.		O
In		O
colony		O
formation		O
assays		O
against		O
the		O
human		O
head		O
and		O
neck		O
squamous		O
carcinoma		O
cell		O
line		O
SCC25		O
after		O
72		O
h		O
of		O
treatment		O
,		O
the		O
5		B-PARTIUPAC
-		I-PARTIUPAC
and		O
8		B-IUPAC
-		I-IUPAC
deaza		I-IUPAC
analogues		B-MODIFIER
were		O
approximately		O
as		O
potent		O
as		O
3		O
,		O
whereas		O
the		O
5,8		B-IUPAC
-		I-IUPAC
dideaza		I-IUPAC
analogue		B-MODIFIER
was		O
3		O
times		O
more		O
potent		O
.		O
These		O
procedures		O
involved		O
site		O
-		O
specific		O
triazolation		O
or		O
N		O
-		O
methylimidazolation		O
at		O
position		O
C		O
(		O
4		O
)		O
,		O
followed		O
by		O
hydroxylamination		O
and		O
deblocking		O
with		O
MeOH		O
-		O
NH		O
(		O
3		O
)		O
.		O
First		O
,		O
the		O
disulfide		O
bridge		O
of		O
this		O
lead		O
compound		O
was		O
shifted		O
and		O
then		O
the		O
modified		O
peptide		O
was		O
shortened		O
from		O
the		O
amino		O
and		O
carboxy		O
terminus		O
to		O
generate		O
cyclo		O
[		O
21,29		O
]		O
[		O
Cys		O
(		O
21,29		O
)		O
]		O
-		O
uPA		O
(		O
21		O
)		O
(		O
-		O
)		O
(		O
30		O
)		O
.		O
S		O
-		O
Alkylation		O
of		O
5		B-IUPAC
-		I-IUPAC
alkyl		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
arylmethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
thiouracils		I-IUPAC
1-4		O
was		O
performed		O
with		O
2		B-IUPAC
-		I-IUPAC
bromoacetaldehyde		I-IUPAC
acetals		I-IUPAC
to		O
furnish		O
the		O
S		B-IUPAC
-		I-IUPAC
[		I-IUPAC
bis		I-IUPAC
(		I-IUPAC
alkoxy		I-IUPAC
)		I-IUPAC
ethyl		I-IUPAC
]		I-IUPAC
derivatives		B-MODIFIER
5-8		O
and		O
with		O
allyl		O
bromide		O
to		O
furnish		O
S		B-IUPAC
-		I-IUPAC
allyl		I-IUPAC
derivatives		B-MODIFIER
17		O
.		O
Potent		O
anxiolytic		O
activity		O
in		O
the		O
black		O
/		O
white		O
box		O
exploration		O
test		O
in		O
rats		O
was		O
found		O
with		O
the		O
two		O
most		O
prominent		O
sigma		O
2		O
ligands		O
Lu		O
29-253		O
and		O
Lu		O
28-179		O
.		O
To		O
provide		O
a		O
firm		O
basis		O
for		O
comparison		O
purposes		O
of		O
future		O
analogues		O
,		O
an		O
X		O
-		O
ray		O
analysis		O
was		O
performed		O
on		O
a		O
single		O
crystal		O
of		O
ethyl		B-IUPAC
(		I-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
p		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4,4		I-IUPAC
-		I-IUPAC
dimethylthiochroman		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
propenyl		I-IUPAC
]		I-IUPAC
benzoate		I-IUPAC
(		O
1b		O
)		O
and		O
a		O
precursor		O
4,4		B-IUPAC
-		I-IUPAC
dimethylthiochroman		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
methyl		I-IUPAC
ketone		I-IUPAC
1,1		I-IUPAC
-		I-IUPAC
dioxide		I-IUPAC
(		O
18		O
)		O
.		O
4		B-IUPAC
-		I-IUPAC
Hydroxyestradiol		I-IUPAC
has		O
weaker		O
affinity		O
for		O
the		O
estrogen		O
receptor		O
and		O
exhibits		O
lower		O
estrogenic		O
activity		O
in		O
vivo		O
;		O
on		O
the		O
other		O
hand		O
,		O
the		O
catechol		O
estrogens		O
are		O
prone		O
to		O
further		O
oxidative		O
metabolism		O
and		O
can		O
form		O
reactive		O
intermediates		O
.		O
The		O
affinity		O
for		O
A2		O
receptors		O
of		O
these		O
compounds		O
was		O
very		O
low		O
or		O
negligible		O
.		O
4		B-IUPAC
-		I-IUPAC
Amino		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
deoxy		I-IUPAC
-		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
erythro		I-IUPAC
-		I-IUPAC
pentofuranosyl		I-IUPAC
)		I-IUPAC
pyrrolo		I-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrida		I-IUPAC
zin		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
one		I-IUPAC
(		O
13		O
)		O
was		O
prepared		O
by		O
the		O
sodium		O
salt		O
condensation		O
of		O
ethyl		B-IUPAC
3		I-IUPAC
-		I-IUPAC
cyanopyrrole		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
carboxylate		I-IUPAC
(		O
5		O
)		O
with		O
2		B-IUPAC
-		I-IUPAC
deoxy		I-IUPAC
-		I-IUPAC
3,5		I-IUPAC
-		I-IUPAC
di		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
p		I-IUPAC
-		I-IUPAC
toluoyl		I-IUPAC
-		I-IUPAC
alpha		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
erythro		I-IUPAC
-		I-IUPAC
pentofuranosyl		I-IUPAC
chloride		I-IUPAC
(		O
11		O
)		O
followed		O
by		O
ring		O
annulation		O
with		O
hydrazine		O
.		O
Treatment		O
of		O
1		O
with		O
benzyl		B-IUPAC
bromide		I-IUPAC
gave		O
4		B-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
benzylpyrazofurin		I-IUPAC
(		O
4		O
)		O
.		O
Reacting		O
free		O
TRODAT		O
-		O
1		O
ligand		O
with		O
[		O
Bu4N		O
]		O
[		O
ReOCl4		O
]		O
yielded		O
two		O
major		O
complexes		O
:		O
Re		O
-		O
TRODAT		O
-		O
1A		O
(		O
3A		O
)		O
and		O
Re		O
-		O
TRODAT		O
-		O
1B		O
(		O
3B		O
)		O
(		O
corresponding		O
with		O
peaks		O
A		O
and		O
B		O
of		O
[		O
99mTc		O
]		O
TRODAT		O
-		O
1		O
,		O
respectively		O
)		O
,		O
whose		O
structures		O
were		O
determined		O
by		O
X		O
-		O
ray		O
analysis		O
.		O
mAZ		O
-		O
pTyr		O
-		O
(		O
alphaMe		O
)		O
pTyr		O
-		O
Asn		O
-		O
NH2		O
was		O
derivatized		O
as		O
the		O
S		B-IUPAC
-		I-IUPAC
acetyl		I-IUPAC
thioester		I-IUPAC
(		O
SATE		O
)		O
of		O
the		O
phosphotyrosine		O
residues		O
,		O
and		O
its		O
surrogates		O
provided		O
prodrugs		O
with		O
very		O
potent		O
antiproliferative		O
activity		O
on		O
cells		O
overexpressing		O
HER2		O
/		O
ErbB2		O
,		O
with		O
ED50		O
values		O
amounting		O
to		O
0.1		O
microM		O
.		O
Replacement		O
of		O
the		O
2'		B-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
group		B-MODIFIER
of		O
(		B-IUPAC
+		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
benzyl		I-IUPAC
-		I-IUPAC
5,9		I-IUPAC
alpha		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
6,7		I-IUPAC
-		I-IUPAC
benzomorphan		I-IUPAC
[		O
(		O
+		O
)		O
-		O
1f		O
]		O
with		O
a		O
2'		O
-		O
NH2		O
and		O
2'		O
-		O
N		O
(		O
CH3		O
)		O
2		O
[		O
(		O
+		O
)		O
-		O
3b		O
and		O
(		O
+		O
)		O
-		O
3c		O
,		O
respectively		O
]		O
had		O
only		O
a		O
small		O
effect		O
on		O
the		O
sigma		O
1		O
Ki		O
values		O
.		O
Beside		O
the		O
central		O
dopaminergic		O
effects		O
of		O
these		O
compounds		O
,		O
previously		O
reported		O
sigma		O
receptor		O
affinity		O
data		O
[		O
[		B-IUPAC
3H		I-IUPAC
]		I-IUPAC
-		I-IUPAC
(		I-IUPAC
+		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
hydroxyphenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
n		I-IUPAC
-		I-IUPAC
propylpiperidine		I-IUPAC
;		O
[		O
3H		O
]		O
-		O
(		O
+		O
)		O
-		O
3		O
-		O
PPP		O
]		O
were		O
also		O
taken		O
into		O
account		O
for		O
a		O
comparison		O
of		O
the		O
structure		O
-		O
activity		O
/		O
affinity		O
relationships		O
of		O
these		O
compounds		O
at		O
these		O
two		O
receptor		O
types		O
.		O
The		O
range		O
of		O
log		O
Dcomplex		O
values		O
covers		O
7		O
orders		O
of		O
magnitude		O
.		O
The		O
target		O
N9		O
-		O
H		O
analogues		O
were		O
obtained		O
via		O
regiospecific		O
reductive		O
amination		O
of		O
the		O
appropriate		O
benzaldehydes		O
with		O
2,4,6		B-IUPAC
-		I-IUPAC
triaminoquinazoline		I-IUPAC
,		O
which		O
,		O
in		O
turn		O
,		O
was		O
synthesized		O
from		O
2,4		B-IUPAC
-		I-IUPAC
diamino		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
nitroquinazoline		I-IUPAC
.		O
The		O
four		O
isomers		O
were		O
synthesized		O
by		O
a		O
modified		O
Hantzsch		O
synthesis		O
by		O
reaction		O
of		O
(		B-PARTIUPAC
-		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
or		O
(		B-IUPAC
+		I-IUPAC
)		I-IUPAC
-		I-IUPAC
tetrahydrofuran		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
ylmethyl		I-IUPAC
3		I-IUPAC
-		I-IUPAC
aminocrotonate		I-IUPAC
and		O
methyl		B-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
nitrophenyl		I-IUPAC
)		I-IUPAC
methylene		I-IUPAC
]		I-IUPAC
acetoacetate		I-IUPAC
or		O
,		O
alternatively		O
,		O
by		O
reaction		O
of		O
(		B-PARTIUPAC
-		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
or		O
(		B-IUPAC
+		I-IUPAC
)		I-IUPAC
-		I-IUPAC
tetrahydrofuran		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
ylmethyl		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
nitrophenyl		I-IUPAC
)		I-IUPAC
methylene		I-IUPAC
]		I-IUPAC
acetoacetate		I-IUPAC
and		O
methyl		B-IUPAC
3		I-IUPAC
-		I-IUPAC
aminocrotonate		I-IUPAC
.		O
Steric		O
factors		O
played		O
an		O
important		O
role		O
in		O
determining		O
the		O
activity		O
of		O
type		O
5		O
compounds		O
possessing		O
an		O
an		O
appropriate		O
degree		O
of		O
hydrophobic		O
character		O
.		O
Dextromethorphan		O
(		O
1		O
,		O
(		B-IUPAC
+		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
-		I-IUPAC
17		I-IUPAC
-		I-IUPAC
methylmorphinan		I-IUPAC
)		O
demonstrates		O
anticonvulsant		O
activity		O
in		O
a		O
variety		O
of		O
in		O
vitro		O
and		O
in		O
vivo		O
models		O
of		O
convulsive		O
action		O
.		O
Treatment		O
of		O
the		O
diester		O
of		O
5		B-IUPAC
-		I-IUPAC
allyl		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxyuridine		I-IUPAC
(		O
17		O
or		O
22		O
)		O
with		O
m		B-IUPAC
-		I-IUPAC
chloroperbenzoic		I-IUPAC
acid		I-IUPAC
gave		O
the		O
corresponding		O
epoxide		O
.		O
A		O
first		O
set		O
of		O
compounds		O
bearing		O
a		O
4		B-MODIFIER
-		I-MODIFIER
(		I-MODIFIER
1		I-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
)		I-MODIFIER
piperazine		O
moiety		B-MODIFIER
as		O
terminal		O
fragment		O
on		O
the		O
alkyl		B-IUPAC
chain		B-MODIFIER
showed		O
moderate		O
to		O
high		O
sigma		O
affinity		O
(		O
Ki		O
=		O
5.3-139		O
nM		O
)		O
,		O
the		O
most		O
active		O
and		O
selective		O
being		O
1		B-IUPAC
-		I-IUPAC
cyclohexyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
[		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
-		I-IUPAC
1,2,3,4		I-IUPAC
-		I-IUPAC
tetrahydronaphthalen		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
n		I-IUPAC
-		I-IUPAC
propyl		I-IUPAC
]		I-IUPAC
piperazine		I-IUPAC
(		O
14		O
)		O
,		O
with		O
probable		O
pronounced		O
sigma		O
2		O
affinity		O
(		O
Ki		O
=		O
5.3		O
nM		O
on		O
[		O
3H		O
]		O
DTG		O
and		O
Ki		O
=		O
71		O
nM		O
on		O
[		O
3H		O
]		O
-		O
(		O
+		O
)		O
-		O
pentazocine		O
)		O
.		O
Finally		O
a		O
new		O
prodrug		O
is		O
put		O
forth		O
under		O
the		O
form		O
of		O
a		O
monobenzyl		O
ester		O
of		O
phosphate		O
group		O
that		O
is		O
as		O
active		O
as		O
and		O
much		O
easier		O
to		O
synthesize		O
than		O
SATE		O
prodrugs		O
.		O
1,8		B-IUPAC
-		I-IUPAC
Naphthyridin		I-IUPAC
-		I-IUPAC
2		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
one		I-IUPAC
22		O
and		O
the		O
corresponding		O
3,4		B-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
derivative		B-MODIFIER
28		O
were		O
prepared		O
from		O
5		B-IUPAC
-		I-IUPAC
bromo		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
[		I-IUPAC
3,4		I-IUPAC
'		I-IUPAC
-		I-IUPAC
bipyridin		I-IUPAC
]		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
amine		I-IUPAC
(		O
21		O
)		O
and		O
5		B-IUPAC
-		I-IUPAC
bromo		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
[		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
bipyridin		I-IUPAC
]		I-IUPAC
-		I-IUPAC
6		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
one		I-IUPAC
(		O
24		O
)		O
,		O
respectively		O
,		O
via		O
Heck		O
reaction		O
.		O
This		O
investigation		O
revealed		O
that		O
9		B-IUPAC
(		I-IUPAC
11		I-IUPAC
)		I-IUPAC
-		I-IUPAC
en		I-IUPAC
-		I-IUPAC
12		I-IUPAC
-		I-IUPAC
one		I-IUPAC
and		O
12		B-IUPAC
-		I-IUPAC
en		I-IUPAC
-		I-IUPAC
11		I-IUPAC
-		I-IUPAC
one		I-IUPAC
functionalities		O
in		O
ring		O
C		O
increase		O
the		O
potency		O
by		O
about		O
2-10		O
times		O
compared		O
with		O
the		O
original		O
12		B-IUPAC
-		I-IUPAC
ene		I-IUPAC
.		O
The		O
pyrimidine		O
acyclonucleoside		O
5		B-IUPAC
-		I-IUPAC
fluoro		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
hydroxyethoxy		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
uracil		I-IUPAC
(		O
3		O
)		O
was		O
synthesized		O
as		O
part		O
of		O
a		O
program		O
aimed		O
at		O
the		O
development		O
of		O
new		O
5		B-IUPAC
-		I-IUPAC
fluorouracil		I-IUPAC
derivatives		B-MODIFIER
with		O
fewer		O
side		O
effects		O
and		O
a		O
broader		O
margin		O
of		O
safety		O
.		O
We		O
synthesized		O
4		B-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
(		I-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
iodomethylidene		I-IUPAC
)		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
furanone		I-IUPAC
(		O
1		O
)		O
,		O
4		B-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
(		I-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
iodomethylidene		I-IUPAC
)		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
furanone		I-IUPAC
(		O
2		O
)		O
,		O
4		B-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
6		I-IUPAC
(		I-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
iodomethylidene		I-IUPAC
)		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
pyranone		I-IUPAC
(		O
3		O
)		O
,		O
and		O
5		B-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
6		I-IUPAC
(		I-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
iodomethylidene		I-IUPAC
)		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
pyranone		I-IUPAC
(		O
4		O
)		O
,		O
using		O
a		O
halolactonization		O
reaction		O
to		O
convert		O
the		O
appropriate		O
phenyl		O
-		O
substituted		O
acetylenic		O
acid		O
precursor		O
into		O
the		O
corresponding		O
5		B-IUPAC
(		I-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
halomethylidene		I-IUPAC
)		I-IUPAC
furanone		I-IUPAC
and		O
6		B-IUPAC
(		I-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
halomethylidene		I-IUPAC
)		I-IUPAC
pyranone		I-IUPAC
system		B-MODIFIER
.		O
Two		O
types		O
of		O
compounds		O
were		O
identified		O
as		O
being		O
significantly		O
more		O
effective		O
than		O
O6		B-IUPAC
-		I-IUPAC
benzylguanine		I-IUPAC
(		O
the		O
prototype		O
low		O
molecular		O
weight		O
inactivator		O
)		O
at		O
inactivating		O
AGT		O
in		O
human		O
HT29		O
colon		O
tumor		O
cell		O
extracts		O
.		O
Hydrazinolysis		O
of		O
the		O
phthalimides		O
liberated		O
the		O
free		O
amines		O
.		O
The		O
binding		O
activity		O
for		O
the		O
more		O
potent		O
bicyclic		O
hydantoin		O
,		O
1,8		B-IUPAC
-		I-IUPAC
diaza		I-IUPAC
-		I-IUPAC
9,10		I-IUPAC
-		I-IUPAC
dioxo		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
phenylbicyclo		I-IUPAC
[		I-IUPAC
5.2.1		I-IUPAC
]		I-IUPAC
decane		I-IUPAC
(		O
4		O
)		O
(		O
IC50		O
=		O
427		O
microM		O
)		O
,		O
was		O
comparable		O
to		O
that		O
of		O
the		O
ring		O
-		O
opened		O
,		O
N3		O
-		O
methylated		O
monocyclic		O
hydantoin		O
model		O
,		O
5		B-IUPAC
-		I-IUPAC
butyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
phenylhydantoin		I-IUPAC
(		O
9		O
)		O
(		O
IC50		O
=		O
285		O
microM		O
)		O
,		O
and		O
these		O
were		O
8-11		O
times		O
less		O
potent		O
than		O
the		O
monocyclic		O
model		O
8		O
,		O
which		O
contains		O
a		O
free		O
imide		O
NH		O
.		O
3.1.1.1		O
)		O
to		O
the		O
labile		O
4		B-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
analogue		B-MODIFIER
2a		O
,		O
which		O
should		O
penetrate		O
cells		O
by		O
passive		O
diffusion		O
and		O
ring		O
open		O
to		O
the		O
aldehyde		O
3a		O
.		O
This		O
uncommon		O
ring		O
system		O
was		O
obtained		O
in		O
a		O
highly		O
substituted		O
form		O
and		O
in		O
high		O
yield		O
by		O
ozonolysis		O
of		O
the		O
enamine		O
bond		O
of		O
1,2,3,4		B-IUPAC
-		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
9H		I-IUPAC
-		I-IUPAC
pyrido		I-IUPAC
[		I-IUPAC
3		I-IUPAC
,		I-IUPAC
4		I-IUPAC
-		I-IUPAC
b		I-IUPAC
]		I-IUPAC
indole		I-IUPAC
derivatives		B-MODIFIER
(		O
4		O
)		O
,		O
in		O
which		O
the		O
configuration		O
of		O
the		O
substituents		O
was		O
established		O
stereoselectively		O
via		O
the		O
Pictet		O
-		O
Spengler		O
reaction		O
.		O
Analogue		O
6c		O
showed		O
16.7%		O
ILS		O
in		O
leukemia		O
P388		O
/		O
o		O
implanted		O
ip		O
in		O
mice		O
at		O
510		O
and		O
1020		O
mg		O
/		O
kg		O
,		O
respectively		O
.		O
In		O
subsequent		O
studies		O
,		O
compounds		O
17a		O
and		O
17c		O
were		O
found		O
to		O
stimulate		O
the		O
efflux		O
of		O
(		O
86		O
)		O
Rb		O
(		O
+		O
)		O
from		O
rat		O
cortical		O
synaptosomes		O
,		O
an		O
indication		O
of		O
agonist		O
activity		O
.		O
Compound		O
5		O
did		O
not		O
bind		O
with		O
appreciable		O
activity		O
to		O
the		O
[		O
3H		O
]		O
1		O
site		O
,		O
in		O
rat		O
brain		O
,		O
but		O
did		O
bind		O
to		O
the		O
[		O
3H		O
]		O
TCP		O
site		O
with		O
lower		O
potency		O
than		O
the		O
parent		O
1		O
(		O
IC50		O
7.8		O
and		O
2.0		O
microM		O
,		O
respectively		O
)		O
.		O
avium		O
DHFR		O
relative		O
to		O
rat		O
DHFR		O
.		O
The		O
most		O
potent		O
compounds		O
(		O
3b		O
,		O
7		O
,		O
and		O
12a		O
)		O
were		O
also		O
administered		O
orally		O
and		O
had		O
potent		O
anticonflict		O
and		O
antiscopolamine		O
amnesia		O
-		O
reversal		O
activity		O
.		O
Interestingly		O
,		O
the		O
4'		O
-		O
Cl		O
analogue		O
(		O
+		O
/		O
-		O
)		O
-		O
6		O
substituted		O
less		O
in		O
rats		O
trained		O
to		O
discriminate		O
cocaine		O
than		O
the		O
4'		O
-		O
F		O
analogue		O
(		O
+		O
/		O
-		O
)		O
-		O
5		O
.		O
In		O
these		O
assay		O
systems		O
,		O
the		O
(		O
2R		O
,		O
3S		O
)		O
-		O
beta		O
-		O
MePhe4		O
-		O
containing		O
analogue		O
5		O
had		O
very		O
weak		O
potency		O
and		O
virtually		O
no		O
receptor		O
selectivity		O
(		O
4.4		O
-		O
fold		O
)		O
.		O
To		O
specify		O
kinetic		O
parameters		O
of		O
inhibition		O
,		O
a		O
new		O
method		O
was		O
derived		O
to		O
characterize		O
selected		O
thieno		B-IUPAC
[		I-IUPAC
1,3		I-IUPAC
]		I-IUPAC
oxazin		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
ones		I-IUPAC
as		O
hyperbolic		O
mixed		O
-		O
type		O
inhibitors		O
of		O
AChE		O
.		O
Treatment		O
of		O
the		O
S		B-IUPAC
-		I-IUPAC
allyl		I-IUPAC
derivatives		B-MODIFIER
17		O
with		O
bromine		O
in		O
dry		O
methylene		O
chloride		O
afforded		O
the		O
3		B-IUPAC
-		I-IUPAC
(		I-IUPAC
bromomethyl		I-IUPAC
)		I-IUPAC
derivatives		B-MODIFIER
18		O
.		O
0		I-IUPAC
(		I-IUPAC
3,7		I-IUPAC
)		I-IUPAC
]		I-IUPAC
decane		I-IUPAC
-		I-IUPAC
2beta		I-IUPAC
-		I-IUPAC
carboxylic		I-IUPAC
acid		I-IUPAC
methyl		I-IUPAC
ester		I-IUPAC
(		O
5a		O
)		O
is		O
a		O
selective		O
inhibitor		O
of		O
norepinephrine		O
reuptake		O
(		O
K		O
(		O
i		O
)		O
=		O
12		O
nM		O
)		O
.		O
This		O
compound		O
5a		O
potently		O
blocked		O
3H		O
-		O
SP		O
binding		O
to		O
guinea		O
pig		O
lung		O
membranes		O
with		O
IC50		O
of		O
(		O
5.8		O
+		O
/		O
-		O
0.78		O
)		O
x		O
10		O
(		O
-		O
9		O
)		O
M		O
.		O
Thus		O
compound		O
39		O
is		O
the		O
most		O
potent		O
and		O
selective		O
H1		O
receptor		O
agonist		O
reported		O
so		O
far		O
.		O
Several		O
of		O
the		O
more		O
potent		O
derivatives		O
effectively		O
antagonized		O
the		O
effects		O
of		O
an		O
agonist		O
in		O
a		O
functional		O
A3		O
receptor		O
assay		O
,		O
i.e.		O
inhibition		O
of		O
adenylyl		B-IUPAC
cyclase		I-IUPAC
in		O
CHO		O
cells		O
expressing		O
cloned		O
rat		O
A3		O
receptors		O
.		O
Similar		O
phosphorylation		O
of		O
4		O
with		O
POCl3		O
and		O
quenching		O
the		O
reaction		O
mixture		O
with		O
either		O
EtOH		O
or		O
MeOH		O
,		O
followed		O
by		O
debenzylation		O
,		O
furnished		O
the		O
5'		B-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
(		I-IUPAC
ethyl		I-IUPAC
phosphate		I-IUPAC
)		I-IUPAC
(		O
19b		O
)		O
and		O
5'		B-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
(		I-IUPAC
dimethyl		I-IUPAC
phosphate		I-IUPAC
)		I-IUPAC
(		O
20b		O
)		O
derivatives		O
of		O
pyrazofurin		O
.		O
The		O
resulting		O
compounds		O
retained		O
high		O
affinity		O
and		O
selectivity		O
for		O
A		O
(		O
1		O
)		O
ARs		O
.		O
The		O
derivatives		O
were		O
evaluated		O
for		O
in		O
vitro		O
cytoxicity		O
against		O
five		O
human		O
tumor		O
cell		O
lines		O
,		O
including		O
HepG2		O
,		O
TSGH		O
8302		O
,		O
COLO		O
205		O
,		O
KB		O
,		O
and		O
MOLT		O
-		O
4		O
.		O
These		O
compounds		O
are		O
useful		O
models		O
for		O
research		O
to		O
determine		O
the		O
molecular		O
basis		O
of		O
the		O
strong		O
enhancement		O
of		O
carcinogenicity		O
consequent		O
upon		O
methyl		B-IUPAC
substitution		B-MODIFIER
in		O
nonbenzo		O
bay		O
molecular		O
sites		O
and		O
meso		O
regions		O
of		O
polycyclic		O
hydrocarbons		O
.		O
Herein		O
,		O
we		O
describe		O
the		O
synthesis		O
of		O
a		O
series		O
of		O
novel		O
N		B-MODIFIER
-		I-MODIFIER
and		O
2		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
-		O
3alpha		B-PARTIUPAC
-		I-PARTIUPAC
[		I-PARTIUPAC
bis		I-PARTIUPAC
(		I-PARTIUPAC
4		I-PARTIUPAC
-		I-PARTIUPAC
fluoro		I-PARTIUPAC
-		I-PARTIUPAC
or		O
4		B-IUPAC
-		I-IUPAC
chlorophenyl		I-IUPAC
)		I-IUPAC
methoxy		I-IUPAC
]		I-IUPAC
tropane		I-IUPAC
analogues		B-MODIFIER
.		O
A		O
comparison		O
of		O
the		O
brain		O
uptake		O
of		O
the		O
N		B-IUPAC
-		I-IUPAC
isopropyl		I-IUPAC
derivative		B-MODIFIER
with		O
the		O
2		B-IUPAC
(		I-IUPAC
RS		I-IUPAC
)		I-IUPAC
-		I-IUPAC
aminopropyl		I-IUPAC
analogue		B-MODIFIER
demonstrated		O
higher		O
initial		O
brain		O
uptake		O
and		O
brain		O
to		O
blood		O
ratios		O
(		O
5		O
min		O
,		O
3.2%		O
dose		O
/		O
g		O
;		O
10.3/1		O
)		O
but		O
more		O
rapid		O
washout		O
(		O
30		O
min		O
,		O
1.37%		O
dose		O
;		O
2.8/1		O
)		O
.		O
This		O
effect		O
is		O
even		O
more		O
marked		O
when		O
the		O
N		B-IUPAC
-		I-IUPAC
chloroethyl		I-IUPAC
group		B-MODIFIER
is		O
in		O
the		O
exocyclic		O
position		O
since		O
the		O
order		O
of		O
stability		O
is		O
1d		O
&		O
gt		O
;		O
1c		O
&		O
gt		O
;		O
1b		O
&		O
gt		O
;		O
1a		O
.		O
In		O
contrast		O
with		O
cisplatin		O
and		O
carboplatin		O
,		O
five		O
complexes		O
selected		O
significantly		O
increased		O
in		O
life		O
span		O
in		O
mice		O
transplanted		O
with		O
cisplatin		O
-		O
resistant		O
L1210		O
cells		O
.		O
In		O
competitive		O
inhibition		O
experiments		O
,		O
all		O
the		O
analogues		O
caused		O
a		O
right		O
shift		O
of		O
the		O
glucagon		O
-		O
stimulated		O
adenylate		O
cyclase		O
dose		O
-		O
response		O
curve		O
.		O
Whereas		O
a		O
number		O
of		O
the		O
carboxamide		O
(		O
5		O
)		O
and		O
thioamide		O
(		O
6		O
)		O
derivatives		O
had		O
modest		O
activity		O
,		O
the		O
corresponding		O
nitrile		B-IUPAC
analogs		B-MODIFIER
(		O
4		O
)		O
were		O
all		O
inactive		O
.		O
Other		O
nitrogen		O
lone		O
pair		O
orientations		O
or		O
compounds		O
representing		O
unlikely		O
staggered		O
conformations		O
of		O
1		O
[		O
as		O
in		O
4		B-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
dichlorophenyl		I-IUPAC
)		I-IUPAC
ethyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
1,4		I-IUPAC
-		I-IUPAC
diazabicyclo		I-IUPAC
[		I-IUPAC
3.2.2		I-IUPAC
]		I-IUPAC
nonane		I-IUPAC
(		O
16		O
)		O
]		O
show		O
very		O
weak		O
sigma		O
interaction		O
.		O
In		O
another		O
substitution		O
pattern		O
,		O
N		B-IUPAC
-		I-IUPAC
aryl		I-IUPAC
/		O
alkylamides		B-IUPAC
were		O
studied		O
;		O
an		O
electron		O
-		O
donating		O
group		O
increased		O
the		O
potency		O
of		O
compound		O
51		O
,		O
whereas		O
an		O
electron		O
-		O
withdrawing		O
group		O
decreased		O
the		O
potency		O
of		O
compounds		O
52		O
and		O
53		O
compared		O
to		O
parent		O
compound		O
50		O
.		O
Catalytic		O
hydrogenation		O
of		O
10		B-IUPAC
-		I-IUPAC
(		I-IUPAC
chloroacetyl		I-IUPAC
)		I-IUPAC
folic		I-IUPAC
acid		I-IUPAC
(		O
2		O
)		O
gave		O
5,10		O
-		O
(		O
CH2CO		O
)		O
-		O
THF		O
(		O
12		O
)		O
.		O
In		O
agreement		O
with		O
previously		O
reported		O
binding		O
data		O
for		O
2		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
5,9		B-IUPAC
alpha		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
6,7		I-IUPAC
-		I-IUPAC
benzomorphans		I-IUPAC
(		O
N		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
-		O
N		B-IUPAC
-		I-IUPAC
normetazocine		I-IUPAC
)		O
,		O
all		O
(		O
1S		O
,		O
5S		O
,		O
9S		O
)		O
-		O
(		O
+		O
)		O
-		O
isomers		O
showed		O
higher		O
affinity		O
for		O
the		O
sigma		O
1		O
site		O
than		O
the		O
corresponding		O
(		O
1R		O
,		O
5R		O
,		O
9R		O
)		O
-		O
(		O
-		O
)		O
-		O
isomers		O
.		O
None		O
of		O
the		O
above		O
compounds		O
show		O
greater		O
activity		O
against		O
maximal		O
electroshock		O
seizures		O
than		O
the		O
parent		O
compounds		O
,		O
however		O
.		O
When		O
injected		O
into		O
rats		O
,		O
[		O
99mTc		O
]		O
CpTT		O
-		O
PA		O
exhibited		O
the		O
maximum		O
myocardial		O
accumulation		O
and		O
heart		O
-		O
to		O
-		O
blood		O
ratio		O
of		O
3.85		O
%		O
ID		O
/		O
g		O
at		O
1		O
min		O
and		O
4.60		O
at		O
10		O
min		O
postinjection		O
,		O
respectively		O
.		O
Induction		O
of		O
cytochrome		O
P450		O
CYP1A1		O
,		O
a		O
crucial		O
event		O
in		O
determining		O
the		O
antitumor		O
specificity		O
of		O
this		O
series		O
of		O
benzothiazoles		O
,		O
was		O
not		O
compromised		O
.		O
Cytotoxic		O
effects		O
of		O
4c		O
,		O
6e		O
,		O
and		O
9d		O
are		O
not		O
reversed		O
with		O
any		O
of		O
the		O
four		O
basic		O
ribonucleosides		O
or		O
2'		B-IUPAC
-		I-IUPAC
deoxyribonucleosides		I-IUPAC
.		O
viteae		O
at		O
50		O
mg		O
/		O
kg		O
x		O
5		O
days		O
(		O
ip		O
)		O
.		O
(		O
FMS		O
)		O
(		O
3		O
)		O
-		O
insulin		O
is		O
more		O
resistant		O
to		O
proteolysis		O
and		O
appears		O
to		O
be		O
nonimmunogenic		O
.		O
These		O
compounds		O
were		O
tested		O
as		O
inhibitors		O
of		O
the		O
enzymes		O
involved		O
in		O
folate		O
metabolism		O
and		O
for		O
activity		O
against		O
lymphocytic		O
leukemia		O
P388		O
in		O
mice		O
.		O
The		O
C		O
-		O
5		O
substituent		O
in		O
the		O
2'		B-IUPAC
-		I-IUPAC
deoxyuridine		I-IUPAC
series		B-MODIFIER
was		O
a		O
determinant		O
of		O
cytotoxic		O
activity		O
,		O
as		O
determined		O
in		O
the		O
in		O
vitro		O
L1210		O
screen		O
,		O
where		O
the		O
relative		O
activity		O
order		O
was		O
CH		O
(		O
OH		O
)		O
CHI2		O
(		O
16		O
)		O
greater		O
than		O
CH		O
(		O
OMe		O
)		O
CH2I		O
(		O
12a		O
)		O
greater		O
than		O
CH		O
(		O
OH		O
)		O
CH2I		O
(		O
11a		O
)		O
congruent		O
to		O
CH		O
(		O
OH		O
)		O
CH2OMe		O
(		O
13		O
)		O
.		O
Interestingly		O
,		O
the		O
IC		O
(		O
50		O
)		O
values		O
of		O
this		O
series		O
of		O
ruthenium		O
compounds		O
(		O
except		O
the		O
beta		O
isomeric		O
compounds		O
)		O
are		O
similar		O
in		O
the		O
cisplatin		O
-		O
resistant		O
A2780cisR		O
cell		O
line		O
compared		O
to		O
the		O
normal		O
cell		O
line		O
A2780		O
,		O
suggesting		O
that		O
the		O
activity		O
of		O
these		O
compounds		O
might		O
not		O
be		O
influenced		O
by		O
the		O
multifactorial		O
resistance		O
mechanism		O
that		O
affect		O
platinum		O
anticancer		O
agents		O
.		O
The		O
cytidine		O
conjugates		O
include		O
CDP		B-IUPAC
-		I-IUPAC
rac		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
S		I-IUPAC
-		I-IUPAC
octadecyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
palmitoyl		I-IUPAC
(		O
or		O
-		B-PARTIUPAC
methyl		I-PARTIUPAC
)		O
-		B-PARTIUPAC
1		I-PARTIUPAC
-		I-PARTIUPAC
thioglycerols		I-PARTIUPAC
(		O
9a		O
and		O
9b		O
)		O
.		O
(		B-IUPAC
4		I-IUPAC
-		I-IUPAC
Aminobutylamine		I-IUPAC
)		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
aminobutyl		I-IUPAC
)		I-IUPAC
azanonaborane		I-IUPAC
and		O
(		B-IUPAC
3		I-IUPAC
-		I-IUPAC
aminopropylamine		I-IUPAC
)		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
aminobutyl		I-IUPAC
)		I-IUPAC
azanonaborane		I-IUPAC
were		O
less		O
toxic		O
in		O
vitro		O
(		O
LD		O
(		O
50		O
)		O
of		O
approximately		O
700		O
and		O
approximately		O
1100		O
microM		O
,		O
respectively		O
)		O
than		O
spermine		O
,		O
while		O
(		B-IUPAC
4		I-IUPAC
-		I-IUPAC
aminobutylamine		I-IUPAC
)		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
isopropylazanonaborane		I-IUPAC
with		O
its		O
hydrophobic		O
isopropyl		B-IUPAC
group		B-MODIFIER
and		O
those		O
with		O
n		O
=		O
5		O
,		O
6		O
,		O
and		O
12		O
were		O
already		O
toxic		O
under		O
similar		O
conditions		O
(		O
LD		O
(		O
50		O
)		O
&		O
lt		O
;		O
&		O
lt		O
;		O
500		O
microM		O
)		O
.		O
On		O
the		O
contrary		O
,		O
the		O
O		O
(		O
6		O
)		O
-		O
isomers		O
,		O
namely		O
the		O
compounds		O
derived		O
from		O
2,4		B-PARTIUPAC
-		I-PARTIUPAC
diamino		I-PARTIUPAC
-		I-PARTIUPAC
,		O
2		B-PARTIUPAC
-		I-PARTIUPAC
amino		I-PARTIUPAC
-		I-PARTIUPAC
4		I-PARTIUPAC
-		I-PARTIUPAC
hydroxy		I-PARTIUPAC
-		I-PARTIUPAC
,		O
or		O
2		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
phosphonomethoxy		I-IUPAC
)		I-IUPAC
ethoxy		I-IUPAC
]		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
hydroxypyrimidine		I-IUPAC
,		O
inhibited		O
the		O
replication		O
of		O
herpes		O
viruses		O
[		O
herpes		O
simplex		O
type		O
1		O
(		O
HSV		O
-		O
1		O
)		O
and		O
type		O
2		O
(		O
HSV		O
-		O
2		O
)		O
,		O
varicella		O
-		O
zoster		O
virus		O
(		O
VZV		O
)		O
,		O
and		O
cytomegalovirus		O
(		O
CMV		O
)		O
]		O
and		O
retroviruses		O
[		O
Moloney		O
sarcoma		O
virus		O
(		O
MSV		O
)		O
and		O
human		O
immunodeficiency		O
virus		O
type		O
1		O
(		O
HIV		O
-		O
1		O
)		O
and		O
type		O
2		O
(		O
HIV		O
-		O
2		O
)		O
]		O
,		O
their		O
activity		O
being		O
most		O
pronounced		O
against		O
the		O
latter		O
.		O
carinii		O
DHFR		O
was		O
20		O
000		O
times		O
greater		O
than		O
that		O
of		O
TMP		O
,		O
with		O
an		O
SI		O
of		O
96		O
,		O
whereas		O
that		O
of		O
TMP		O
was		O
only		O
14		O
.		O
Compound		O
4o		O
was		O
found		O
to		O
possess		O
antitumor		O
activity		O
against		O
murine		O
K1735		O
/		O
M2		O
melanoma		O
xenografts		O
.		O
In		O
this		O
assay		O
,		O
PCP		O
exhibited		O
affinities		O
of		O
64.5		O
nM		O
at		O
PCP		O
and		O
1090		O
nM		O
at		O
sigma		O
sites		O
.		O
Potent		O
SQS		O
inhibitory		O
activity		O
equivalent		O
to		O
that		O
of		O
H1		O
is		O
retained		O
by		O
a		O
C3		B-IUPAC
-		I-IUPAC
(		I-IUPAC
tetrazol		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
analogue		B-MODIFIER
,		O
i.e.		O
,		O
a		O
carboxylic		O
acid		O
mimetic		O
.		O
All		O
target		O
compounds		O
were		O
synthesized		O
as		O
racemates		O
from		O
1,3		B-IUPAC
-		I-IUPAC
dihydroxy		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
propanone		I-IUPAC
.		O
(		O
+		O
)		O
-		O
and		O
(		O
-		O
)		O
-		O
8		O
and		O
(		O
+		O
/		O
-		O
)		O
-		O
9		O
were		O
examined		O
for		O
their		O
ability		O
to		O
interact		O
with		O
PCP		O
and		O
sigma		O
binding		O
sites		O
in		O
vitro		O
using		O
[		O
3H		O
]		O
TCP		O
and		O
[		O
3H		O
]		O
pentazocine		O
as		O
radioligands		O
.		O
Biological		O
activities		O
in		O
L1210		O
(		O
murine		O
leukemia		O
)		O
,		O
Chinese		O
hamster		O
ovary		O
(		O
CHO		O
)		O
,		O
and		O
CHO		O
's		O
polyamine		O
transport		O
-		O
deficient		O
mutant		O
(		O
CHO		O
-		O
MG		O
)		O
cell		O
lines		O
were		O
investigated		O
via		O
IC		O
(		O
50		O
)		O
cytotoxicity		O
determinations		O
.		O
Furthermore		O
,		O
a		O
potent		O
benzazepine		O
,		O
21		O
(		O
7,8		B-IUPAC
-		I-IUPAC
dichloro		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
[		I-IUPAC
4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
methylimidazo		I-IUPAC
[		I-IUPAC
4,5		I-IUPAC
-		I-IUPAC
c		I-IUPAC
]		I-IUPAC
pyrid		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
phenyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2,3,4,5		I-IUPAC
-		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
benzazepin		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
one		I-IUPAC
)		O
(		O
IC50		O
=		O
0.5		O
nM		O
,		O
ED50		O
=		O
0.03		O
mg		O
/		O
kg		O
po		O
)		O
,		O
was		O
discovered		O
.		O
We		O
have		O
previously		O
developed		O
two		O
positron		O
emission		O
tomography		O
(		O
PET		O
)		O
ligands		O
,		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
11		I-IUPAC
)		I-IUPAC
C		I-IUPAC
]		I-IUPAC
,		I-IUPAC
5		I-IUPAC
-		I-IUPAC
dimethoxybenzyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
(		I-IUPAC
5		I-IUPAC
-		I-IUPAC
fluoro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
phenoxyphenyl		I-IUPAC
)		I-IUPAC
acetamide		I-IUPAC
(		O
[		O
(		O
11		O
)		O
C		O
]		O
2		O
)		O
and		O
its		O
[		B-IUPAC
(		I-IUPAC
18		I-IUPAC
)		I-IUPAC
F		I-IUPAC
]		I-IUPAC
fluoroethyl		I-IUPAC
analogue		B-MODIFIER
(		O
[		O
(		O
18		O
)		O
F		O
]		O
6		O
)		O
,		O
for		O
the		O
current		O
investigation		O
of		O
PBR		O
in		O
the		O
human		O
brain		O
.		O
Compound		O
2		O
did		O
not		O
exhibit		O
any		O
antifolate		O
activity		O
against		O
Lactobacillus		O
casei		O
or		O
Streptococcus		O
faecium		O
.		O
b		O
.		O
Other		O
analogs		O
from		O
this		O
series		O
,		O
including		O
(		B-IUPAC
3S		I-IUPAC
,		I-IUPAC
4aR		I-IUPAC
,		I-IUPAC
6S		I-IUPAC
,		I-IUPAC
8aR		I-IUPAC
)		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
tetrazol		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1,2,3,4,4		I-IUPAC
a		I-IUPAC
,		I-IUPAC
5,6,7,8,8		I-IUPAC
a		I-IUPAC
-		I-IUPAC
decahydroisoquinoline		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
carboxylic		I-IUPAC
acid		I-IUPAC
(		O
32		O
)		O
and		O
(		B-IUPAC
3S		I-IUPAC
,		I-IUPAC
4aR		I-IUPAC
,		I-IUPAC
6S		I-IUPAC
,		I-IUPAC
8aR		I-IUPAC
)		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
phosphonomethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1,2,3,4,4		I-IUPAC
a		I-IUPAC
,		I-IUPAC
5,6,7,8,8		I-IUPAC
a		I-IUPAC
-		I-IUPAC
decahydroisoquinoline		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
ca		I-IUPAC
rboxylic		I-IUPAC
acid		I-IUPAC
(		O
61		O
)		O
are		O
potent		O
,		O
selective		O
,		O
and		O
systemically		O
active		O
NMDA		O
antagonists		O
.		O
All		O
of		O
the		O
molecules		O
tested		O
had		O
relatively		O
low		O
affinity		O
for		O
serotonin		O
receptors		O
,		O
yet		O
a		O
preliminary		O
screen		O
indicated		O
that		O
compound		O
4d		O
had		O
affinity		O
for		O
muscarinic		O
receptors		O
.		O
Glycosylation		O
of		O
the		O
trimethylsilyl		O
4		O
with		O
1		B-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
deoxy		I-IUPAC
-		I-IUPAC
3,5		I-IUPAC
-		I-IUPAC
di		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
p		I-IUPAC
-		I-IUPAC
toluoyl		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
ribofuranose		I-IUPAC
in		O
the		O
presence		O
of		O
trimethylsilyl		B-IUPAC
trifluoromethanesulfonate		I-IUPAC
gave		O
the		O
corresponding		O
N		B-IUPAC
-		I-IUPAC
1		I-IUPAC
and		O
N		B-IUPAC
-		I-IUPAC
3		I-IUPAC
glycosyl		I-IUPAC
derivatives		B-MODIFIER
with		O
alpha		O
-		O
configuration		O
(		O
18		O
and		O
20		O
)		O
as		O
the		O
major		O
products		O
,		O
along		O
with		O
minor		O
amounts		O
of		O
the		O
beta		O
-		O
anomers		O
(		O
19		O
and		O
21		O
)		O
.		O
We		O
have		O
previously		O
shown		O
it		O
to		O
be		O
the		O
most		O
potent		O
NMDA		O
agonist		O
known		O
,		O
with		O
a		O
unique		O
and		O
marked		O
in		O
vitro		O
neutrotoxicity		O
at		O
depolarizing		O
concentrations		O
.		O
This		O
result		O
prompted		O
an		O
exploration		O
of		O
the		O
structure		O
-		O
activity		O
relationship		O
of		O
related		O
derivatives		O
,		O
synthesized		O
via		O
sequential		O
substitution		O
of		O
6		B-IUPAC
-		I-IUPAC
chloro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
fluoropurine		I-IUPAC
with		O
selected		O
nucleophiles		O
.		O
Reaction		O
of		O
14		B-IUPAC
-		I-IUPAC
bromoadunorubicin		I-IUPAC
with		O
alpha		O
,		O
omega		O
-		O
alkanedithiols		O
gave		O
bis		O
(		O
thiaadriamycin		O
)		O
analogues		O
as		O
potential		O
difunctional		O
intercalating		O
agents		O
.		O
The		O
therapeutic		O
indices		O
(		O
LD50		O
-		O
/		O
ID90		O
)		O
for		O
2		O
against		O
the		O
ADJ		O
/		O
PC6		O
mouse		O
tumor		O
and		O
the		O
Walker		O
256		O
tumor		O
in		O
the		O
rat		O
were		O
28.6		O
and		O
7.7		O
,		O
respectively		O
,		O
and		O
were		O
lower		O
than		O
the		O
corresponding		O
values		O
for		O
1		O
(		O
91.8		O
and		O
33.2		O
,		O
respectively		O
)		O
although		O
the		O
toxicities		O
toward		O
Walker		O
cells		O
in		O
a		O
bioassay		O
system		O
of		O
1		O
and		O
2		O
following		O
microsomal		O
metabolism		O
were		O
similar		O
.		O
One		O
of		O
these		O
compounds		O
,		O
(		B-IUPAC
RS		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
carboxy		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
isoxazolyl		I-IUPAC
)		I-IUPAC
propionic		I-IUPAC
acid		I-IUPAC
(		O
ACPA		O
,		O
8		O
)		O
,		O
was		O
shown		O
in		O
[		O
3H		O
]		O
AMPA		O
binding		O
studies		O
to		O
be		O
more		O
active		O
than		O
AMPA		O
itself		O
(		O
IC50		O
=		O
20		O
nM		O
compared		O
to		O
IC50		O
=		O
79		O
nM		O
for		O
AMPA		O
)		O
.		O
The		O
effects		O
on		O
biological		O
activity		O
of		O
substitution		O
and		O
structural		O
modification		O
of		O
the		O
4		B-PARTIUPAC
-		I-PARTIUPAC
and		O
5		B-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
rings		B-MODIFIER
of		O
3		O
was		O
examined		O
.		O
Pyridinium		O
chlorochromate		O
(		O
PCC		O
)		O
oxidation		O
of		O
the		O
N		O
-		O
t		O
-		O
Boc		O
-		O
protected		O
derivative		O
of		O
(		O
+		O
/		O
-		O
)		O
-		O
3		O
afforded		O
(		B-IUPAC
+		I-IUPAC
/		I-IUPAC
-		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
N		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
tert		I-IUPAC
-		I-IUPAC
butyloxy		I-IUPAC
)		I-IUPAC
carbonyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
methylamino		I-IUPAC
]		I-IUPAC
cyclohexanone		I-IUPAC
[		O
(		O
+		O
/		O
-		O
)		O
-		O
5		O
]		O
.		O
Binding		O
studies		O
demonstrated		O
that		O
the		O
activities		O
of		O
2		O
-		O
alkynylAdos		O
were		O
slightly		O
increased		O
for		O
the		O
adenosine		O
A		O
(		O
1		O
)		O
receptor		O
and		O
slightly		O
decreased		O
for		O
both		O
A		O
(		O
3		O
)		O
and		O
A		O
(		O
2B		O
)		O
subtypes		O
compared		O
to		O
those		O
of		O
their		O
corresponding		O
NECA		O
derivatives		O
,		O
whereas		O
the		O
A		O
(		O
2A		O
)		O
receptor		O
affinities		O
of		O
the		O
two		O
series		O
of		O
nucleosides		O
were		O
similar		O
.		O
The		O
compound		O
7		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
nitrophenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
quinoxalinecarbonitrile		I-IUPAC
1,4		I-IUPAC
-		I-IUPAC
di		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
oxide		I-IUPAC
(		O
5k		O
)		O
is		O
150		O
-		O
fold		O
more		O
potent		O
than		O
tirapazamine		O
(		O
3		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
1,2,4		I-IUPAC
-		I-IUPAC
benzotriazine		I-IUPAC
1,4		I-IUPAC
-		I-IUPAC
di		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
oxide		I-IUPAC
)		O
,		O
which		O
has		O
been		O
used		O
as		O
a		O
standard		O
.		O
N		B-IUPAC
-		I-IUPAC
Methoxy		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
5		I-IUPAC
-		I-IUPAC
[		I-IUPAC
4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
N		I-IUPAC
-		I-IUPAC
methoxyamidino		I-IUPAC
)		I-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
furan		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
imidazo		I-IUPAC
[		I-IUPAC
1,2		I-IUPAC
-		I-IUPAC
a		I-IUPAC
]		I-IUPAC
pyridine		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
carboxamidine		I-IUPAC
(		O
6		O
)		O
was		O
prepared		O
via		O
methylation		O
of		O
the		O
respective		O
diamidoxime		O
5a		O
with		O
dimethyl		O
sulfate		O
.		O
(		O
ABSTRACT		O
TRUNCATED		O
AT		O
400		O
WORDS		O
)		O
To		O
develop		O
a		O
novel		O
cerebroprotective		O
agent		O
with		O
central		O
nervous		O
system		O
(		O
CNS		O
)		O
stimulating		O
activity		O
,		O
a		O
series		B-MODIFIER
of		O
1		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
hydroxyindan		I-IUPAC
derivatives		B-MODIFIER
was		O
synthesized		O
,		O
and		O
their		O
effects		O
on		O
the		O
survival		O
time		O
of		O
mice		O
under		O
hypoxic		O
conditions		O
were		O
tested		O
.		O
The		O
synthesis		O
of		O
6,7		B-IUPAC
-		I-IUPAC
dichloro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
pyrrolidinyl		I-IUPAC
)		I-IUPAC
ethyl		I-IUPAC
]		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
tetralin		I-IUPAC
(		O
19		O
)		O
and		O
its		O
desmethyl		B-IUPAC
derivative		I-IUPAC
20		O
permitted		O
constraint		O
of		O
the		O
3,4		B-IUPAC
-		I-IUPAC
dichlorophenyl		I-IUPAC
and		O
N		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
moieties		B-MODIFIER
of		O
1		O
into		O
a		O
gauche		O
orientation		O
.		O
4		B-IUPAC
-		I-IUPAC
Amino		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
butyl		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
chlorophenyl		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
pyrazolo		I-IUPAC
[		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidin		I-IUPAC
-		I-IUPAC
6		I-IUPAC
(		I-IUPAC
5H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
one		I-IUPAC
was		O
the		O
most		O
potent		O
compound		O
with		O
an		O
IC50		O
of		O
19.2		O
x		O
10		O
(		O
-		O
6		O
)		O
M		O
.		O
No		O
regiospecific		O
syntheses		O
were		O
available		O
for		O
many		O
of		O
these		O
,		O
and		O
separation		O
of		O
the		O
mixtures		O
of		O
regioisomers		O
obtained		O
was		O
sometimes		O
difficult		O
.		O
A		O
novel		O
conversion		O
of		O
(		B-IUPAC
-		I-IUPAC
)		I-IUPAC
-		I-IUPAC
nicotine		I-IUPAC
to		O
its		O
6		B-IUPAC
-		I-IUPAC
chloro		I-IUPAC
analogue		B-MODIFIER
increased		O
the		O
potency		O
2		O
-		O
fold		O
.		O
Potencies		O
in		O
the		O
dipropyl		B-IUPAC
series		B-MODIFIER
at		O
the		O
A1		O
receptor		O
ranged		O
from		O
Ki		O
values		O
of		O
1.2		O
nM		O
for		O
a		O
congener		O
with		O
a		O
terminal		O
amidoethyleneamine		B-IUPAC
moiety		B-MODIFIER
to		O
a		O
Ki		O
value		O
of		O
58		O
nM		O
for		O
the		O
parent		O
carboxylic		O
acid		O
to		O
a		O
Ki		O
of		O
96		O
nM		O
for		O
the		O
bulky		O
ureido		O
congener		O
.		O
Biophys		O
.		O
A		O
new		O
procedure		O
for		O
the		O
preparation		O
of		O
the		O
antiviral		O
and		O
antitumor		O
agent		O
3		B-IUPAC
-		I-IUPAC
deazaguanine		I-IUPAC
(		O
1		O
)		O
and		O
its		O
metabolite		O
3		B-IUPAC
-		I-IUPAC
deazaguanosine		I-IUPAC
(		O
2		O
)		O
has		O
been		O
developed		O
by		O
reacting		O
methyl		B-IUPAC
5		I-IUPAC
(		I-IUPAC
4		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
cyanomethyl		I-IUPAC
)		I-IUPAC
imidazole		I-IUPAC
-		I-IUPAC
4		I-IUPAC
(		I-IUPAC
5		I-IUPAC
)		I-IUPAC
-		I-IUPAC
carboxylate		I-IUPAC
(		O
4		O
)		O
and		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
cyanomethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2,3,5		I-IUPAC
-		I-IUPAC
tri		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
benzoyl		I-IUPAC
-		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
ribofuranosyl		I-IUPAC
)		I-IUPAC
imidazole		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
carboxylate		I-IUPAC
(		O
6		O
)		O
,		O
respectively		O
,		O
with		O
hydrazine		O
.		O
Nephrotoxicity		O
studies		O
in		O
ICR		O
mice		O
indicated		O
that		O
serum		O
BUN		O
and		O
creatinine		O
levels		O
were		O
not		O
elevated		O
when		O
five		O
complexes		O
were		O
given		O
at		O
a		O
dose		O
equal		O
to		O
1.5		O
times		O
the		O
optimal		O
dose		O
determined		O
in		O
the		O
in		O
vivo		O
L1210		O
screening		O
system		O
.		O
However		O
,		O
the		O
perpendicular		O
ring		O
of		O
cis		B-IUPAC
-		I-IUPAC
1,2		I-IUPAC
-		I-IUPAC
cyclohexanediamine		I-IUPAC
complexes		B-MODIFIER
would		O
prevent		O
their		O
interactions		O
with		O
dna		O
molecules		O
due		O
to		O
the		O
steric		O
hindrance		O
.		O
Compounds		O
containing		O
pyridylalanine		O
and		O
thiazolylalanine		O
were		O
intermediate		O
in		O
binding		O
affinity		O
,		O
with		O
delta		O
KiS		O
ranging		O
from		O
39.5		O
to		O
62.4		O
nM		O
.		O
Acylation		O
of		O
THF		O
with		O
chloroacetyl		O
chloride		O
gave		O
a		O
N5		O
,		O
N10		O
-		O
diacylated		O
product		O
(		O
18		O
or		O
19		O
)		O
,		O
which		O
could		O
not		O
be		O
converted		O
to		O
5,10		O
-		O
COCH2		O
)		O
-		O
THF		O
(		O
17		O
)		O
.		O
While		O
vasorelaxant		O
activity		O
was		O
critically		O
dependent		O
on		O
the		O
size		O
of		O
the		O
C5		O
ester		B-IUPAC
group		B-MODIFIER
,		O
isopropyl		O
ester		O
being		O
the		O
best		O
,		O
a		O
variety		O
of		O
substituents		B-MODIFIER
(		O
carbamate		B-IUPAC
,		O
acyl		B-IUPAC
,		O
sulfonyl		B-IUPAC
,		O
alkyl		B-IUPAC
)		O
were		O
tolerated		O
at		O
N3		O
.		O
A		O
series		O
of		O
21		O
1,3		B-IUPAC
-		I-IUPAC
dialkylpyrazolo		I-IUPAC
[		I-IUPAC
4,3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidin		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
ones		I-IUPAC
substituted		O
in		O
the		O
5		O
-		O
position		O
with		O
various		O
phenyl		B-IUPAC
substituents		B-MODIFIER
has		O
been		O
synthesized		O
and		O
found		O
to		O
have		O
affinity		O
for		O
the		O
adenosine		O
A1		O
receptor		O
.		O
The		O
highly		O
lipophilic		O
acid		O
amides		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
7		I-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
oxochroman		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2,2		I-IUPAC
-		I-IUPAC
dimethyldodecanamide		I-IUPAC
(		O
35		O
)		O
and		O
4		B-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
chlorophenoxy		I-IUPAC
)		I-IUPAC
hexyl		I-IUPAC
]		I-IUPAC
oxy		I-IUPAC
]		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
(		I-IUPAC
7		I-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
oxochroman		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
benzamide		I-IUPAC
(		O
63		O
)		O
showed		O
potent		O
activity		O
.		O
All		O
of		O
these		O
compounds		O
were		O
tested		O
in		O
vitro		O
against		O
certain		O
viruses		O
,		O
tumor		O
cells		O
,		O
and		O
the		O
parasite		O
Leishmania		O
tropica		O
.		O
In		O
this		O
study		O
,		O
structure		O
-		O
activity		O
relationships		O
at		O
various		O
positions		O
of		O
the		O
dihydropyridine		O
ring		O
(		O
the		O
3		B-PARTIUPAC
-		I-PARTIUPAC
and		O
5		B-IUPAC
-		I-IUPAC
acyl		I-IUPAC
substituents		B-MODIFIER
,		O
the		O
4		B-IUPAC
-		I-IUPAC
aryl		I-IUPAC
substituent		B-MODIFIER
,		O
and		O
1		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
group		B-MODIFIER
)		O
were		O
probed		O
synthetically		O
.		O
The		O
ability		O
of		O
these		O
5		B-PARTIUPAC
-		I-PARTIUPAC
halo		I-PARTIUPAC
-		I-PARTIUPAC
6		I-PARTIUPAC
-		I-PARTIUPAC
alkoxy		I-PARTIUPAC
(		O
or		O
azido		B-PARTIUPAC
)		O
-		B-PARTIUPAC
5,6		I-PARTIUPAC
-		I-PARTIUPAC
dihydro		I-PARTIUPAC
-		I-PARTIUPAC
3'		I-PARTIUPAC
-		I-PARTIUPAC
azido		I-PARTIUPAC
-		I-PARTIUPAC
3'		I-PARTIUPAC
-		I-PARTIUPAC
deoxythymidines		I-PARTIUPAC
to		O
protect		O
CEM		O
cells		O
against		O
HIV		O
-		O
induced		O
cytopathogenicity		O
was		O
evaluated		O
.		O
Sugar		O
-		O
modified		O
analogs		O
of		O
4		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
ribofuranosyl		I-IUPAC
)		I-IUPAC
pyrrolo		I-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyridazin		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
one		I-IUPAC
(		O
1		O
)		O
and		O
4		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
bromo		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
ribofuranosyl		I-IUPAC
)		I-IUPAC
pyrrolo		I-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyridazin		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
one		I-IUPAC
(		O
3		O
)		O
were		O
prepared		O
in		O
an		O
effort		O
to		O
obtain		O
selective		O
antiviral		O
agents		O
.		O
All		O
11		O
of		O
the		O
2		O
-		O
thioethers		O
of		O
ATP		O
stimulated		O
the		O
production		O
of		O
inositol		O
phosphates		O
with		O
K0		O
.5		O
values		O
of		O
1.5-770		O
nM		O
,		O
with		O
an		O
(		O
aminophenyl		O
)		O
ethyl		O
derivative		O
being		O
most		O
potent		O
.		O
A		O
new		O
means		O
of		O
accessing		O
N		B-IUPAC
(		I-IUPAC
1		I-IUPAC
)		I-IUPAC
-		I-IUPAC
cyclopropylmethyl		I-IUPAC
-		I-IUPAC
N		I-IUPAC
(		I-IUPAC
11		I-IUPAC
)		I-IUPAC
-		I-IUPAC
ethylnorspermine		I-IUPAC
(		O
CPMENSPM		O
)		O
and		O
the		O
first		O
synthesis		O
of		O
(		B-IUPAC
2R		I-IUPAC
,		I-IUPAC
10S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
N		I-IUPAC
(		I-IUPAC
1		I-IUPAC
)		I-IUPAC
-		I-IUPAC
cyclopropylmethyl		I-IUPAC
-		I-IUPAC
2,10		I-IUPAC
-		I-IUPAC
dihydroxy		I-IUPAC
-		I-IUPAC
N		I-IUPAC
(		I-IUPAC
11		I-IUPAC
)		I-IUPAC
-		I-IUPAC
ethylnorspermine		I-IUPAC
[		O
(		O
2R		O
,		O
10S		O
)		O
-		O
(		O
HO		O
)		O
(		O
2		O
)		O
CPMENSPM		O
]		O
are		O
described		O
.		O
Of		O
the		O
26		O
analogues		O
in		O
the		O
series		O
,		O
11		O
had		O
diminished		O
potencies		O
of		O
less		O
than		O
10%		O
that		O
of		O
the		O
agonist		O
standard		O
,		O
4		O
were		O
weak		O
agonists		O
(		O
15-40%		O
relative		O
potency		O
)		O
,		O
and		O
4		O
analogues		O
were		O
equipotent		O
to		O
the		O
standard		O
.		O
trans		O
-		O
2		O
-		O
Carboxy		O
-		O
5,7		O
-		O
dichloro		O
-		O
4		O
-		O
amidotetrahydroquinolines		O
,		O
evolved		O
from		O
the		O
lead		O
5,7		B-IUPAC
-		I-IUPAC
dichlorokynurenic		I-IUPAC
acid		I-IUPAC
,		O
have		O
been		O
synthesized		O
and		O
tested		O
for		O
in		O
vitro		O
antagonist		O
activity		O
at		O
the		O
glycine		O
site		O
on		O
the		O
N		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
aspartate		I-IUPAC
(		O
NMDA		O
)		O
receptor		O
.		O
Pirenzepine		O
displayed		O
the		O
lowest		O
affinity		O
for		O
thalamic		O
and		O
brainstem		O
regions		O
with		O
IC50		O
values		O
generally		O
greater		O
than		O
1.0		O
microM		O
.		O
Structurally		O
related		O
quinoxaline		B-IUPAC
-		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
diones		I-IUPAC
are		O
also		O
glycine		O
/		O
NMDA		O
antagonists		O
,		O
but		O
are		O
not		O
selective		O
and		O
are		O
less		O
potent		O
than		O
the		O
1		O
derivatives		O
,		O
and		O
additionally		O
show		O
different		O
structure		O
-		O
activity		O
requirements		O
for		O
aromatic		O
ring		O
substitution		O
.		O
Dehydration		O
of		O
the		O
pentaacetylpyrazofurin		O
(		O
9		O
)		O
with		O
phosgene		O
furnished		O
4		B-IUPAC
-		I-IUPAC
acetoxy		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2,3,5		I-IUPAC
-		I-IUPAC
tri		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
acetyl		I-IUPAC
-		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
ribofuranosyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
acetylpyrazol		I-IUPAC
e		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
carbonitrile		I-IUPAC
(		O
10		O
)		O
.		O
These		O
compounds		O
proved		O
to		O
be		O
selective		O
CB1		O
cannabinoid		O
receptor		O
ligands		O
,		O
acting		O
as		O
inverse		O
agonists		O
in		O
a		O
[		O
35S		O
]		O
-		O
GTPgammaS		O
assay		O
.		O
The		O
X		O
-		O
ray		O
crystal		O
structures		O
of		O
6b		O
,		O
6c		O
,		O
and		O
6d		O
were		O
found		O
to		O
be		O
in		O
reasonable		O
agreement		O
with		O
the		O
corresponding		O
AM1		O
calculated		O
geometries		O
.		O
As		O
part		O
of		O
investigations		O
to		O
probe		O
its		O
postulated		O
mode		O
of		O
action		O
using		O
PET		O
we		O
have		O
developed		O
two		O
rapid		O
radiosynthetic		O
routes		O
for		O
the		O
preparation		O
of		O
temozolomide		O
labeled		O
with		O
the		O
short		O
-		O
lived		O
positron		O
emitter		O
,		O
carbon		O
-		O
11		O
(		O
t		O
(		O
1/2		O
)		O
=		O
20.4		O
min		O
)		O
.		O
IC50		O
ratios		O
for		O
[		O
3H		O
]		O
cocaine		O
binding		O
/		O
[		O
3H		O
]		O
DA		O
uptake		O
ranged		O
from		O
0.47		O
for		O
1		B-IUPAC
-		I-IUPAC
[		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
benzo		I-IUPAC
[		I-IUPAC
b		I-IUPAC
]		I-IUPAC
thienyl		I-IUPAC
)		I-IUPAC
cyclopentyl		I-IUPAC
]		I-IUPAC
homopiperidine		I-IUPAC
(		O
11		O
)		O
to		O
8.8		O
for		O
1		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
benzo		I-IUPAC
[		I-IUPAC
b		I-IUPAC
]		I-IUPAC
thienyl		I-IUPAC
)		I-IUPAC
cyclohexylamine		I-IUPAC
(		O
4		O
)		O
.		O
Synthesis		O
was		O
accomplished		O
via		O
a		O
Schmidt		O
reaction		O
with		O
5,6,7,8		B-IUPAC
-		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
methoxynaphthalene		I-IUPAC
-		I-IUPAC
1,4		I-IUPAC
-		I-IUPAC
diones		I-IUPAC
(		O
THMNDs		O
)		O
followed		O
by		O
demethylation		O
.		O
N		O
(		O
1		O
)		O
-		O
Tethers		O
longer		O
than		O
ethylene		O
showed		O
dramatic		O
loss		O
of		O
selectivity		O
for		O
the		O
polyamine		O
transporter		O
(		O
PAT		O
)		O
as		O
shown		O
in		O
a		O
CHO		O
/		O
CHO		O
-		O
MG		O
cytotoxicity		O
screen		O
.		O
The		O
tabulated		O
results		O
from		O
a		O
3		O
-		O
hr		O
test		O
period		O
revealed		O
that		O
generally		O
the		O
diuretic		O
profile		O
and		O
potency		O
could		O
be		O
retained		O
when		O
3		B-IUPAC
-		I-IUPAC
alkoxy		I-IUPAC
,		O
3		B-IUPAC
-		I-IUPAC
alkylthio		I-IUPAC
,		O
and		O
3		B-IUPAC
-		I-IUPAC
phenethyl		I-IUPAC
were		O
substituted		O
for		O
the		O
3		B-IUPAC
-		I-IUPAC
alkylamino		I-IUPAC
moiety		B-MODIFIER
.		O
In		O
order		O
to		O
investigate		O
the		O
role		O
of		O
receptor		O
subtypes		O
,		O
we		O
have		O
carried		O
out		O
a		O
chemical		O
synthesis		O
program		O
to		O
seek		O
selective		O
retinoids		O
for		O
these		O
receptors		O
.		O
A		O
series		O
of		O
squalestatins		O
modified		O
at		O
the		O
C3		O
-		O
position		O
with		O
a		O
heterocyclic		O
functionality		O
was		O
prepared		O
and		O
evaluated		O
in		O
vitro		O
as		O
inhibitors		O
of		O
squalene		O
synthase		O
(		O
SQS		O
)		O
.		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
Isoxazol		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxyuridine		I-IUPAC
was		O
synthesized		O
from		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
oxopropyn		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxyuridine		I-IUPAC
.		O
Tranferase		O
A		O
was		O
the		O
most		O
active		O
isozyme		O
tested		O
.		O
Several		O
potentially		O
bis		O
(		O
alkylating		O
)		O
bis		O
(		O
quinones		O
)		O
(		O
3-5		O
)		O
and		O
1,4		B-PARTIUPAC
-		I-PARTIUPAC
and		O
1,3		B-IUPAC
-		I-IUPAC
bis		I-IUPAC
(		I-IUPAC
alkylating		I-IUPAC
)		I-IUPAC
monoquinones		I-IUPAC
(		O
6-13		O
)		O
belonging		O
to		O
general		O
structure		O
2,2		B-PARTIUPAC
'		I-PARTIUPAC
-		I-PARTIUPAC
ethylenebis		I-PARTIUPAC
[		I-PARTIUPAC
5		I-PARTIUPAC
-		I-PARTIUPAC
[		I-PARTIUPAC
(		O
leaving		O
group		O
)		O
methyl		B-PARTIUPAC
]		I-PARTIUPAC
-		I-PARTIUPAC
1,4		I-PARTIUPAC
-		I-PARTIUPAC
benzoquinone		I-PARTIUPAC
]		I-PARTIUPAC
(		O
3-5		O
)		O
and		O
2,5		B-PARTIUPAC
-		I-PARTIUPAC
and		O
2,6		B-PARTIUPAC
-		I-PARTIUPAC
bis		I-PARTIUPAC
[		I-PARTIUPAC
(		O
leaving		O
group		O
)		O
methyl		B-PARTIUPAC
]		I-PARTIUPAC
-		I-PARTIUPAC
1,4		I-PARTIUPAC
-		I-PARTIUPAC
benzoquinone		I-PARTIUPAC
water		O
-		O
soluble		O
and		O
-		O
insoluble		O
classes		O
were		O
prepared		O
by		O
oxidative		O
demethylation		O
of		O
the		O
corresponding		O
tetramethoxydiphenylethanes		O
(		O
17-19		O
)		O
and		O
dimethoxybenzenes		O
(		O
24		O
,		O
27		O
,		O
36-39		O
)		O
,		O
respectively		O
.		O
PET		O
brain		O
imaging		O
studies		O
in		O
monkeys		O
demonstrated		O
high		O
[		O
(		O
18		O
)		O
F		O
]		O
(		O
R		O
)		O
-		O
FIPCT		O
and		O
[		O
(		O
18		O
)		O
F		O
]		O
(		O
S		O
)		O
-		O
FIPCT		O
uptake		O
in		O
the		O
caudate		O
and		O
putamen		O
which		O
resulted		O
in		O
caudate		O
-		O
to		O
-		O
cerebellum		O
and		O
putamen		O
-		O
to		O
-		O
cerebellum		O
ratios		O
of		O
2.5-3.5		O
at		O
115		O
min		O
.		O
Several		O
analogues		O
in		O
this		O
series		O
compared		O
favorably		O
with		O
the		O
non		O
-		O
peptide		O
L		O
-		O
803,087		O
(		O
37		O
)		O
in		O
terms		O
of		O
affinity		O
and		O
selectivity		O
.		O
The		O
N		O
-		O
substituent		O
in		O
spiro		B-IUPAC
[		I-IUPAC
isobenzofuran		I-IUPAC
-		I-IUPAC
1		I-IUPAC
(		I-IUPAC
3H		I-IUPAC
)		I-IUPAC
,		I-IUPAC
4'		I-IUPAC
-		I-IUPAC
piperidines		I-IUPAC
]		I-IUPAC
is		O
highly		O
important		O
,		O
both		O
for		O
affinity		O
and		O
selectivity		O
.		O
Most		O
6beta		B-IUPAC
-		I-IUPAC
acyloxy		I-IUPAC
(		I-IUPAC
nor		I-IUPAC
)		I-IUPAC
tropanes		I-IUPAC
had		O
higher		O
affinity		O
versus		O
oxotremorine		O
-		O
M		O
binding		O
compared		O
to		O
quinuclidinyl		O
benzilate		O
binding		O
at		O
transfected		O
m		O
(		O
1		O
)		O
-		O
and		O
native		O
M		O
(		O
1		O
)		O
-		O
receptors		O
,		O
indicative		O
of		O
agonist		O
activity		O
.		O
A		O
series		O
of		O
bis		O
(		O
hydroxymethyl		O
)		O
-		O
substituted		O
heterocycles		O
were		O
synthesized		O
and		O
converted		O
to		O
the		O
corresponding		O
bis		B-IUPAC
(		I-IUPAC
methylcarbamate		I-IUPAC
)		I-IUPAC
derivatives		B-MODIFIER
.		O
Most		O
compounds		O
were		O
potent		O
competitive		O
inhibitors		O
of		O
pol		O
IIIC		O
(		O
K		O
(		O
i		O
)		O
s		O
0.02-0.5		O
microM		O
)		O
,		O
and		O
those		O
with		O
neutral		O
,		O
moderately		O
polar		O
3		O
-		O
substituents		O
had		O
potent		O
antibacterial		O
activity		O
against		O
Gram+		O
organisms		O
in		O
culture		O
(		O
MICs		O
0.125-10		O
microg		O
/		O
mL		O
)		O
.		O
1,8		B-MODIFIER
-		I-MODIFIER
Disubstituted		I-MODIFIER
xanthines		B-IUPAC
had		O
high		O
affinity		O
for		O
adenosine		O
receptors		O
;		O
some		O
were		O
highly		O
selective		O
for		O
A1		O
receptors		O
.		O
The		O
site		O
has		O
stereoselectivity		O
for		O
the		O
(		O
1R		O
,		O
3S		O
)		O
-		O
(		O
-		O
)		O
-		O
isomer		O
of		O
1		B-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
N		I-IUPAC
,		I-IUPAC
N		I-IUPAC
-		I-IUPAC
dimethylamino		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1,2,3,4		I-IUPAC
-		I-IUPAC
tetrahydronaphthalene		I-IUPAC
;		O
this		O
isomer		O
is		O
also		O
more		O
active		O
at		O
stimulating		O
TH		O
.		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
Chlorophenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
N'		I-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
3,5		I-IUPAC
-		I-IUPAC
dichloro		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
nitrophenoxy		I-IUPAC
)		I-IUPAC
phenyl		I-IUPAC
]		I-IUPAC
sulfonyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
N		I-IUPAC
"		I-IUPAC
-		I-IUPAC
hydroxyguanidine		I-IUPAC
(		O
4n		O
)		O
and		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
chlorophenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
N'		I-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
3,5		I-IUPAC
-		I-IUPAC
dichloro		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
chloro		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
nitrophenoxy		I-IUPAC
)		I-IUPAC
phenyl		I-IUPAC
]		I-IUPAC
sulfonyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
N		I-IUPAC
"		I-IUPAC
-		I-IUPAC
hydroxyguanidine		I-IUPAC
(		O
4o		O
)		O
exhibited		O
the		O
greatest		O
growth		O
inhibition		O
of		O
solid		O
tumor		O
cell		O
lines		O
.		O
Here		O
,		O
we		O
describe		O
the		O
synthesis		O
and		O
some		O
pharmacological		O
properties		O
of		O
a		O
series		O
of		O
fluorescent		O
compounds		O
structurally		O
related		O
to		O
the		O
NET		O
substrate		O
,		O
MIBG		O
,		O
or		O
to		O
the		O
NET		O
inhibitors		O
,		O
(		B-IUPAC
-		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2R		I-IUPAC
,		I-IUPAC
3S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
cocaine		I-IUPAC
and		O
nisoxetine		O
.		O
From		O
the		O
reaction		O
of		O
silylated		B-MODIFIER
4		B-IUPAC
-		I-IUPAC
(		I-IUPAC
3,3		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
triazeno		I-IUPAC
)		I-IUPAC
imidazole		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
carboxamide		I-IUPAC
(		O
DTIC		O
,		O
5		O
)		O
and		O
3		B-IUPAC
-		I-IUPAC
(		I-IUPAC
3,3		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
triazeno		I-IUPAC
)		I-IUPAC
pyrazole		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
carboxamide		I-IUPAC
(		O
DTPC		O
,		O
9		O
)		O
with		O
2		B-IUPAC
-		I-IUPAC
chlorotetrahydrofuran		I-IUPAC
,		O
we		O
have		O
isolated		O
in		O
both		O
cases		O
a		O
single		O
tetrahydrofuran		B-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
derivative		B-MODIFIER
.		O
The		O
simplest		O
target		O
compound		O
(		O
9c		O
)		O
derived		O
from		O
the		O
ineffective		O
4,4		B-IUPAC
-		I-IUPAC
bis		I-IUPAC
-		I-IUPAC
(		I-IUPAC
hydroxymethyl		I-IUPAC
)		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
furanone		I-IUPAC
template		O
was		O
investigated		O
only		O
with		O
a		O
myristoyl		O
acyl		O
chain		O
.		O
In		O
order		O
to		O
test		O
this		O
proposal		O
the		O
acenaphthene		O
derivative		O
and		O
the		O
4,5		B-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
3H		I-IUPAC
-		I-IUPAC
naphtho		I-IUPAC
[		I-IUPAC
1,8		I-IUPAC
-		I-IUPAC
bc		I-IUPAC
]		I-IUPAC
thiophene		I-IUPAC
derivative		B-MODIFIER
were		O
prepared		O
.		O
Two		O
diastereomeric		O
series		O
with		O
H4a		O
,		O
H5		O
-		O
trans		O
,		O
H4a		O
,		O
H9b		O
-		O
cis		O
and		O
H4a		O
,		O
H5		O
-		O
cis		O
,		O
H4a		O
,		O
H9b		O
-		O
cis		O
configurations		O
have		O
been		O
tested		O
biologically		O
.		O
Analogues		O
14		O
,		O
15		O
,		O
and		O
33		O
were		O
the		O
most		O
effective		O
agents		O
against		O
HCMV		O
(		O
IC50		O
1-2.1		O
,		O
0.04-2.1		O
,		O
and		O
0.8-5.6		O
microM		O
)		O
,		O
MCMV		O
(		O
IC50		O
2.1		O
,		O
0.3		O
,		O
and		O
0.3		O
microM		O
)		O
and		O
EBV		O
in		O
H		O
-		O
1		O
(		O
IC50		O
0.2		O
,		O
0.3		O
,		O
and		O
0.7		O
microM		O
)		O
and		O
Daudi		O
cells		O
(		O
IC50		O
3.2		O
,		O
5.6		O
,		O
and		O
1.2		O
microM		O
)		O
.		O
The		O
dopaminergic		O
receptor		O
profile		O
of		O
a		O
series		O
of		O
trans		B-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
phenylcyclopropyl		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
arylpiperazines		I-IUPAC
was		O
examined		O
.		O
An		O
alternate		O
route		O
,		O
using		O
the		O
dibenzyloxyfluoroaldehyde		B-IUPAC
,		O
was		O
also		O
used		O
to		O
prepare		O
6		B-IUPAC
-		I-IUPAC
fluoronorepinephrine		I-IUPAC
.		O
Two		O
series		O
of		O
pyrazolo		B-IUPAC
[		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
analogues		B-MODIFIER
of		O
1		B-IUPAC
-		I-IUPAC
methylisoguanosine		I-IUPAC
have		O
been		O
synthesized		O
.		O
In		O
order		O
to		O
assess		O
steric		O
,		O
lipophilic		O
,		O
and		O
electronic		O
influences		O
on		O
opioid		O
binding		O
affinity		O
,		O
analogs		O
of		O
the		O
delta		O
receptor		O
selective		O
peptide		O
deltorphin		O
I		O
(		O
Tyr		O
-		O
D		O
-		O
Ala		O
-		O
Phe		O
-		O
Asp		O
-		O
Val		O
-		O
Val		O
-		O
GlyNH2		O
)		O
were		O
prepared		O
in		O
which		O
the		O
residue		O
3		O
phenylalanine		O
was		O
replaced		O
with		O
lipophilic		O
fluoro		B-IUPAC
-		O
and		O
methyl		B-IUPAC
-		O
substituted		B-MODIFIER
phenylalanines		B-IUPAC
or		O
with		O
the		O
heterocyclic		O
aromatic		O
amino		O
acids		O
3		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
thiazolyl		I-IUPAC
)		I-IUPAC
alanine		I-IUPAC
,		O
3		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
pyridyl		I-IUPAC
)		I-IUPAC
alanine		I-IUPAC
,		O
3		B-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
pyridyl		I-IUPAC
)		I-IUPAC
alanine		I-IUPAC
,		O
histidine		O
,		O
and		O
3		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
thiazolyl		I-IUPAC
)		I-IUPAC
alanine		I-IUPAC
.		O
Similarly		O
,		O
the		O
reaction		O
of		O
5		B-IUPAC
-		I-IUPAC
diazoimidazole		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
carboxamide		I-IUPAC
(		O
7		O
)		O
with		O
[		B-IUPAC
(		I-IUPAC
11		I-IUPAC
)		I-IUPAC
C		I-IUPAC
-		I-IUPAC
carbonyl		I-IUPAC
]		I-IUPAC
methyl		I-IUPAC
isocyanate		I-IUPAC
(		O
10		O
)		O
gave		O
[		B-IUPAC
4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
11		I-IUPAC
)		I-IUPAC
C		I-IUPAC
-		I-IUPAC
carbonyl		I-IUPAC
]		I-IUPAC
temozolomide		I-IUPAC
(		O
11		O
)		O
in		O
10-15%		O
radiochemical		O
yield		O
from		O
[		B-IUPAC
(		I-IUPAC
11		I-IUPAC
)		I-IUPAC
C		I-IUPAC
-		I-IUPAC
carbonyl		I-IUPAC
]		I-IUPAC
methyl		I-IUPAC
isocyanate		I-IUPAC
(		O
10		O
)		O
(		O
decay		O
corrected		O
)		O
.		O
This		O
enhancement		O
of		O
sigma		O
2		O
receptor		O
affinity		O
is		O
accompanied		O
by		O
substantial		O
selectivity		O
of		O
all		O
of		O
these		O
dextrorotatory		O
products		O
for		O
the		O
sigma		O
2		O
relative		O
to		O
the		O
sigma		O
1		O
subtype		O
(		O
32-238		O
-		O
fold		O
)		O
,		O
and		O
thus		O
,		O
they		O
are		O
among		O
the		O
most		O
sigma		O
2		O
selective		O
compounds		O
currently		O
known		O
.		O
The		O
title		O
compounds		O
are		O
9alpha		B-IUPAC
-		I-IUPAC
fluoro		I-IUPAC
-		I-IUPAC
11beta		I-IUPAC
,		I-IUPAC
16alpha		I-IUPAC
,		I-IUPAC
17alpha		I-IUPAC
,		I-IUPAC
21		I-IUPAC
-		I-IUPAC
tetrahydroxypregna		I-IUPAC
-		I-IUPAC
1,4		I-IUPAC
-		I-IUPAC
diene		I-IUPAC
-		I-IUPAC
3,20		I-IUPAC
-		I-IUPAC
dione		I-IUPAC
21		I-IUPAC
-		I-IUPAC
[		I-IUPAC
bis		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
chloroethyl		I-IUPAC
)		I-IUPAC
carbamate		I-IUPAC
]		I-IUPAC
16,17		I-IUPAC
-		I-IUPAC
acetonide		I-IUPAC
(		O
I		O
)		O
and		O
11beta		B-IUPAC
,		I-IUPAC
17alpha		I-IUPAC
,		I-IUPAC
21		I-IUPAC
-		I-IUPAC
trihydroxypregn		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
ene		I-IUPAC
-		I-IUPAC
3,20		I-IUPAC
-		I-IUPAC
dione		I-IUPAC
21		I-IUPAC
-		I-IUPAC
[		I-IUPAC
bis		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
chloroethyl		I-IUPAC
)		I-IUPAC
carbamate		I-IUPAC
]		I-IUPAC
(		O
II		O
)		O
,		O
prepared		O
from		O
triamcinolone		O
acetonide		O
and		O
cortisol		O
,		O
respectively		O
,		O
through		O
the		O
reaction		O
of		O
the		O
C		O
-		O
21		O
hydroxyl		B-IUPAC
group		B-MODIFIER
with		O
phosgene		O
and		O
di		B-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
chloroethylamine		I-IUPAC
in		O
the		O
presence		O
of		O
triethylamine		O
.		O
The		O
present		O
work		O
gives		O
new		O
insights		O
into		O
the		O
role		O
of		O
the		O
substituent		O
in		O
both		O
the		O
7		O
-		O
and		O
the		O
3		O
-		O
position		O
for		O
the		O
design		O
of		O
4H		B-IUPAC
-		I-IUPAC
1,2,4		I-IUPAC
-		I-IUPAC
benzothiadiazine		I-IUPAC
1,1		I-IUPAC
-		I-IUPAC
dioxide		I-IUPAC
potassium		O
channel		O
openers		O
exhibiting		O
different		O
tissue		O
selectivity		O
profiles		O
.		O
In		O
combination		O
with		O
1,3		B-IUPAC
-		I-IUPAC
bis		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
chloroethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
nitrosourea		I-IUPAC
(		O
BCNU		O
)		O
,		O
the		O
prodrugs		O
were		O
not		O
effective		O
adjuvants		O
for		O
HT29		O
cell		O
killing		O
.		O
When		O
assayed		O
in		O
vivo		O
,		O
it		O
was		O
found		O
to		O
decrease		O
ODC		O
activity		O
by		O
60%		O
,		O
when		O
the		O
latter		O
was		O
measured		O
1		O
h		O
after		O
administration		O
.		O
The		O
depolarizing		O
effect		O
of		O
ACPA		O
could		O
be		O
fully		O
antagonized		O
by		O
the		O
selective		O
non		O
-		O
NMDA		O
antagonist		O
6		B-IUPAC
-		I-IUPAC
cyano		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
nitro		I-IUPAC
-		I-IUPAC
quinoxazoline		I-IUPAC
-		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
dione		I-IUPAC
(		O
CNQX		O
)		O
,		O
but		O
was		O
unaffected		O
by		O
the		O
selective		O
NMDA		O
antagonist		O
D		B-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
phosphonovaleric		I-IUPAC
acid		I-IUPAC
(		O
AP5		O
)		O
.		O
Metabolite		O
analysis		O
demonstrated		O
that		O
these		O
[		O
(		O
11		O
)		O
C		O
]		O
ligands		O
were		O
metabolized		O
by		O
debenzylation		O
to		O
polar		O
products		O
mainly		O
in		O
the		O
plasma		O
.		O
There		O
was		O
a		O
significant		O
correlation		O
for		O
the		O
2		O
-		O
thioether		O
compounds		O
between		O
the		O
pK0		O
.5		O
values		O
for		O
inositol		O
phosphate		O
production		O
and		O
the		O
pD2		O
values		O
for		O
relaxation		O
mediated		O
via		O
the		O
P2Y		O
-		O
purinoceptors		O
in		O
the		O
guinea		O
pig		O
taenia		O
coli		O
,		O
but		O
not		O
for		O
the		O
vascular		O
P2Y		O
-		O
receptors		O
or		O
for		O
the		O
P2X		O
-		O
receptors		O
.		O
In		O
general		O
the		O
members		O
of		O
this		O
series		O
were		O
prepared		O
by		O
the		O
alkaline		O
cyclization		O
of		O
1		B-IUPAC
-		I-IUPAC
aroyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
alkylsemicarbazides		I-IUPAC
.		O
Alkylation		O
of		O
appropriate		O
alpha		O
-		O
alkyl		O
homoterephthalate		O
esters		O
with		O
2,4		B-IUPAC
-		I-IUPAC
diamino		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
bromomethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
deazapteridine		I-IUPAC
afforded		O
10		B-IUPAC
-		I-IUPAC
alkyl		I-IUPAC
-		I-IUPAC
10		I-IUPAC
-		I-IUPAC
carboxy		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
deoxy		I-IUPAC
-		I-IUPAC
8,10		I-IUPAC
-		I-IUPAC
dideazapteroic		I-IUPAC
acid		I-IUPAC
diesters		I-IUPAC
.		O
In		O
vitro		O
antiviral		O
activities		O
against		O
HSV		O
-		O
1		O
-		O
TK		O
(		O
+		O
)		O
(		O
KOS		O
and		O
E		O
-		O
377		O
)		O
,		O
HSV		O
-		O
1		O
-		O
TK		O
(		O
-		O
)		O
,		O
HSV		O
-		O
2		O
,		O
VZV		O
,		O
HCMV		O
,		O
and		O
DHBV		O
were		O
determined		O
.		O
The		O
former		O
lactone		O
contains		O
embedded		O
within		O
its		O
structure		O
an		O
exact		O
glycerol		O
moiety		O
,		O
while		O
in		O
the		O
latter		O
the		O
ring		O
oxygen		O
has		O
been		O
transposed		O
to		O
the		O
other		O
side		O
of		O
the		O
carbonyl		O
group		O
.		O
rhodesiense		O
with		O
two		O
exhibiting		O
values		O
of		O
6		O
nM		O
and		O
1		O
nM		O
.		O
These		O
two		O
derivatives		O
reduced		O
KA		O
and		O
ATPA		O
currents		O
to		O
a		O
larger		O
extent		O
than		O
that		O
shown		O
by		O
reference		O
compound		O
1		O
.		O
The		O
methyl		B-IUPAC
-		O
substituted		B-MODIFIER
derivatives		B-MODIFIER
(		B-IUPAC
+		I-IUPAC
/		I-IUPAC
-		I-IUPAC
)		I-IUPAC
-		I-IUPAC
trans		I-IUPAC
-		I-IUPAC
N		I-IUPAC
,		I-IUPAC
alpha		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
pyrrolidinyl		I-IUPAC
)		I-IUPAC
cyclohexyl		I-IUPAC
]		I-IUPAC
benzo		I-IUPAC
-		I-IUPAC
[		I-IUPAC
b		I-IUPAC
]		I-IUPAC
thiophene		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
acetamide		I-IUPAC
monohydrochloride		I-IUPAC
(		O
6a		O
,		O
b		O
)		O
possess		O
significantly		O
weaker		O
affinity		O
than		O
1		O
for		O
the		O
kappa		O
opioid		O
receptor		O
(		O
Ki		O
=		O
172		O
and		O
3.7		O
nM		O
,		O
respectively		O
)		O
.		O
The		O
3		B-IUPAC
-		I-IUPAC
nitro		I-IUPAC
-		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
quinolones		I-IUPAC
and		O
2		B-IUPAC
-		I-IUPAC
carboxy		I-IUPAC
-		I-IUPAC
1,2,3,4		I-IUPAC
-		I-IUPAC
tetrahydroquinolines		I-IUPAC
show		O
quite		O
different		O
structure		O
-		O
activity		O
relationships		O
at		O
the		O
4		O
-		O
position		O
.		O
The		O
enantiomers		O
of		O
trans		B-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
n		I-IUPAC
-		I-IUPAC
propyl		I-IUPAC
and		O
-		B-PARTIUPAC
N		I-PARTIUPAC
-		I-PARTIUPAC
allyl		I-PARTIUPAC
analogs		B-MODIFIER
were		O
obtained		O
via		O
fractional		O
recrystallization		O
of		O
their		O
di		B-IUPAC
-		I-IUPAC
p		I-IUPAC
-		I-IUPAC
toluoyl		I-IUPAC
-		I-IUPAC
L		I-IUPAC
(		O
or		O
D		B-PARTIUPAC
)		O
tartaric		B-IUPAC
acid		I-IUPAC
salts		I-IUPAC
.		O
None		O
of		O
the		O
six		O
analogues		O
were		O
substrates		O
.		O
Instead		O
,		O
these		O
compounds		O
have		O
the		O
highest		O
activities		O
in		O
their		O
respective		O
series		O
,		O
with		O
the		O
delta		O
(		O
22		O
)		O
-		O
24		O
-		O
one		O
compounds		O
having		O
activities		O
comparable		O
to		O
those		O
of		O
the		O
reference		O
anesthetic		O
steroids		O
.		O
Selective		O
protection		O
of		O
the		O
5'		B-IUPAC
-		I-IUPAC
hydroxyl		I-IUPAC
group		B-MODIFIER
of		O
14		O
with		O
tert		B-IUPAC
-		I-IUPAC
butyldimethylsilyl		I-IUPAC
chloride		I-IUPAC
followed		O
by		O
a		O
Barton		O
type		O
deoxygenation		O
sequence		O
of		O
the		O
3'		B-IUPAC
-		I-IUPAC
hydroxyl		I-IUPAC
groups		B-MODIFIER
afforded		O
ethyl		B-IUPAC
3		I-IUPAC
-		I-IUPAC
cyano		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
dideoxy		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
tert		I-IUPAC
-		I-IUPAC
butyldimethylsilyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
glycero		I-IUPAC
-		I-IUPAC
pentofuranosyl		I-IUPAC
]		I-IUPAC
pyrrole		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
carboxylate		I-IUPAC
(		O
18		O
)		O
.		O
Compound		O
3		O
showed		O
moderate		O
activity		O
(		O
IC50		O
10		O
(		O
-		O
6		O
)		O
-		O
10		O
(		O
-		O
7		O
)		O
M		O
)		O
.		O
In		O
all		O
three		O
series		O
,		O
substituents		O
placed		O
peri		O
to		O
the		O
carboxamide		O
sidechain		O
(		O
the		O
5		O
-		O
position		O
in		O
the		O
acridines		O
,		O
and		O
the		O
9		O
-		O
position		O
in		O
the		O
phenazines		O
and		O
dibenzo		B-IUPAC
[		I-IUPAC
1,4		I-IUPAC
]		I-IUPAC
dioxins		I-IUPAC
)		O
enhance		O
activity		O
and		O
potency		O
.		O
A		O
series		O
of		O
PGE2		O
,		O
16,16		B-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
PGE2		I-IUPAC
,		O
and		O
PGF2		O
alpha		O
analogues		O
modified		O
at		O
the		O
carboxyl		O
terminus		O
with		O
tetrazole		O
,		O
amide		O
,		O
acylurea		O
,		O
imide		O
,		O
and		O
sulfonimide		O
functionalities		O
was		O
evaluated		O
for		O
uterine		O
stimulant		O
,		O
bronchodilator		O
,		O
hypotensive		O
,		O
gastric		O
antisecretory		O
,		O
and		O
diarrheal		O
activity		O
.		O
The		O
data		O
for		O
inhibition		O
of		O
[		O
3H		O
]		O
paroxetine		O
binding		O
show		O
that		O
(		O
1R		O
)		O
-		O
2		O
beta		O
,		O
3		O
alpha		O
-		O
4c		O
,		O
which		O
has		O
the		O
same		O
stereochemistry		O
as		O
paroxetine		O
,		O
has		O
the		O
highest		O
affinity		O
at		O
the		O
5		O
-		O
HTT		O
.		O
These		O
5		B-IUPAC
-		I-IUPAC
halo		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
-		I-IUPAC
5,6		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
compounds		B-MODIFIER
,		O
like		O
AZT		O
,		O
did		O
not		O
undergo		O
glycosidic		O
bond		O
cleavage		O
upon		O
incubation		O
with		O
Escherichia		O
coli		O
thymidine		O
phosphorylase		O
.		O
1		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
6		I-IUPAC
-		I-IUPAC
Chloro		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
pyridinyl		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
imidazolidine		I-IUPAC
(		O
1		O
)		O
,		O
the		O
N		B-IUPAC
-		I-IUPAC
desnitro		I-IUPAC
metabolite		B-MODIFIER
of		O
the		O
major		O
insecticide		O
imidacloprid		O
,		O
is		O
known		O
to		O
have		O
similar		O
potency		O
to		O
that		O
of		O
(		B-IUPAC
-		I-IUPAC
)		I-IUPAC
-		I-IUPAC
nicotine		I-IUPAC
as		O
an		O
inhibitor		O
of		O
[		B-IUPAC
3H		I-IUPAC
]		I-IUPAC
(		I-IUPAC
-		I-IUPAC
)		I-IUPAC
-		I-IUPAC
nicotine		I-IUPAC
binding		O
at		O
the		O
rat		O
recombinant		O
alpha4beta2		O
neuronal		O
nicotinic		O
acetylcholine		O
receptor		O
(		O
nAChR		O
)		O
;		O
IC50		O
values		O
in		O
the		O
present		O
study		O
are		O
3.8		O
nM		O
for		O
(		B-IUPAC
-		I-IUPAC
)		I-IUPAC
-		I-IUPAC
nicotine		I-IUPAC
,		O
6.0		O
nM		O
for		O
1		O
,		O
and		O
155		O
nM		O
for		O
imidacloprid		O
.		O
7		B-IUPAC
-		I-IUPAC
(		I-IUPAC
Aminosulfonyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1,2,3,4		I-IUPAC
-		I-IUPAC
tetrahydroisoquinoline		I-IUPAC
(		O
SK		O
&		O
amp		O
;		O
F		O
29661		O
,		O
1		O
)		O
is		O
a		O
potent		O
inhibitor		O
of		O
the		O
enzyme		O
phenylethanolamine		O
N		O
-		O
methyltransferase		O
(		O
PNMT		O
,		O
EC		O
2.1.1.28		O
)		O
.		O
The		O
retinoic		O
acid		O
receptors		O
(		O
RARs		O
)		O
transduce		O
retinoid		O
dependant		O
gene		O
regulation		O
,		O
and		O
many		O
biological		O
effects		O
of		O
retinoids		O
are		O
mediated		O
through		O
binding		O
and		O
activation		O
of		O
three		O
closely		O
related		O
receptor		O
subtypes		O
(		O
RAR		O
alpha		O
,		O
RAR		O
beta		O
,		O
and		O
RAR		O
gamma		O
)		O
.		O
Addition		O
of		O
4		B-PARTIUPAC
-		I-PARTIUPAC
methoxy		I-PARTIUPAC
-		I-PARTIUPAC
or		O
4		B-IUPAC
-		I-IUPAC
(		I-IUPAC
benzyloxy		I-IUPAC
)		I-IUPAC
phenyl		I-IUPAC
Grignard		O
reagents		O
to		O
p		B-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
,		O
p		B-IUPAC
-		I-IUPAC
benzyloxy		I-IUPAC
,		O
or		O
unsubstituted		O
deoxybenzoins		O
,		O
followed		O
by		O
dehydration		O
of		O
the		O
resulting		O
carbinols		O
produced		O
a		O
mixture		O
of		O
E		O
and		O
Z		O
olefins		O
,		O
which		O
were		O
reacted		O
with		O
dichlorocarbene		O
to		O
give		O
O		O
-		O
protected		O
DTACs		O
.		O
Induction		O
of		O
cell		O
death		O
in		O
a		O
variety		O
of		O
tumor		O
cell		O
lines		O
was		O
determined		O
in		O
a		O
monolayer		O
assay		O
using		O
propidium		O
iodide		O
.		O
All		O
the		O
bis		B-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
phenylazopyridine		I-IUPAC
)		I-IUPAC
ruthenium		I-IUPAC
(		I-IUPAC
II		I-IUPAC
)		I-IUPAC
compounds		B-MODIFIER
display		O
a		O
promising		O
cytotoxicity		O
in		O
the		O
A2780		O
cell		O
line		O
(		O
IC		O
(		O
50		O
)		O
=		O
0.9-10		O
microM		O
)		O
,		O
with		O
an		O
activity		O
comparable		O
to		O
that		O
of		O
cisplatin		O
and		O
even		O
higher		O
than		O
the		O
activity		O
of		O
carboplatin		O
.		O
In		O
analogy		O
to		O
N		B-IUPAC
(		I-IUPAC
9		I-IUPAC
)		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
phosphonomethoxy		I-IUPAC
)		I-IUPAC
propyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2,6		I-IUPAC
-		I-IUPAC
diaminopurine		I-IUPAC
(		O
PMPDAP		O
)		O
,		O
solely		O
the		O
(		B-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2,4		I-IUPAC
-		I-IUPAC
diamino		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
phosphonomethoxy		I-IUPAC
)		I-IUPAC
propoxy		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
exerted		O
antiviral		O
activity		O
,		O
whereas		O
its		O
(		O
S		O
)		O
-		O
enantiomer		O
was		O
essentially		O
inactive		O
.		O
However		O
,		O
upon		O
iv		O
administration		O
,		O
35		O
(		O
3-100		O
mg		O
/		O
kg		O
)		O
and		O
39		O
(		O
3-300		O
mg		O
/		O
kg		O
)		O
failed		O
to		O
inhibit		O
the		O
binding		O
of		O
[		O
3H		O
]		O
mepyramine		O
to		O
mouse		O
cerebral		O
cortex		O
in		O
vivo		O
,		O
thereby		O
indicating		O
that		O
these		O
histamine		O
derivatives		O
are		O
not		O
able		O
to		O
penetrate		O
the		O
blood		O
-		O
brain		O
barrier		O
.		O
These		O
purine		O
acyclic		O
nucleosides		O
were		O
prepared		O
by		O
reaction		O
of		O
tris		B-PARTIUPAC
(		I-PARTIUPAC
trimethylsilyl		I-PARTIUPAC
)		I-PARTIUPAC
guanine		I-PARTIUPAC
or		O
2,6		B-IUPAC
-		I-IUPAC
diaminopurine		I-IUPAC
sodium		I-IUPAC
salt		I-IUPAC
with		O
the		O
chloromethyl		O
ethers		O
prepared		O
from		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
hydroxyethyl		I-IUPAC
)		I-IUPAC
phthalimide		I-IUPAC
,		O
N		B-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
hydroxyethoxy		I-IUPAC
)		I-IUPAC
ethyl		I-IUPAC
]		I-IUPAC
phthalimide		I-IUPAC
,		O
or		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
hydroxyethyl		I-IUPAC
)		I-IUPAC
oxazolidin		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
one		I-IUPAC
to		O
give		O
the		O
N		O
-		O
blocked		O
intermediates		O
5-8		O
.		O
Alkyl		O
substitution		O
at		O
C		O
-		O
5		O
or		O
C		O
-		O
10		O
was		O
generally		O
detrimental		O
to		O
antiinflammatory		O
activity		O
in		O
this		O
series		O
.		O
This		O
study		O
supports		O
the		O
notion		O
that		O
the		O
key		O
remote		O
aromatic		O
ring		O
present		O
in		O
the		O
5		B-IUPAC
-		I-IUPAC
arylpentadienecarboxamides		I-IUPAC
(		O
5		O
)		O
is		O
preferentially		O
coplanar		O
with		O
the		O
diene		O
system		O
for		O
good		O
PAF		O
antagonist		O
activity		O
.		O
A		O
comparison		O
of		O
the		O
biological		O
properties		O
of		O
these		O
compounds		O
clearly		O
demonstrates		O
that		O
the		O
tetraamines		O
must		O
be		O
charged		O
to		O
be		O
"		O
recognized		O
"		O
by		O
the		O
cell		O
.		O
The		O
efficiency		O
of		O
aminolysis		O
was		O
partially		O
dependent		O
upon		O
the		O
linkage		O
between		O
4		B-IUPAC
-		I-IUPAC
(		I-IUPAC
hydroxymethyl		I-IUPAC
)		I-IUPAC
phenoxy		I-IUPAC
(		O
HMP		O
)		O
handles		B-MODIFIER
and		O
the		O
resin		O
and		O
/		O
or		O
resin		O
particle		O
size		O
.		O
Affinity		O
was		O
determined		O
in		O
radioligand		O
binding		O
assays		O
at		O
rat		O
brain		O
A1		O
and		O
A2a		O
receptors		O
using		O
[		O
3H		O
]		O
-		O
N6		O
-		O
PIA		O
(		O
[		B-IUPAC
3H		I-IUPAC
]		I-IUPAC
-		I-IUPAC
(		I-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
N6		I-IUPAC
-		I-IUPAC
phenylisopropyladenosine		I-IUPAC
)		O
and		O
[		O
3H		O
]		O
CGS21680		O
[		O
[		B-IUPAC
3H		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
carboxyethyl		I-IUPAC
)		I-IUPAC
phenyl		I-IUPAC
]		I-IUPAC
ethylamino		I-IUPAC
]		I-IUPAC
-		I-IUPAC
5'		I-IUPAC
-		I-IUPAC
(		I-IUPAC
N		I-IUPAC
-		I-IUPAC
ethylcarbamoyl+		I-IUPAC
+		I-IUPAC
+		I-IUPAC
)		I-IUPAC
adenosine		I-IUPAC
]		O
,		O
respectively		O
.		O
Compound		O
19		O
also		O
showed		O
long		O
duration		O
of		O
activity		O
.		O
In		O
vivo		O
biodistribution		O
and		O
blocking		O
studies		O
were		O
performed		O
in		O
male		O
rats		O
and		O
demonstrated		O
that		O
the		O
brain		O
uptake		O
of		O
[		O
(		O
123		O
)		O
I		O
]		O
ZIENT		O
was		O
selective		O
and		O
specific		O
for		O
SERT		O
-		O
rich		O
regions		O
(		O
hypothalamus		O
,		O
striatum		O
,		O
pons		O
,		O
and		O
prefrontal		O
cortex		O
)		O
.		O
A		O
three		O
-		O
dimensional		O
quantitative		O
structure		O
-		O
activity		O
relationship		O
(		O
3D		O
QSAR		O
)		O
study		O
was		O
performed		O
on		O
five		O
different		O
chemical		O
series		O
reported		O
as		O
selective		O
uPA		O
inhibitors		O
employing		O
comparative		O
molecular		O
field		O
analysis		O
(		O
CoMFA		O
)		O
/		O
comparative		O
molecular		O
similarity		O
indices		O
analysis		O
(		O
CoMSIA		O
)		O
techniques		O
to		O
investigate		O
the		O
structural		O
requirements		O
for		O
substrates		O
and		O
derive		O
a		O
predictive		O
model		O
that		O
may		O
be		O
used		O
for		O
the		O
design		O
of		O
novel		O
uPA		O
inhibitors		O
.		O
Saponification		O
of		O
the		O
protecting		O
groups		O
gave		O
2,5		B-IUPAC
-		I-IUPAC
anhydro		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
deoxy		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
lyxo		I-IUPAC
-		I-IUPAC
hexonic		I-IUPAC
acid		I-IUPAC
(		O
4		O
)		O
which		O
reacted		O
with		O
4,5,6		B-IUPAC
-		I-IUPAC
triaminopyrimidine		I-IUPAC
forming		O
an		O
amide		O
(		O
5		O
)		O
that		O
was		O
pyrolized		O
to		O
give		O
8		B-IUPAC
-		I-IUPAC
(		I-IUPAC
3'		I-IUPAC
-		I-IUPAC
deoxy		I-IUPAC
-		I-IUPAC
alpha		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
threo		I-IUPAC
-		I-IUPAC
pentofuranosyl		I-IUPAC
)		I-IUPAC
adenine		I-IUPAC
(		O
6		O
)		O
.		O
Aryl		O
groups		O
such		O
as		O
thienyl		O
,		O
indoloyl		O
,		O
or		O
naphthyl		O
also		O
support		O
A2		O
agonist		O
activity		O
.		O
Following		O
oral		O
administration		O
of		O
tritiated		O
tolazamide		O
to		O
male		O
humans		O
,		O
85%		O
of		O
the		O
radioactivity		O
was		O
excreted		O
in		O
urine		O
during		O
a		O
5		O
-		O
day		O
period		O
.		O
At		O
least		O
the		O
guanidine		O
derivative		O
4		O
might		O
represent		O
a		O
potentially		O
useful		O
agent		O
for		O
imaging		O
of		O
neuroblastoma		O
cells		O
.		O
Two		O
series		O
of		O
compounds		O
that		O
are		O
structurally		O
related		O
to		O
benzomorphans		O
,		O
derived		O
by		O
structural		O
modification		O
of		O
arylpiperazines		O
with		O
high		O
5		O
-		O
HT1A		O
affinity		O
and		O
moderate		O
sigma		O
affinity		O
,		O
were		O
prepared		O
in		O
order		O
to		O
increase		O
sigma		O
affinity		O
and		O
selectivity		O
.		O
The		O
ED		O
(		O
50		O
)		O
was		O
about		O
4		O
-		O
fold		O
that		O
of		O
etretinate		O
.		O
The		O
development		O
of		O
99mTc		O
-		O
labeled		O
fatty		O
acid		O
analogues		O
metabolized		O
by		O
beta		O
-		O
oxidation		O
in		O
the		O
myocardium		O
constitutes		O
an		O
unsolved		O
challenge		O
.		O
Analogues		O
of		O
1t		O
(		O
3		O
)		O
,		O
which		O
have		O
(		B-PARTIUPAC
S		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
and		O
(		B-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
groups		B-MODIFIER
at		O
the		O
benzylic		O
methylene		O
portion		O
of		O
1t		O
,		O
were		O
prepared		O
and		O
separated		O
into		O
the		O
diastereomeric		O
atropisomers		O
,		O
3a		O
-		O
A		O
,		O
3a		O
-		O
B		O
and		O
3b		O
-		O
A		O
,		O
3b		O
-		O
B		O
,		O
in		O
enantiomerically		O
pure		O
forms		O
.		O
In		O
these		O
cases		O
,		O
6		O
-		O
and		O
7		O
-		O
substitution		O
was		O
disfavored		O
,		O
whereas		O
8		O
-		O
substitution		O
was		O
largely		O
tolerated		O
.		O
Drugs		O
were		O
given		O
at		O
various		O
concentrations		O
on		O
days		O
0		O
,		O
5		O
,		O
and		O
9		O
.		O
The		O
space		O
group		O
for		O
both		O
molecules		O
was		O
P1		O
in		O
triclinic		O
systems		O
.		O
Furthermore		O
,		O
several		O
of		O
the		O
2,4		B-IUPAC
-		I-IUPAC
pteridinediamines		I-IUPAC
exhibited		O
potent		O
prophylactic		O
activity		O
against		O
Plasmodium		O
gallinaceum		O
infections		O
in		O
the		O
chick		O
and		O
also		O
showed		O
strong		O
antibacterial		O
action		O
against		O
Streptococcus		O
faecalis		O
and		O
Staphylococcus		O
aureus		O
.		O
Compounds		O
7a		O
,		O
b		O
were		O
prepared		O
from		O
3g		O
in		O
the		O
multistep		O
synthesis		O
from		O
compounds		O
5		O
and		O
6		O
.		O
The		O
various		O
compounds		O
are		O
relatively		O
weak		O
with		O
respect		O
to		O
potentiation		O
of		O
L		B-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
hydroxytryptophan		I-IUPAC
-		O
induced		O
seizures		O
.		O
The		O
in		O
vitro		O
values		O
for		O
inhibition		O
of		O
[		O
(		O
3		O
)		O
H		O
]		O
-		O
GABA		O
uptake		O
in		O
rat		O
synaptosomes		O
was		O
determined		O
for		O
each		O
compound		O
in		O
this		O
new		O
series		O
,		O
and		O
it		O
was		O
found		O
that		O
several		O
of		O
the		O
novel		O
compounds		O
showed		O
a		O
high		O
potency		O
comparable		O
with		O
that		O
of		O
the		O
reference		O
compounds		O
4		O
,		O
5		O
(		O
tiagabine		O
)		O
,		O
and		O
6		O
(		O
CI		O
-		O
966		O
)		O
.		O
(		O
ABSTRACT		O
TRUNCATED		O
AT		O
400		O
WORDS		O
)		O
Previously		O
,		O
(		B-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
quinuclidinyl		I-IUPAC
(		I-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
iodobenzilate		I-IUPAC
(		O
(		O
R		O
,		O
R		O
)		O
-		O
IQNB		O
)		O
,		O
a		O
muscarinic		O
receptor		O
antagonist		O
,		O
has		O
been		O
labeled		O
with		O
123I		O
and		O
125I		O
for		O
use		O
in		O
in		O
vitro		O
and		O
in		O
vivo		O
studies		O
in		O
animals		O
and		O
humans		O
.		O
The		O
effect		O
of		O
limiting		O
glutathione		O
concentrations		O
on		O
the		O
stereochemical		O
outcome		O
of		O
the		O
transferase		O
A		O
catalyzed		O
conjugation		O
of		O
the		O
chiral		O
substrate		O
,		O
(		B-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
phenethyl		I-IUPAC
chloride		I-IUPAC
(		O
4		O
mM		O
)		O
,		O
was		O
investigated		O
.		O
The		O
palladium		O
-		O
catalyzed		O
coupling		O
of		O
3		B-PARTIUPAC
-		I-PARTIUPAC
and		O
4		B-IUPAC
-		I-IUPAC
(		I-IUPAC
trialkylstannyl		I-IUPAC
)		I-IUPAC
pyridines		I-IUPAC
with		O
7		B-IUPAC
-		I-IUPAC
bromo		I-IUPAC
or		O
7		B-IUPAC
-		I-IUPAC
chloro		I-IUPAC
1		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
1,4		B-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
oxo		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
quinolinecarboxylates		I-IUPAC
has		O
provided		O
access		O
to		O
the		O
corresponding		O
1		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
1,4		B-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
oxo		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
pyridinyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
quinolinecarboxylic		I-IUPAC
acids		I-IUPAC
.		O
These		O
cis		O
and		O
trans		O
analogs		O
of		O
2,3,3		B-IUPAC
a		I-IUPAC
,		I-IUPAC
4,9,9		I-IUPAC
a		I-IUPAC
-		I-IUPAC
hexahydro		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
benz		I-IUPAC
[		I-IUPAC
f		I-IUPAC
]		I-IUPAC
indole		I-IUPAC
(		O
3		O
)		O
,		O
where		O
a		O
five		O
-		O
membered		O
ring		O
is		O
fused		O
between		O
the		O
nitrogen		O
and		O
C		O
-		O
3		O
carbon		O
of		O
2		B-IUPAC
-		I-IUPAC
aminotetralin		I-IUPAC
,		O
were		O
synthesized		O
from		O
5		B-PARTIUPAC
-		I-PARTIUPAC
methoxy		I-PARTIUPAC
-		I-PARTIUPAC
and		O
8		B-IUPAC
-		I-IUPAC
methoxytetralones		I-IUPAC
.		O
The		O
compounds		O
1,1		B-IUPAC
-		I-IUPAC
cyclobutanedicarboxylatobis		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
phenylazopyridine		I-IUPAC
)		I-IUPAC
ruthenium		I-IUPAC
(		I-IUPAC
II		I-IUPAC
)		I-IUPAC
,		O
alpha		O
-		O
[		O
Ru		O
(		O
azpy		O
)		O
(		O
2		O
)		O
(		O
cbdca		O
-		O
O		O
,		O
O'		O
)		O
]		O
(		O
1		O
)		O
,		O
oxalatobis		B-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
phenylazopyridine		I-IUPAC
)		I-IUPAC
ruthenium		I-IUPAC
(		I-IUPAC
II		I-IUPAC
)		I-IUPAC
,		O
alpha		O
-		O
[		O
Ru		O
(		O
azpy		O
)		O
(		O
2		O
)		O
(		O
ox		O
)		O
]		O
(		O
2		O
)		O
,		O
and		O
malonatobis		B-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
phenylazopyridine		I-IUPAC
)		I-IUPAC
ruthenium		I-IUPAC
(		I-IUPAC
II		I-IUPAC
)		I-IUPAC
,		O
alpha		O
-		O
[		O
Ru		O
(		O
azpy		O
)		O
(		O
2		O
)		O
(		O
mal		O
)		O
]		O
(		O
3		O
)		O
,		O
have		O
been		O
synthesized		O
and		O
fully		O
characterized		O
.		O
The		O
aryl		O
group		O
in		O
the		O
5,6		O
-		O
disubstituted		O
analogues		O
was		O
either		O
attached		O
directly		O
to		O
the		O
hetero		O
ring		O
or		O
was		O
separated		O
from		O
it		O
by		O
one		O
or		O
two		O
carbons		O
,		O
whereas		O
the		O
aryl		O
group		O
in		O
the		O
5		O
-		O
monosubstituted		O
analogues		O
was		O
separated		O
from		O
the		O
hetero		O
ring		O
by		O
two		O
or		O
three		O
carbons		O
.		O
The		O
AII		O
antagonistic		O
activity		O
of		O
the		O
benzimidazoles		O
was		O
investigated		O
by		O
in		O
vitro		O
assays		O
,		O
which		O
included		O
an		O
AII		O
receptor		O
binding		O
assay		O
and		O
AII		O
-		O
induced		O
vasocontraction		O
assay		O
,		O
as		O
well		O
as		O
by		O
in		O
vivo		O
assays		O
such		O
as		O
an		O
AII		O
-		O
induced		O
pressor		O
response		O
in		O
rats		O
.		O
(		O
2R		O
)		O
-		O
1		O
,		O
which		O
was		O
metabolized		O
to		O
2		O
to		O
a		O
lesser		O
extent		O
,		O
afforded		O
considerably		O
more		O
(		O
2R		O
,		O
2		O
"		O
R		O
)		O
-		O
2		O
than		O
(		O
2R		O
,		O
2		O
"		O
S		O
)		O
-		O
2		O
.		O
When		O
the		O
p		O
-		O
anisyl		O
group		O
of		O
1		O
was		O
replaced		O
by		O
an		O
n		O
-		O
pentyl		O
group		O
,		O
the		O
resultant		O
antagonist		O
3		O
exhibited		O
substantially		O
increased		O
ETB		O
/		O
ETA		O
activity		O
ratio		O
,		O
but		O
a		O
decreased		O
ETA		O
affinity		O
.		O
The		O
results		O
indicated		O
that		O
PDE		O
isolated		O
from		O
beef		O
heart		O
tissue		O
was		O
most		O
sensitive		O
to		O
changes		O
in		O
the		O
length		O
of		O
the		O
alkyl		O
group		O
in		O
the		O
5		O
position		O
of		O
the		O
pyrazolo		B-IUPAC
[		I-IUPAC
1,5		I-IUPAC
-		I-IUPAC
a		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
ring		B-MODIFIER
,		O
whereas		O
the		O
PDE		O
isolated		O
from		O
rabbit		O
lung		O
tissue		O
was		O
more		O
sensitive		O
to		O
changes		O
in		O
the		O
length		O
of		O
the		O
7		O
-		O
alkyl		O
group		O
.		O
In		O
contrast		O
,		O
high		O
activity		O
against		O
aminopyrine		O
demethylase		O
was		O
frequently		O
displayed		O
in		O
this		O
series		O
,		O
3,5		B-IUPAC
-		I-IUPAC
dibromo		I-IUPAC
-		I-IUPAC
2,4		I-IUPAC
-		I-IUPAC
dihydroxypropiophenone		I-IUPAC
(		O
36		O
)		O
showing		O
greatest		O
inhibitory		O
potency		O
.		O
In		O
particular		O
,		O
compound		O
7		O
,		O
the		O
4		B-IUPAC
-		I-IUPAC
triazolyl		I-IUPAC
derivative		B-MODIFIER
of		O
BVDU		O
,		O
would		O
seem		O
worth		O
pursuing		O
for		O
its		O
potential		O
as		O
an		O
inhibitor		O
of		O
herpes		O
simplex		O
virus		O
type		O
1		O
and		O
varicella		O
-		O
zoster		O
virus		O
.		O
Subsequent		O
coupling		O
of		O
the		O
enantiomeric		B-MODIFIER
(		B-IUPAC
fluoroalkyl		I-IUPAC
)		I-IUPAC
benzilic		I-IUPAC
acid		I-IUPAC
with		O
a		O
selected		O
enantiomer		O
of		O
quinuclidinol		O
provides		O
fluorinated		O
analogs		O
of		O
QNB		O
with		O
known		O
stereochemistry		O
at		O
each		O
of		O
the		O
stereogenic		O
centers		O
.		O
Several		O
partial		O
structures		O
of		O
2		O
,		O
either		O
monocyclic		O
lactams		O
or		O
monocyclic		O
2,4		B-IUPAC
-		I-IUPAC
oxazolidinediones		I-IUPAC
,		O
were		O
also		O
evaluated		O
in		O
these		O
assays		O
,		O
but		O
no		O
correlation		O
was		O
observed		O
between		O
sodium		O
channel		O
binding		O
and		O
anti		O
-		O
MES		O
effects		O
.		O
Its		O
inhibition		O
of		O
the		O
enzyme		O
,		O
5,10		B-IUPAC
-		I-IUPAC
methenyltetrahydrofolate		I-IUPAC
cyclohydrolase		O
(		O
EC		O
3.5.4.9		O
)		O
,		O
was		O
competitive		O
against		O
(		B-IUPAC
+		I-IUPAC
)		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
5,10		I-IUPAC
-		I-IUPAC
methenyltetrahydrofolate		I-IUPAC
,		O
with		O
a		O
Ki		O
=		O
41		O
micro		O
M		O
.		O
Regarding		O
replacements		O
of		O
quinazoline		O
by		O
other		O
heterocyclic		O
rings		O
,		O
pyrazolo		B-IUPAC
[		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
(		O
39a		O
,		O
IC		O
(		O
50		O
)		O
=		O
0.17		O
microM		O
)		O
and		O
quinoline		O
(		O
IC		O
(		O
50		O
)		O
of		O
40a		O
is		O
0.18		O
microM		O
;		O
IC		O
(		O
50		O
)		O
of		O
40b		O
is		O
0.09		O
microM		O
)		O
derivatives		O
showed		O
potent		O
activity		O
.		O
The		O
cytotoxicity		O
was		O
also		O
determined		O
in		O
human		O
PBM		O
cells		O
as		O
well		O
as		O
Vero		O
cells		O
.		O
By		O
this		O
method		O
,		O
two		O
possible		O
orders		O
of		O
hydration		O
for		O
the		O
candidates		O
were		O
obtained		O
:		O
p		B-IUPAC
-		I-IUPAC
amidinophenylpyruvate		I-IUPAC
&		O
gt		O
;		O
p		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
oxo		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
propyl		I-IUPAC
)		I-IUPAC
benzamidine		I-IUPAC
&		O
gt		O
;		O
p		B-IUPAC
-		I-IUPAC
methylbenzamidine		I-IUPAC
&		O
gt		O
;		O
p		B-IUPAC
-		I-IUPAC
ethylbenzamidine		I-IUPAC
&		O
gt		O
;		O
p		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
propyl		I-IUPAC
)		I-IUPAC
benzamidine		I-IUPAC
&		O
gt		O
;		O
benzamidine		B-IUPAC
and		O
p		B-IUPAC
-		I-IUPAC
amidinophenylpyruvate		I-IUPAC
&		O
gt		O
;		O
p		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
oxo		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
propyl		I-IUPAC
)		I-IUPAC
benzamidine		I-IUPAC
&		O
gt		O
;		O
p		B-IUPAC
-		I-IUPAC
methylbenzamidine		I-IUPAC
&		O
gt		O
;		O
p		B-IUPAC
-		I-IUPAC
ethylbenzamidine		I-IUPAC
&		O
gt		O
;		O
benzamidine		B-IUPAC
&		O
gt		O
;		O
p		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
propyl		I-IUPAC
)		I-IUPAC
benzamidine		I-IUPAC
.		O
For		O
the		O
latter		O
complexes		O
,		O
cis		O
isomers		O
seem		O
to		O
be		O
somewhat		O
more		O
active		O
than		O
trans		O
isomers		O
.		O
In		O
this		O
model		O
,		O
using		O
both		O
rats		O
and		O
guinea		O
pigs		O
,		O
compounds		O
31		O
and		O
58		O
were		O
found		O
to		O
be		O
as		O
active		O
as		O
the		O
reference		O
PAF		O
antagonist		O
3		B-IUPAC
-		I-IUPAC
[		I-IUPAC
4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
chlorophenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
9		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
6H		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
morpholinyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
propanone		I-IUPAC
(		O
45		O
)		O
.		O
The		O
cholesterol		O
-		O
lowering		O
sterols		O
did		O
not		O
significantly		O
alter		O
lipoprotein		O
levels		O
;		O
however		O
,		O
the		O
two		O
compounds		O
have		O
been		O
shown		O
to		O
inhibit		O
acyl		O
-		O
coenzyme		O
A		O
:		O
cholesterol		O
acyl		O
-		O
transferase		O
(		O
ACAT		O
)		O
in		O
tissue		O
culture		O
studies		O
.		O
The		O
double		O
bond		O
in		O
compounds		O
2		O
and		O
11		O
was		O
saturated		O
by		O
hydrogenation		O
to		O
give		O
23		O
and		O
24		O
.		O
(		O
31		O
)		O
P		O
NMR		O
determination		O
of		O
the		O
N		O
-		O
dechloroethylated		O
metabolites		O
of		O
IF		O
or		O
its		O
structural		O
isomer		O
,		O
cyclophosphamide		O
(		O
CP		O
)		O
,		O
and		O
their		O
degradation		O
compounds		O
could		O
provide		O
an		O
indirect		O
and		O
accurate		O
estimation		O
of		O
chloroacetaldehyde		O
amounts		O
formed		O
from		O
CP		O
or		O
IF		O
.		O
The		O
7,8		B-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
derivative		B-MODIFIER
of		O
propargylfolic		O
acid		O
served		O
as		O
a		O
synthetic		O
substrate		O
of		O
Lactobacillus		O
casei		O
dihydrofolate		O
reductase		O
.		O
In		O
vivo		O
biodistribution		O
studies		O
were		O
performed		O
in		O
male		O
rats		O
and		O
demonstrated		O
that		O
the		O
brain		O
uptake		O
of		O
[		O
(		O
18		O
)		O
F		O
]		O
(		O
R		O
)		O
-		O
FIPCT		O
and		O
[		O
(		O
18		O
)		O
F		O
]		O
(		O
S		O
)		O
-		O
FIPCT		O
were		O
selective		O
and		O
specific		O
for		O
DAT		O
rich		O
regions		O
(		O
caudate		O
and		O
putamen		O
)		O
.		O
Introduction		O
of		O
a		O
highly		O
lipophilic		O
alkoxy		O
group		O
at		O
position		O
7		O
of		O
the		O
4		B-IUPAC
-		I-IUPAC
chromanone		I-IUPAC
moiety		B-MODIFIER
instead		O
of		O
methoxy		O
group		O
also		O
resulted		O
in		O
potent		O
activity		O
.		O
In		O
a		O
similar		O
way		O
,		O
diamidines		O
8b		O
and		O
8c		O
were		O
prepared		O
from		O
the		O
dicyano		B-IUPAC
derivatives		B-MODIFIER
4c		O
and		O
4d		O
,		O
respectively		O
.		O
In		O
vitro		O
bioassay		O
data		O
for		O
the		O
gamma		B-IUPAC
-		I-IUPAC
methylene		I-IUPAC
and		O
gamma		B-IUPAC
-		I-IUPAC
cyano		I-IUPAC
compounds		B-MODIFIER
support		O
the		O
idea		O
that		O
the		O
active		O
site		O
of		O
DHFR		O
,		O
already		O
known		O
for		O
its		O
ability		O
to		O
tolerate		O
modification		O
of		O
the		O
gamma		B-IUPAC
-		I-IUPAC
carboxyl		I-IUPAC
group		B-MODIFIER
of		O
MTX		O
and		O
AMT		O
,		O
can		O
likewise		O
accommodate		O
substitution		O
on		O
the		O
gamma		O
-		O
carbon		O
itself		O
.		O
Subsequent		O
separation		O
of		O
the		O
anomers		O
,		O
followed		O
by		O
deprotection		O
and		O
reduction		O
of		O
5b		O
,		O
6b		O
,		O
and		O
5c		O
,		O
afforded		O
the		O
respective		O
8R		O
and		O
8S		O
isomers		O
.		O
Remarkable		O
differences		O
were		O
found		O
between		O
the		O
binding		O
modes		O
of		O
10		O
,		O
13		O
,		O
and		O
14		O
and		O
that		O
of		O
1		O
.		O
Extension		O
of		O
the		O
side		O
chain		O
of		O
7b		O
by		O
two		O
carbons		O
gave		O
(		B-IUPAC
1		I-IUPAC
,		I-IUPAC
1		B-IUPAC
-		I-IUPAC
dioxido		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
oxo		I-IUPAC
-		I-IUPAC
1,2		I-IUPAC
-		I-IUPAC
benzisothiazol		I-IUPAC
-		I-IUPAC
2		I-IUPAC
(		I-IUPAC
3H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
5		I-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
(		I-IUPAC
phenylmethoxy		I-IUPAC
)		I-IUPAC
carbonyl		I-IUPAC
]		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
pentanoate		I-IUPAC
(		O
7d		O
)		O
which		O
was		O
an		O
8		O
-		O
fold		O
more		O
potent		O
inhibitor		O
(		O
IC50		O
=		O
0.1		O
microM		O
)		O
.		O
2		B-IUPAC
-		I-IUPAC
Deoxy		I-IUPAC
-		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
arabino		I-IUPAC
-		I-IUPAC
hexopyranoside		I-IUPAC
2		O
was		O
also		O
an		O
effective		O
growth		O
inhibitor		O
of		O
two		O
drug		O
-		O
resistant		O
leukemic		O
cell		O
lines		O
,		O
P388		O
/		O
Adr		O
and		O
L1210		O
/		O
vmdr		O
.		O
The		O
biological		O
profiles		O
of		O
reported		O
compounds		O
at		O
alpha		O
(		O
1		O
)		O
-		O
adrenoreceptor		O
subtypes		O
were		O
assessed		O
by		O
functional		O
experiments		O
in		O
isolated		O
rat		O
vas		O
deferens		O
(		O
alpha		O
(		O
1A		O
)		O
)		O
,		O
spleen		O
(		O
alpha		O
(		O
1B		O
)		O
)		O
,		O
and		O
aorta		O
(		O
alpha		O
(		O
1D		O
)		O
)		O
and		O
by		O
binding		O
assays		O
in		O
CHO		O
and		O
HeLa		O
cells		O
membranes		O
expressing		O
the		O
human		O
cloned		O
alpha		O
(		O
1		O
)		O
-		O
adrenoreceptor		O
subtypes		O
and		O
5		O
-		O
HT		O
(		O
1A		O
)		O
receptors		O
,		O
respectively		O
.		O
This		O
report		O
also		O
describes		O
the		O
synthesis		O
of		O
several		O
aryl		O
-		O
alkyl		O
and		O
aryl		O
-		O
aryl		O
carbonates		O
(		O
12-14		O
,		O
16-23		O
)		O
as		O
efficient		O
reagents		O
for		O
the		O
preparation		O
of		O
carbamate		O
derivatives		O
from		O
bis		O
-		O
arylamidines		O
.		O
A		O
series		O
of		O
monoamidic		B-MODIFIER
derivatives		I-MODIFIER
of		I-MODIFIER
cis		B-PARTIUPAC
-		I-PARTIUPAC
and		O
trans		B-PARTIUPAC
-		I-PARTIUPAC
1,2		I-PARTIUPAC
-		I-PARTIUPAC
cyclohexanedicarboxylic		I-PARTIUPAC
and		O
1,2		B-IUPAC
-		I-IUPAC
cyclopentanedicarboxylic		I-IUPAC
acids		I-IUPAC
bearing		O
either		O
a		O
carboxylic		O
,		O
sulfhydrylic		O
,		O
or		O
hydroxamic		O
group		O
in		O
the		O
side		O
chain		O
were		O
synthesized		O
and		O
evaluated		O
in		O
vitro		O
for		O
their		O
inhibitory		O
activity		O
against		O
angiotensin		O
converting		O
enzyme		O
.		O
The		O
second		O
one		O
is		O
the		O
presence		O
of		O
a		O
N		O
-		O
phenyl		O
ring		O
bearing		O
a		O
relatively		O
small		O
,		O
not		O
electron		O
-		O
withdrawing		O
para		O
substituent		O
that		O
could		O
favorably		O
interact		O
with		O
a		O
hydrophobic		O
cavity		O
close		O
to		O
the		O
NOS		O
catalytic		O
site		O
.		O
Preliminary		O
evaluation		O
of		O
these		O
compounds		O
in		O
electric		O
organ		O
synaptic		O
vesicles		O
revealed		O
several		O
potent		O
vesamicol		O
receptor		O
ligands		O
,		O
such		O
as		O
1'		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
1,2,3,4		I-IUPAC
-		I-IUPAC
tetrahydronaphth		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
spiro		I-IUPAC
[		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
indene		I-IUPAC
-		I-IUPAC
1,4		I-IUPAC
'		I-IUPAC
-		I-IUPAC
p		I-IUPAC
iperidine		I-IUPAC
(		O
11b		O
)		O
and		O
1'		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
1,2,3,4		I-IUPAC
-		I-IUPAC
tetrahydronaphth		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
spiro		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
bromo		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
in		I-IUPAC
den		I-IUPAC
e		I-IUPAC
-		I-IUPAC
1,4		I-IUPAC
'		I-IUPAC
-		I-IUPAC
piperidine		I-IUPAC
]		I-IUPAC
(		O
14		O
)		O
,		O
which		O
display		O
subnanomolar		O
affinity		O
for		O
this		O
receptor		O
.		O
The		O
3		O
-		O
chlorophenyl		O
group		O
showed		O
the		O
greatest		O
activity		O
in		O
the		O
N1		O
-		O
position		O
and		O
the		O
butyl		O
group		O
produced		O
the		O
greatest		O
activity		O
in		O
the		O
N5		O
-		O
position		O
.		O
Moreover		O
,		O
compound		O
13		O
,		O
a		O
1		B-IUPAC
-		I-IUPAC
benzylpiperazine		I-IUPAC
analogue		B-MODIFIER
of		O
14		O
,		O
preserved		O
a		O
dual		O
high		O
5		O
-		O
HT1A		O
and		O
sigma		O
affinity		O
(		O
Ki		O
=		O
3.6		O
nM		O
on		O
[		O
3H		O
]		O
-		O
5		O
-		O
HT		O
and		O
Ki		O
=		O
7.0		O
nM		O
on		O
[		O
3H		O
]		O
DTG		O
)		O
.		O
In		O
general		O
,		O
calpain		O
II		O
was		O
more		O
sensitive		O
to		O
these		O
inhibitors		O
than		O
calpain		O
I		O
,		O
with		O
a		O
large		O
number		O
of		O
inhibitors		O
displaying		O
dissociation		O
constants		O
(		O
Ki		O
)		O
in		O
the		O
10-100		O
nM		O
range		O
.		O
gondii		O
cells		O
in		O
culture		O
.		O
2		B-IUPAC
-		I-IUPAC
Amino		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
cyano		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
aryl		I-IUPAC
/		I-IUPAC
alkyl		I-IUPAC
)		I-IUPAC
thiophene		I-IUPAC
intermediates		O
for		O
the		O
preparation		O
of		O
the		O
5,6		O
-		O
disubstituted		O
analogues		O
were		O
prepared		O
from		O
omega		B-IUPAC
-		I-IUPAC
aryl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
alkylidene		I-IUPAC
-		I-IUPAC
malononitriles		I-IUPAC
and		O
sulfur		O
in		O
the		O
presence		O
of		O
a		O
secondary		O
amine		O
,		O
and		O
2		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
cyano		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
aryl		I-IUPAC
/		I-IUPAC
aralkyl		I-IUPAC
)		I-IUPAC
thiophene		I-IUPAC
intermediates		B-MODIFIER
for		O
the		O
preparation		O
of		O
the		O
5		O
-		O
monosubstituted		O
analogues		O
were		O
obtained		O
from		O
omega		B-IUPAC
-		I-IUPAC
aryl		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
chloro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
alkylidenemalononitriles		I-IUPAC
and		O
sodium		O
hydrosulfide		O
.		O
The		O
adenosine		O
antagonist		O
9		B-IUPAC
-		I-IUPAC
chloro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
furanyl		I-IUPAC
)		I-IUPAC
[		I-IUPAC
1,2,4		I-IUPAC
]		I-IUPAC
triazolo		I-IUPAC
[		I-IUPAC
1		I-IUPAC
,		I-IUPAC
5		I-IUPAC
-		I-IUPAC
c		I-IUPAC
]		I-IUPAC
quinazolin		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
amine		I-IUPAC
(		O
CGS		O
15943		O
)		O
binds		O
nonselectively		O
to		O
human		O
A1		O
,		O
A2A		O
,		O
and		O
A3		O
receptors		O
with		O
high		O
affinity		O
.		O
Reaction		O
of		O
alpha		O
,		O
omega		O
-		O
diaminoalkanes		O
with		O
8		O
-		O
Br		O
-		O
ATP		O
gave		O
8		O
-		O
NH		O
(		O
CH2		O
)		O
nNH2		O
derivatives		O
of		O
ATP		O
,		O
which		O
upon		O
iodoacetylation		O
gave		O
8		O
-		O
NH		O
(		O
CH2		O
)		O
nNHCOCH2I		O
derivatives		O
of		O
ATP		O
(		O
n		O
=		O
2		O
,		O
4		O
,		O
6		O
,		O
or		O
8		O
)		O
.		O
Most		O
were		O
noncytotoxic		O
in		O
their		O
antiviral		O
concentration		O
range		O
.		O
One		O
of		O
the		O
most		O
potent		O
compounds		O
,		O
1		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
ethoxyethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
homopiperazinyl		I-IUPAC
)		I-IUPAC
benzimidazole		I-IUPAC
(		O
69		O
)		O
,		O
was		O
39		O
times		O
more		O
potent		O
than		O
chlorpheniramine		O
maleate		O
in		O
H1		O
-		O
antihistaminic		O
activity		O
in		O
vivo		O
and		O
was		O
selected		O
for		O
clinical		O
evaluation		O
.		O
Cytotoxicity		O
which		O
was		O
observed		O
appeared		O
to		O
be		O
a		O
consequence		O
of		O
DNA		O
synthesis		O
inhibition		O
.		O
Preference		O
for		O
the		O
Northern		O
(		O
N		O
)		O
ring		O
conformation		O
of		O
the		O
ribose		O
moiety		O
of		O
nucleotide		O
5'		O
-		O
triphosphate		O
agonists		O
at		O
P2Y		O
(		O
1		O
)		O
,		O
P2Y		O
(		O
2		O
)		O
,		O
P2Y		O
(		O
4		O
)		O
,		O
and		O
P2Y		O
(		O
11		O
)		O
receptors		O
,		O
but		O
not		O
P2Y		O
(		O
6		O
)		O
receptors		O
,		O
was		O
established		O
using		O
a		O
ring		O
-		O
constrained		O
methanocarba		O
(		O
a		O
3.1.0		O
-		O
bicyclohexane		O
)		O
ring		O
as		O
a		O
ribose		O
substitute		O
(		O
Kim		O
et		O
al.		O
J		O
.		O
However		O
,		O
even		O
higher		O
dopaminergic		O
potency		O
is		O
observed		O
for		O
trans		O
-		O
7		O
-		O
OH		O
-		O
OHBQs		O
and		O
(		B-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
hydroxyphenyl		I-IUPAC
)		I-IUPAC
piperidines		I-IUPAC
with		O
N		O
-		O
substituents		O
larger		O
than		O
n		B-IUPAC
-		I-IUPAC
propyl		I-IUPAC
.		O
The		O
EC50s		O
of		O
coronary		O
vasoactivity		O
of		O
several		O
para		O
-		O
substituted		O
analogues		O
are		O
in		O
the		O
subnanomolar		O
range		O
.		O
The		O
general		O
trend		O
is		O
that		O
,		O
up		O
to		O
a		O
certain		O
size		O
,		O
the		O
more		O
lipophilic		O
the		O
N		O
-		O
substituent		O
,		O
the		O
higher		O
the		O
affinity		O
for		O
sigma		O
receptor		O
sites		O
.		O
These		O
compounds		O
were		O
generally		O
more		O
toxic		O
to		O
V		O
-		O
79		O
cells		O
than		O
the		O
2		B-IUPAC
-		I-IUPAC
nitroimidazole		I-IUPAC
derivatives		B-MODIFIER
and		O
were		O
found		O
to		O
be		O
more		O
effective		O
radiosensitizers		O
in		O
vitro		O
.		O
These		O
isomers		O
are		O
both		O
shown		O
to		O
be		O
excellent		O
substrates		O
for		O
COMT		O
,		O
with		O
a		O
slight		O
preference		O
for		O
the		O
S		O
-		O
(		O
-		O
)		O
enantiomer		O
.		O
Leukemia		O
and		O
colorectal		O
carcinoma		O
cell		O
lines		O
were		O
generally		O
most		O
sensitive		O
,		O
though		O
good		O
activity		O
was		O
also		O
observed		O
against		O
CNS		O
tumors		O
and		O
carcinomas		O
of		O
the		O
breast		O
and		O
prostate		O
.		O
The		O
effect		O
was		O
reverted		O
4		O
h		O
after		O
administration		O
of		O
the		O
drug		O
.		O
A		O
novel		O
series		O
of		O
(		B-IUPAC
2R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
1R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3		I-IUPAC
,		I-IUPAC
3		I-IUPAC
-		I-IUPAC
difluorocyclopentyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
phenylacetamides		I-IUPAC
was		O
designed		O
and		O
synthesized		O
based		O
on		O
the		O
structure		O
and		O
biological		O
profiles		O
of		O
an		O
active		O
metabolite		O
2		O
of		O
our		O
prototype		O
muscarinic		O
M		O
(		O
3		O
)		O
receptor		O
selective		O
antagonist		O
1		O
,		O
to		O
develop		O
a		O
potent		O
,		O
long		O
-		O
acting		O
,		O
orally		O
active		O
M		O
(		O
3		O
)		O
antagonist		O
for		O
the		O
treatment		O
of		O
urinary		O
tract		O
disorders		O
,		O
irritable		O
bowel		O
syndrome		O
,		O
and		O
respiratory		O
disorders		O
.		O
A		O
series		B-MODIFIER
of		O
3		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
fluorophenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
indoles		I-IUPAC
substituted		B-MODIFIER
in		I-MODIFIER
the		I-MODIFIER
1		I-MODIFIER
-		I-MODIFIER
position		I-MODIFIER
with		O
4		B-IUPAC
-		I-IUPAC
piperidinyl		I-IUPAC
,		O
1,2,3,6		B-IUPAC
-		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
pyridinyl		I-IUPAC
,		O
and		O
4		B-IUPAC
-		I-IUPAC
piperazinyl		I-IUPAC
was		O
synthesized		O
.		O
Oral		O
activity		O
was		O
seen		O
in		O
this		O
series		O
of		O
compounds		O
with		O
duration		O
of		O
activity		O
up		O
to		O
120		O
min		O
.		O
Reductive		O
cleavage		O
of		O
7a		O
-		O
e		O
and		O
subsequent		O
methylation		O
or		O
acylations		O
gave		O
the		O
title		O
compounds		O
(		O
3		O
,		O
8-24		O
)		O
.		O
Analogues		O
8		O
,		O
10		O
,		O
and		O
21		O
potently		O
inhibited		O
the		O
forskolin		O
-		O
stimulated		O
cAMP		O
production		O
in		O
sst		O
(		O
4		O
)		O
-		O
transfected		O
cells		O
,		O
therefore		O
acting		O
as		O
full		O
agonists		O
.		O
Furthermore		O
,		O
5		B-IUPAC
-		I-IUPAC
butyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
phenylhydantoin		I-IUPAC
(		O
7		O
;		O
IC50		O
=		O
103		O
microM		O
)		O
was		O
less		O
potent		O
than		O
8		O
,		O
suggesting		O
that		O
increased		O
log		O
P		O
may		O
enhance		O
binding		O
.		O
These		O
results		O
suggest		O
that		O
the		O
potent		O
antagonistic		O
properties		O
of		O
the		O
bicyclic		O
analogues		O
[		O
Mpa1		O
,		O
cyclo		O
(		O
Glu4		O
,		O
Lys8		O
)		O
]		O
oxytocin		O
and		O
[		O
dPen1		O
,		O
cyclo		O
(		O
Glu4		O
,		O
Lys8		O
)		O
]		O
oxytocin		O
can		O
be		O
attributed		O
to		O
the		O
effect		O
of		O
the		O
lactam		O
bridge		O
on		O
the		O
conformational		O
flexibility		O
and		O
topographical		O
properties		O
of		O
the		O
analogues		O
,		O
rendering		O
them		O
more		O
favorable		O
for		O
binding		O
to		O
the		O
receptor		O
in		O
such		O
a		O
manner		O
as		O
to		O
prevent		O
transduction		O
of		O
a		O
biological		O
response		O
.		O
Introduction		O
of		O
the		O
N		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
group		B-MODIFIER
enhanced		O
potency		O
about		O
twofold		O
.		O
Comparison		O
of		O
about		O
38		O
PAT		O
analogues		O
,		O
10		O
structurally		O
diverse		O
H		O
(		O
1		O
)		O
ligands		O
,		O
and		O
several		O
other		O
CNS		O
-		O
active		O
compounds		O
revealed		O
no		O
significant		O
differences		O
in		O
affinity		O
at		O
[		O
(		O
3		O
)		O
H		O
]		O
-		O
(		O
-		O
)		O
-		O
trans		O
-		O
H		O
(		O
2		O
)		O
-		O
PAT		O
sites		O
versus		O
[		O
(		O
3		O
)		O
H		O
]		O
mepyramine		O
-		O
labeled		O
H		O
(		O
1		O
)		O
receptors		O
.		O
In		O
this		O
study		O
,		O
we		O
synthesized		O
and		O
evaluated		O
a		O
series		O
of		O
multimeric		O
RGD		O
compounds		O
constructed		O
on		O
a		O
dicarboxylic		O
acid		O
-		O
containing		O
near		O
-		O
infrared		O
(		O
NIR		O
)		O
fluorescent		O
dye		O
(		O
cypate		O
)		O
for		O
tumor		O
targeting		O
.		O
Tricyclo		O
(		O
1-3/4-10/5-8		O
)		O
[		O
Ac		O
-		O
DGlu		O
(		O
1		O
)		O
,		O
DCpa		O
(		O
2		O
)		O
,		O
DLys		O
(		O
3		O
)		O
,		O
Asp		O
(		O
4		O
)		O
,		O
Glu		O
(		O
5		O
)		O
,		O
DNal		O
(		O
6		O
)		O
,		O
Lys		O
(		O
8		O
)		O
,		O
Dpr		O
(		O
10		O
)		O
]		O
GnRH		O
(		O
27		O
)		O
was		O
inactive		O
at		O
500		O
microgram		O
/		O
rat		O
with		O
a		O
corresponding		O
low		O
affinity		O
(		O
K		O
(		O
i		O
)		O
=		O
4.6		O
nM		O
)		O
when		O
compared		O
to		O
those		O
of		O
the		O
most		O
potent		O
analogues		O
(		O
K		O
(		O
i		O
)		O
&		O
lt		O
;		O
0.5		O
nM		O
)		O
.		O
Conformation		O
of		O
each		O
nucleoside		O
in		O
D		O
(		O
2		O
)		O
O		O
solution		O
,		O
deduced		O
from		O
(		O
1		O
)		O
H		O
NMR		O
spectra		O
and		O
confirmed		O
by		O
molecular		O
mechanics		O
calculations		O
,		O
showed		O
the		O
pentose		O
ring		O
to		O
exist		O
predominantly		O
in		O
the		O
conformation		O
S		O
(		O
C		O
-		O
2'		O
-		O
endo		O
)		O
and		O
the		O
N		O
(		O
4		O
)		O
-		O
OH		O
group		O
as		O
the		O
cis		O
rotamer		O
.		O
(		B-IUPAC
-		I-IUPAC
)		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
Propyl		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
butyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
4		I-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
phenylethoxy		I-IUPAC
)		I-IUPAC
phenyl		I-IUPAC
]		I-IUPAC
ethylam		I-IUPAC
ine		I-IUPAC
hydrochloride		I-IUPAC
(		O
(		O
-		O
)		O
-		O
6d		O
,		O
NE		O
-		O
537		O
)		O
and		O
(		B-IUPAC
-		I-IUPAC
)		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
propyl		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
methybutyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
4		I-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
phenylethoxy		I-IUPAC
)		I-IUPAC
phenyl		I-IUPAC
]		I-IUPAC
e		I-IUPAC
thylamine		I-IUPAC
hydrochloride		I-IUPAC
(		O
(		O
-		O
)		O
-		O
6i		O
,		O
NE		O
-		O
535		O
)		O
,		O
typical		O
compounds		O
in		O
this		O
series		O
,		O
have		O
potent		O
and		O
selective		O
sigma		O
(		O
1		O
)		O
affinity		O
.		O
Antiimmunosuppresive		O
activity		O
was		O
evaluated		O
by		O
the		O
ability		O
of		O
the		O
different		O
steroids		O
to		O
block		O
dexamethasone		O
-		O
mediated		O
apoptosis		O
in		O
thymocytes		O
and		O
dexamethasone		O
-		O
mediated		O
inhibition		O
of		O
the		O
NFkappa		O
-		O
B		O
transcription		O
factor		O
activity		O
.		O
The		O
7		B-MODIFIER
-		I-MODIFIER
mono		I-MODIFIER
-		I-MODIFIER
and		O
5,7		B-MODIFIER
-		I-MODIFIER
disubstituted		I-MODIFIER
-		O
5		B-IUPAC
-		I-IUPAC
deazaaminopterins		I-IUPAC
(		O
1b		O
,		O
d		O
-		O
g		O
)		O
were		O
prepared		O
from		O
the		O
respective		O
pyrido		B-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidines		I-IUPAC
12b		O
,		O
d		O
-		O
g		O
.		O
Separation		O
of		O
compound		O
14		O
into		O
the		O
corresponding		O
beta		O
and		O
alpha		O
anomers		O
was		O
achieved		O
by		O
conversion		O
to		O
the		O
3'		B-IUPAC
,		I-IUPAC
5'		I-IUPAC
-		I-IUPAC
di		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
acetyl		I-IUPAC
derivatives		B-MODIFIER
17		O
and		O
18		O
,		O
which		O
after		O
chromatographic		O
separation		O
were		O
deacetylated		O
to		O
give		O
1		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
deoxy		I-IUPAC
-		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
erythro		I-IUPAC
-		I-IUPAC
pentofuranosyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methylimidazole		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
carboxa		I-IUPAC
mid		I-IUPAC
e		I-IUPAC
and		O
its		O
alpha		O
anomer		O
20		O
.		O
In		O
contrast		O
,		O
trans		O
-		O
4		O
-		O
n		O
-		O
Bu		O
-		O
9		O
-		O
OH		O
-		O
OHBQ		O
is		O
inactive		O
,		O
and		O
(		B-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
hydroxyphenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
n		I-IUPAC
-		I-IUPAC
butylpiperidine		I-IUPAC
is		O
less		O
active		O
at		O
central		O
DA		O
receptors		O
than		O
its		O
corresponding		O
n		B-IUPAC
-		I-IUPAC
propyl		I-IUPAC
analogue		B-MODIFIER
.		O
We		O
now		O
report		O
on		O
fluorescence		O
,		O
one		O
-		O
and		O
two		O
-		O
dimensional		O
proton		O
NMR		O
,		O
and		O
molecular		O
modeling		O
studies		O
of		O
the		O
tomaymycin		O
-		O
d		O
(		O
ATGCAT		O
)		O
2		O
adduct		O
,		O
which		O
corroborate		O
these		O
earlier		O
observations		O
.		O
The		O
reaction		O
of		O
3		B-IUPAC
-		I-IUPAC
aminopyrazole		I-IUPAC
with		O
unsymmetrical		O
beta		O
-		O
diketones		O
(		O
hexane		B-IUPAC
-		I-IUPAC
2,4		I-IUPAC
-		I-IUPAC
dione		I-IUPAC
,		O
heptane		B-IUPAC
-		I-IUPAC
3,5		I-IUPAC
-		I-IUPAC
dione		I-IUPAC
,		O
etc		O
.		O
Ki		O
values		O
for		O
the		O
in		O
vitro		O
adenosine		O
deaminase		O
(		O
EC		O
3.5.4.4		O
;		O
type		O
I		O
;		O
calf		O
intestinal		O
mucosa		O
)		O
inhibitory		O
activities		O
of		O
1b		O
,		O
1c		O
,		O
and		O
2		O
were		O
determined		O
to		O
be		O
1.6		O
X		O
10		O
(		O
-		O
8		O
)		O
,		O
1.5		O
X		O
10		O
(		O
-		O
6		O
)		O
,		O
and		O
9.8		O
X		O
10		O
(		O
-		O
8		O
)		O
M		O
,		O
respectively		O
.		O
Compound		O
10		O
was		O
synthesized		O
via		O
N		O
-		O
ethylation		O
of		O
the		O
N		O
-		O
Boc		O
-		O
protected		O
primary		O
amine		O
25		O
.		O
The		O
antagonist		O
/		O
agonist		O
binding		O
ratio		O
method		O
is		O
clearly		O
not		O
always		O
reliable		O
for		O
predicting		O
agonist		O
activity		O
at		O
muscarinic		O
receptors		O
.		O
THHBADs		O
are		O
antagonists		O
of		O
NMDA		O
and		O
AMPA		O
receptors		O
with		O
functional		O
potency		O
being		O
dependent		O
upon		O
the		O
substitution		O
pattern		O
on		O
the		O
tetrahydrobenzene		O
moiety		O
.		O
Introduction		O
of		O
an		O
alkyl		O
group		O
at		O
the		O
3		O
position		O
of		O
the		O
pyridine		O
ring		O
of		O
4		B-IUPAC
-		I-IUPAC
morpholino		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
formylpyridine		I-IUPAC
thiosemicarbazone		I-IUPAC
was		O
achieved		O
by		O
utilizing		O
2,3		B-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
nitropyridine		I-IUPAC
N		I-IUPAC
-		I-IUPAC
oxide		I-IUPAC
;		O
this		O
material		O
was		O
converted		O
to		O
the		O
corresponding		O
4		B-IUPAC
-		I-IUPAC
chloro		I-IUPAC
derivative		B-MODIFIER
which		O
was		O
then		O
subjected		O
to		O
nucleophilic		O
substitution		O
.		O
An		O
in		O
vitro		O
assay		O
employing		O
the		O
A		O
(		O
1		O
)		O
AR		O
agonist		O
[		O
(		O
125		O
)		O
I		O
]		O
ABA		O
and		O
membranes		O
from		O
CHO		O
-		O
K1		O
cells		O
stably		O
expressing		O
the		O
hA		O
(		O
1		O
)		O
AR		O
measured		O
an		O
index		O
of		O
AE		O
activity		O
,		O
the		O
ability		O
of		O
a		O
candidate		O
AE		O
to		O
stabilize		O
the		O
agonist		O
-		O
A		O
(		O
1		O
)		O
AR		O
-		O
G		O
protein		O
ternary		O
complex		O
,		O
scored		O
as		O
the		O
percentage		O
of		O
ternary		O
complex		O
remaining		O
after		O
10		O
min		O
of		O
dissociation		O
initiated		O
by		O
CPX		O
and		O
GTPgammaS		O
.		O
Hypoxic		O
cells		O
are		O
an		O
important		O
target		O
for		O
antitumor		O
therapy		O
because		O
tumors		O
are		O
typically		O
characterized		O
by		O
such		O
cells		O
.		O
D		O
.		O
The		O
protected		O
precursors		O
required		O
for		O
these		O
peptides		O
were		O
obtained		O
by		O
a		O
combination		O
of		O
solid		O
-		O
phase		O
and		O
solutions		O
methods		O
.		O
The		O
affinities		O
of		O
these		O
ligands		O
for		O
PK		O
-		O
C		O
were		O
assessed		O
in		O
terms		O
of		O
their		O
ability		O
to		O
displace		O
bound		O
[		B-IUPAC
3H		I-IUPAC
-		I-IUPAC
20		I-IUPAC
]		I-IUPAC
phorbol		I-IUPAC
12,13		I-IUPAC
-		I-IUPAC
dibutyrate		I-IUPAC
(		O
PDBU		O
)		O
from		O
the		O
single		O
isozyme		O
PK		O
-		O
C		O
alpha		O
.		O
Thus		O
,		O
compounds		O
bearing		O
in		O
the		O
7		O
-		O
position		O
a		O
methyl		O
or		O
a		O
methoxy		O
group		O
or		O
devoid		O
of		O
a		O
substituent		O
in		O
this		O
position		O
,		O
and		O
bearing		O
an		O
ethyl		O
,		O
an		O
isopropyl		O
,		O
or		O
a		O
cyclobutylamino		O
group		O
in		O
the		O
3		O
-		O
position		O
were		O
found		O
to		O
be		O
potent		O
and		O
selective		O
inhibitors		O
of		O
insulin		O
release		O
from		O
rat		O
pancreatic		O
B		O
-		O
cells		O
(		O
i.e.		O
10a		O
,		O
10b		O
,		O
12b		O
,		O
12d		O
,		O
22c		O
)		O
.		O
ClogP		O
has		O
been		O
used		O
as		O
an		O
additional		O
descriptor		O
in		O
the		O
CoMFA		O
analysis		O
to		O
study		O
the		O
effects		O
of		O
lipophilic		O
parameters		O
on		O
activity		O
.		O
The		O
pyrrolidine		O
ring		O
(		O
present		O
in		O
most		O
of		O
the		O
polyamines		O
tested		O
in		O
this		O
series		O
)		O
proved		O
to		O
be		O
an		O
important		O
recognition		O
site		O
for		O
sigma		O
receptor		O
binding		O
activity		O
.		O
N6		B-IUPAC
-		I-IUPAC
(		I-IUPAC
omega		I-IUPAC
-		I-IUPAC
Aminoalkyl		I-IUPAC
)		I-IUPAC
derivatives		B-MODIFIER
of		O
adenosine		B-IUPAC
5'		I-IUPAC
-		I-IUPAC
monophosphate		I-IUPAC
(		O
AMP		O
)		O
were		O
converted		O
into		O
their		O
omega		B-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
carbobenzyloxy		I-IUPAC
derivatives		B-MODIFIER
,		O
and		O
these		O
were		O
converted		O
,		O
via		O
the		O
2'		B-IUPAC
,		I-IUPAC
3'		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
carbonyl		I-IUPAC
derivatives		B-MODIFIER
of		O
their		O
5'		B-IUPAC
-		I-IUPAC
phosphorimidazolidates		I-IUPAC
,		O
into		O
the		O
corresponding		O
ATP		O
derivatives		O
.		O
This		O
paper		O
describes		O
the		O
synthesis		O
and		O
kappa		O
and		O
mu		O
opioid		O
receptor		O
binding		O
affinity		O
of		O
some		O
conformationally		O
restrained		O
derivatives		O
of		O
the		O
arylacetamide		O
group		O
in		O
the		O
selective		O
kappa		O
opioid		O
receptor		O
agonist		O
(		B-IUPAC
+		I-IUPAC
/		I-IUPAC
-		I-IUPAC
)		I-IUPAC
-		I-IUPAC
trans		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
pyrrolidinyl		I-IUPAC
)		I-IUPAC
cyclohexyl		I-IUPAC
]		I-IUPAC
benzo		I-IUPAC
[		I-IUPAC
b		I-IUPAC
]		I-IUPAC
thiophene		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
acetamide		I-IUPAC
monohydrochloride		I-IUPAC
(		O
1		O
,		O
PD117302		O
)		O
,		O
which		O
is		O
an		O
analogue		O
of		O
U		O
-		O
50		O
,		O
488		O
.		O
Thus		O
5		B-IUPAC
-		I-IUPAC
propyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
deazaaminopterin		I-IUPAC
,		O
5		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
10		I-IUPAC
-		I-IUPAC
propargyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
deazaaminopterin		I-IUPAC
,		O
5		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
10		I-IUPAC
-		I-IUPAC
allyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
deazaaminopterin		I-IUPAC
,		O
5		B-IUPAC
-		I-IUPAC
ethyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
deazamethotrexate		I-IUPAC
,		O
and		O
2,5		B-MODIFIER
-		I-MODIFIER
disubstituted		I-MODIFIER
thiophene		B-IUPAC
analogue		B-MODIFIER
of		O
5		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
deazaaminopterin		I-IUPAC
showed		O
potencies		O
greater		O
than		O
methotrexate		O
by		O
intraperitoneal		O
or		O
oral		O
administration		O
and		O
were		O
active		O
over		O
a		O
considerably		O
broader		O
dose		O
range		O
.		O
Compounds		O
10		O
and		O
13-17		O
relaxed		O
precontracted		O
rat		O
aortic		O
rings		O
(		O
intact		O
endothelium		O
)		O
with		O
relative		O
potencies		O
of		O
3.3		O
-		O
up		O
to		O
28		O
-		O
fold		O
(		O
compared		O
with		O
1		O
)		O
,		O
displaying		O
partial		O
agonism		O
as		O
well		O
.		O
When		O
compounds		O
2		O
and		O
9b		O
were		O
tested		O
in		O
combination		O
with		O
vidarabine		O
against		O
herpes		O
simplex		O
virus		O
,		O
type		O
1		O
,		O
in		O
an		O
HEp		O
-		O
2		O
plaque		O
reduction		O
assay		O
,		O
only		O
compound		O
2		O
was		O
able		O
to		O
potentiate		O
the		O
antiviral		O
activity		O
of		O
vidarabine		O
.		O
N		B-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
Dihydroxyphenyl		I-IUPAC
)		I-IUPAC
ethyl		I-IUPAC
]		I-IUPAC
imidazoline		I-IUPAC
hydrochloride		I-IUPAC
(		O
2		O
)		O
and		O
N		B-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
dihydroxyphenyl		I-IUPAC
)		I-IUPAC
ethyl		I-IUPAC
]		I-IUPAC
ethylenediamine		I-IUPAC
dihydrochloride		I-IUPAC
(		O
4		O
)		O
,		O
both		O
with		O
two		O
methylene		O
groups		O
between		O
the		O
catechol		O
and		O
amine		O
segment		O
,		O
were		O
found		O
to		O
be		O
somewhat		O
selective		O
for		O
alpha		O
2		O
-		O
adrenergic		O
receptors		O
while		O
1		B-IUPAC
-		I-IUPAC
(		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
dihydroxybenzyl		I-IUPAC
)		I-IUPAC
imidazoline		I-IUPAC
hydrochloride		I-IUPAC
(		O
1		O
)		O
and		O
N		B-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
dihydroxybenzyl		I-IUPAC
)		I-IUPAC
ethylenediamine		I-IUPAC
dihydrochloride		I-IUPAC
(		O
3		O
)		O
,		O
both		O
with		O
one		O
methylene		B-IUPAC
group		B-MODIFIER
between		O
the		O
catechol		O
and		O
amine		O
segment		O
,		O
were		O
more		O
selective		O
for		O
alpha1		O
-		O
adrenergic		O
receptors		O
in		O
a		O
pithed		O
rat		O
model		O
.		O
This		O
compound		O
has		O
excellent		O
oral		O
activity		O
at		O
4		O
h		O
after		O
oral		O
dosing		O
(		O
1		O
mg		O
/		O
kg		O
)		O
,		O
inhibiting		O
methacholine		O
-		O
induced		O
bronchoconstriction		O
in		O
dogs		O
,		O
and		O
may		O
be		O
useful		O
in		O
clinical		O
situations		O
in		O
which		O
M		O
(		O
3		O
)		O
over		O
M		O
(		O
2		O
)		O
selectivity		O
is		O
desirable		O
.		O
The		O
E		O
and		O
Z		O
isomers		O
were		O
separated		O
by		O
fractional		O
crystallization		O
and		O
the		O
central		O
or		O
geminal		O
phenyl		O
ring		O
was		O
deprotected		O
to		O
provide		O
phenolic		O
DTACs		O
.		O
Although		O
1		B-IUPAC
-		I-IUPAC
(		I-IUPAC
carboxyalkyl		I-IUPAC
)		I-IUPAC
hydroxypyridinones		I-IUPAC
are		O
active		O
,		O
they		O
do		O
not		O
demonstrate		O
any		O
clear		O
advantage		O
over		O
Deferiprone		O
(		O
1,2		B-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
hydroxypyridin		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
one		I-IUPAC
)		O
.		O
A		O
possible		O
receptor		O
-		O
active		O
conformation		O
is		O
suggested		O
.		O
All		O
of		O
the		O
compounds		O
investigated		O
did		O
not		O
show		O
any		O
detectable		O
toxicity		O
to		O
several		O
stationary		O
and		O
proliferating		O
host		O
cell		O
lines		O
or		O
to		O
mitogen		O
stimulated		O
proliferating		O
human		O
T		O
lymphocytes		O
,		O
up		O
to		O
the		O
highest		O
concentration		O
tested		O
.		O
Monocyclic		O
derivatives		O
of		O
[		O
Mpa1		O
,		O
Gln4		O
,		O
Lys		O
(		O
CHO		O
)		O
8		O
]		O
oxytocin		O
were		O
moderate		O
to		O
weak		O
agonists		O
of		O
oxytocin		O
all		O
following		O
classical		O
structure		O
-		O
activity		O
profiles		O
of		O
oxytocin		O
.		O
Thus		O
the		O
3		B-PARTIUPAC
-		I-PARTIUPAC
chloro		I-PARTIUPAC
(		O
9a		O
)		O
,		O
3		B-PARTIUPAC
-		I-PARTIUPAC
bromo		I-PARTIUPAC
(		O
9b		O
)		O
,		O
and		O
3		B-PARTIUPAC
-		I-PARTIUPAC
nitro		I-PARTIUPAC
(		O
9c		O
)		O
analogues		B-MODIFIER
of		O
3		O
and		O
the		O
3		B-PARTIUPAC
-		I-PARTIUPAC
chloro		I-PARTIUPAC
(		O
9d		O
)		O
,		O
3		B-PARTIUPAC
-		I-PARTIUPAC
bromo		I-PARTIUPAC
(		O
9e		O
)		O
,		O
and		O
3		B-PARTIUPAC
-		I-PARTIUPAC
nitro		I-PARTIUPAC
(		O
9f		O
)		O
analogues		B-MODIFIER
of		O
4		O
were		O
prepared		O
by		O
standard		O
glycosylating		O
procedures		O
.		O
A		O
series		O
of		O
2,4		B-PARTIUPAC
-		I-PARTIUPAC
diamino		I-PARTIUPAC
-		I-PARTIUPAC
6		I-PARTIUPAC
-		I-PARTIUPAC
[		I-PARTIUPAC
(		I-PARTIUPAC
aralkyl		I-PARTIUPAC
and		O
alicyclic		B-PARTIUPAC
)		I-PARTIUPAC
thio		I-PARTIUPAC
-		I-PARTIUPAC
,		O
sulfinyl		B-PARTIUPAC
-		I-PARTIUPAC
,		O
and		O
sulfonyl		B-PARTIUPAC
]		I-PARTIUPAC
quinazolines		I-PARTIUPAC
was		O
prepared		O
via		O
condensation		O
of		O
5		B-IUPAC
-		I-IUPAC
chloro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
nitrobenzonitrile		I-IUPAC
or		O
5,6		B-IUPAC
-		I-IUPAC
dichloro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
nitrobenzonitrile		I-IUPAC
with		O
the		O
appropriate		O
aralkyl		O
or		O
alicyclic		O
thiopseudourea		O
,		O
reduction		O
of		O
the		O
resulting		O
2		B-IUPAC
-		I-IUPAC
nitro		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
aralkyl		I-IUPAC
or		I-IUPAC
alicyclic		I-IUPAC
)		I-IUPAC
thio		I-IUPAC
]		I-IUPAC
benzonitrile		I-IUPAC
with		O
stannous		O
chloride		O
to		O
the		O
amine		O
,		O
and		O
cyclization		O
with		O
chloroformamidine		B-IUPAC
hydrochloride		I-IUPAC
.		O
F		O
-		O
A		O
-		O
85380		O
has		O
been		O
labeled		O
with		O
the		O
positron		O
emitter		O
fluorine		O
-		O
18		O
(		O
t1/2		O
(		O
half		O
-		O
life		O
)		O
=		O
110		O
min		O
)		O
by		O
no		O
-		O
carrier		O
-		O
added		O
nucleophilic		O
aromatic		O
substitution		O
by		O
K		O
[		O
18F		O
]		O
F		O
-		O
K222		O
complex		O
with		O
(		B-IUPAC
3		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
(		I-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
(		I-IUPAC
tert		I-IUPAC
-		I-IUPAC
butoxycarbonyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
azetidinylmethoxy		I-IUPAC
]		I-IUPAC
pyridin		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
tri		I-IUPAC
methylammonium		I-IUPAC
trifluoromethanesulfonate		I-IUPAC
as		O
a		O
highly		O
efficient		O
labeling		O
precursor		O
,		O
followed		O
by		O
TFA		O
removal		O
of		O
the		O
Boc		O
protective		O
group		O
.		O
On		O
the		O
other		O
hand		O
,		O
conversion		O
of		O
the		O
carboxyl		B-IUPAC
group		B-MODIFIER
of		O
the		O
side		O
chain		O
to		O
an		O
amide		O
,		O
to		O
give		O
[		B-IUPAC
6		I-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
oxo		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
benzopyran		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
methylbutyl		I-IUPAC
]		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
-		I-IUPAC
4,5		I-IUPAC
-		I-IUPAC
dihydroxy		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
oxo		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
hexanamido		I-IUPAC
]		I-IUPAC
ammonium		I-IUPAC
chloride		I-IUPAC
(		O
10		O
)		O
,		O
caused		O
a		O
considerable		O
increase		O
in		O
both		O
activity		O
and		O
toxicity		O
.		O
New		O
water		O
-		O
soluble		O
bis		B-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
phenylazopyridine		I-IUPAC
)		I-IUPAC
ruthenium		I-IUPAC
(		I-IUPAC
II		I-IUPAC
)		I-IUPAC
complexes		B-MODIFIER
,		O
all		O
derivatives		O
of		O
the		O
highly		O
cytotoxic		O
alpha		O
-		O
[		O
Ru		O
(		O
azpy		O
)		O
(		O
2		O
)		O
Cl		O
(		O
2		O
)		O
]		O
(		O
alpha		O
denoting		O
the		O
coordinating		O
pairs		O
Cl		O
,		O
N		O
(		O
py		O
)		O
,		O
and		O
N		O
(		O
azo		O
)		O
as		O
cis		O
,		O
trans		O
,		O
cis		O
,		O
respectively		O
)		O
have		O
been		O
developed		O
.		O
All		O
the		O
activity		O
was		O
observed		O
in		O
the		O
intraperitoneally		O
innoculated		O
tumor		O
systems		O
.		O
Electrophysiological		O
data		O
showed		O
that		O
compound		O
8a		O
was		O
devoid		O
of		O
activity		O
in		O
the		O
rat		O
cortical		O
wedge		O
model		O
(		O
EC		O
(		O
50		O
)		O
&		O
gt		O
;		O
1000		O
microM		O
)		O
,		O
whereas		O
the		O
corresponding		O
4		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
analogue		B-MODIFIER
8b		O
was		O
a		O
potent		O
AMPA		O
receptor		O
agonist		O
(		O
EC		O
(		O
50		O
)		O
=		O
15		O
+		O
/		O
-		O
2		O
microM		O
)		O
.		O
4		B-IUPAC
-		I-IUPAC
Benzoyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
sulfamoyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
thenyloxy		I-IUPAC
)		I-IUPAC
benzoic		I-IUPAC
acid		I-IUPAC
(		O
118		O
)		O
is		O
among		O
the		O
most		O
potent		O
benzoic		O
acid		O
diuretics		O
hitherto		O
synthesized		O
and		O
shows		O
significant		O
diuretic		O
activity		O
in		O
dogs		O
at		O
1		O
mug		O
/		O
kg		O
.		O
Accordingly		O
,		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
trifluoroacetyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
14		I-IUPAC
-		I-IUPAC
bromodaunorubicin		I-IUPAC
was		O
used		O
for		O
reaction		O
with		O
thiols		O
to		O
yield		O
thia		O
analogues		O
of		O
the		O
clinically		O
active		O
but		O
non		O
-		O
DNA		O
-		O
binding		O
adriamycin		O
analogue		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
trifluoroacetyl		I-IUPAC
)		I-IUPAC
adriamycin		I-IUPAC
14		I-IUPAC
-		I-IUPAC
valerate		I-IUPAC
(		O
AD		O
32		O
)		O
.		O
The		O
7		O
most		O
potent		O
analogues		O
ranged		O
in		O
potency		O
from		O
3		O
to		O
14		O
times		O
greater		O
than		O
that		O
of		O
the		O
standard		O
and		O
contained		O
the		O
[		O
i		O
-		O
(		O
i		O
+		O
3		O
)		O
]		O
cycles		O
between		O
residues		O
4-7		O
,		O
5-8		O
,		O
9-12		O
,		O
16-19		O
,		O
21-24		O
,		O
22-25		O
,		O
and		O
25-28		O
.		O
A		O
series		O
of		O
4'		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
spiro		B-IUPAC
[		I-IUPAC
4H		I-IUPAC
-		I-IUPAC
3,1		I-IUPAC
-		I-IUPAC
benzoxazine		I-IUPAC
-		I-IUPAC
4,4		I-IUPAC
'		I-IUPAC
-		I-IUPAC
piperidin		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
ones		I-IUPAC
was		O
prepared		O
and		O
evaluated		O
for		O
antihypertensive		O
activity		O
in		O
the		O
spontaneously		O
hypertensive		O
rat		O
(		O
SHR		O
)		O
.		O
tuberculosis		O
.		O
Since		O
the		O
presence		O
and		O
position		O
of		O
a		O
chloro		O
substituent		O
on		O
the		O
5H		B-IUPAC
-		I-IUPAC
dibenzo		I-IUPAC
[		I-IUPAC
b		I-IUPAC
,		I-IUPAC
e		I-IUPAC
]		I-IUPAC
[		I-IUPAC
1,4		I-IUPAC
]		I-IUPAC
diazepine		I-IUPAC
moiety		B-MODIFIER
have		O
a		O
marked		O
influence		O
on		O
the		O
respective		O
binding		O
affinities		O
of		O
1,4		B-IUPAC
-		I-IUPAC
diazepines		I-IUPAC
related		O
to		O
clozapine		O
,		O
chloro		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
5,11		B-IUPAC
-		I-IUPAC
dicarbo		I-IUPAC
analogues		B-MODIFIER
of		O
clozapine		O
were		O
prepared		O
in		O
order		O
to		O
further		O
examine		O
structure		O
-		O
activity		O
relationships		O
.		O
In		O
the		O
purine		O
series		O
,		O
the		O
antiviral		O
potency		O
is		O
found		O
to		O
be		O
in		O
the		O
following		O
decreasing		O
order		O
:		O
adenine		O
(		O
beta		O
-		O
isomer		O
)		O
&		O
gt		O
;		O
6		B-IUPAC
-		I-IUPAC
chloropurine		I-IUPAC
(		O
beta		O
-		O
isomer		O
)		O
&		O
gt		O
;		O
6		B-IUPAC
-		I-IUPAC
chloropurine		I-IUPAC
(		O
alpha		O
-		O
isomer		O
)		O
&		O
gt		O
;		O
2		O
-		O
NH2		O
-		O
6		O
-		O
Cl		O
-		O
purine		O
(		O
beta		O
-		O
isomer		O
)		O
&		O
gt		O
;		O
guanine		O
(		O
beta		O
-		O
isomer		O
)		O
&		O
gt		O
;		O
N6		B-IUPAC
-		I-IUPAC
methyladenine		I-IUPAC
(		O
alpha		O
-		O
isomer		O
)		O
&		O
gt		O
;		O
N6		B-IUPAC
-		I-IUPAC
methyladenine		I-IUPAC
(		O
beta		O
-		O
isomer		O
)		O
.		O
To		O
increase		O
the		O
potency		O
of		O
1		O
and		O
/		O
or		O
3		O
in		O
vivo		O
,		O
we		O
extended		O
their		O
chain		O
length		O
by		O
one		O
(		O
5-8		O
)		O
,		O
two		O
(		O
9		O
,		O
10		O
)		O
,		O
and		O
three		O
(		O
11		O
,		O
12		O
)		O
residues		O
at		O
the		O
N		O
-		O
terminus		O
and		O
acetylated		O
(		O
6		O
,		O
8		O
,		O
10		O
,		O
12		O
)		O
.		O
Moreover		O
,		O
the		O
3		B-IUPAC
-		I-IUPAC
(		I-IUPAC
alkylamino		I-IUPAC
)		I-IUPAC
pyridothiadiazines		I-IUPAC
appeared		O
to		O
be		O
more		O
selective		O
for		O
the		O
pancreatic		O
than		O
for		O
the		O
vascular		O
tissue		O
.		O
Fourteen		O
125I		O
-		O
labeled		O
aralkylguanidines		O
were		O
synthesized		O
and		O
evaluated		O
as		O
potential		O
imaging		O
agents		O
for		O
the		O
adrenal		O
medullae		O
and		O
tumors		O
of		O
adrenomedullary		O
origin		O
.		O
9		O
-		O
Methylation		O
of		O
12		O
,		O
but		O
not		O
19		O
,		O
was		O
well		O
-		O
tolerated		O
in		O
A		O
(		O
3		O
)		O
AR		O
binding		O
.		O
These		O
studies		O
demonstrate		O
that		O
manipulation		O
of		O
the		O
2		B-MODIFIER
-		I-MODIFIER
,		O
N		B-MODIFIER
-		I-MODIFIER
,		O
and		O
3		B-MODIFIER
-		I-MODIFIER
position		I-MODIFIER
substituents		I-MODIFIER
in		O
the		O
3alpha		B-IUPAC
-		I-IUPAC
(		I-IUPAC
diphenylmethoxy		I-IUPAC
)		I-IUPAC
tropane		I-IUPAC
class		B-MODIFIER
of		O
dopamine		O
uptake		O
inhibitors		O
can		O
result		O
in		O
ligands		O
with		O
high		O
affinity		O
and		O
selectivity		O
for		O
the		O
DAT		O
,		O
and		O
distinctive		O
in		O
vivo		O
pharmacological		O
profiles		O
that		O
cannot		O
be		O
predicted		O
by		O
their		O
effects		O
in		O
vitro		O
.		O
Eight		O
of		O
the		O
twelve		O
compounds		O
significantly		O
reactivate		O
ethyl		O
methylphosphonyl		O
-		O
AChE		O
,		O
but		O
inherent		O
reactivities		O
are		O
moderate		O
to		O
low		O
:		O
the		O
most		O
potent		O
nonquaternary		O
reactivator		O
,		O
3		B-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
hydroxyimino		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
1,2,4		I-IUPAC
-		I-IUPAC
oxadiazole		I-IUPAC
,		O
is		O
17		O
times		O
less		O
reactive		O
than		O
the		O
well		O
-		O
known		O
reactivator		O
2		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
hydroxyimino		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
methylpyridinium		I-IUPAC
iodide		I-IUPAC
(		O
2		O
-		O
PAM		O
)		O
.		O
The		O
pharmacology		O
of		O
the		O
[		O
3H		O
]		O
4		O
binding		O
site		O
is		O
unique		O
from		O
that		O
of		O
any		O
known		O
sigma		O
or		O
dopamine		O
receptor		O
,		O
thus		O
the		O
effects		O
appear		O
to		O
be		O
mediated		O
by		O
a		O
previously		O
uncharacterized		O
binding		O
site		O
/		O
receptor		O
.		O
From		O
this		O
library		O
,		O
(		B-IUPAC
1,1		I-IUPAC
-		I-IUPAC
dioxido		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
oxo		I-IUPAC
-		I-IUPAC
1		I-IUPAC
,		I-IUPAC
2		I-IUPAC
-		I-IUPAC
benzisothiazol		I-IUPAC
-		I-IUPAC
2		I-IUPAC
(		I-IUPAC
3H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
N		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
phenylmethoxy		I-IUPAC
)		I-IUPAC
carbonyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
alanate		I-IUPAC
(		O
7b		O
)		O
emerged		O
as		O
a		O
potent		O
inhibitor		O
of		O
human		O
mast		O
cell		O
tryptase		O
(		O
IC50		O
=		O
0.85		O
microM		O
)		O
.		O
Several		O
compounds		O
in		O
the		O
2		B-IUPAC
-		I-IUPAC
(		I-IUPAC
arylamino		I-IUPAC
)		I-IUPAC
-		I-IUPAC
9,10		I-IUPAC
-		I-IUPAC
dimethoxy		I-IUPAC
-		I-IUPAC
6,7		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
4H		I-IUPAC
-		I-IUPAC
pyrimido		I-IUPAC
[		I-IUPAC
6,1		I-IUPAC
-		I-IUPAC
a		I-IUPAC
]		I-IUPAC
isoquinolin		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
one		I-IUPAC
series		B-MODIFIER
display		O
a		O
high		O
order		O
of		O
activity		O
.		O
[		O
18F		O
]		O
F		O
-		O
A		O
-		O
85380		O
appears		O
to		O
be		O
a		O
suitable		O
radioligand		O
for		O
brain		O
imaging		O
nAChRs		O
with		O
PET		O
.		O
The		O
polyamine		O
architecture		O
was		O
also		O
altered		O
and		O
ranged		O
from		O
diamine		O
to		O
triamine		O
and		O
tetraamine		O
systems		O
.		O
Diarylguanidines		O
,		O
acting		O
as		O
NMDA		O
receptor		O
ion		O
channel		O
site		O
ligands		O
,		O
represent		O
a		O
new		O
class		O
of		O
potential		O
neuroprotective		O
drugs		O
.		O
b		O
.		O
These		O
results		O
indicate		O
that		O
this		O
non		O
-		O
amino		O
acid		O
structure		O
of		O
inhibitors		O
meets		O
the		O
ACE		O
active		O
site		O
requirements		O
for		O
the		O
binding		O
.		O
N		B-IUPAC
-		I-IUPAC
Acetyl		I-IUPAC
-		I-IUPAC
2,6		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
p		I-IUPAC
-		I-IUPAC
benzoquinone		I-IUPAC
imine		I-IUPAC
and		O
N		B-IUPAC
-		I-IUPAC
acetyl		I-IUPAC
-		I-IUPAC
3,5		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
p		I-IUPAC
-		I-IUPAC
benzoquinone		I-IUPAC
imine		I-IUPAC
were		O
prepared		O
from		O
2,6		B-IUPAC
-		I-IUPAC
dimethylacetaminophen		I-IUPAC
and		O
3,5		B-IUPAC
-		I-IUPAC
dimethylacetaminophen		I-IUPAC
by		O
oxidation		O
with		O
lead		O
tetraacetate		O
.		O
